













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 





Genome editing using site-specific 
nucleases: Targeting highly expressed 
genomic regions for robust transgene 











Thesis submitted for the degree of Doctor of Philosophy 



















(a) that this thesis has been composed by myself, and  
(b) that this work is my own, unless otherwise stated, and  

























It feels like only yesterday that I embarked upon my PhD, but alas, four years have 
passed and it has drawn to an end. I have thoroughly enjoyed my time, but none of 
this would have been possible without the support and encouragement of a good 
number of people, whom I shall endeavour to thank here.  
Firstly, I would like to thank my supervisor Chris Boyd, both for agreeing to take me 
on as a PhD student and for providing support and advice throughout. I want to thank 
you for challenging me intellectually and allowing me to find my own path. I would 
not have been able to complete this project without you, so thank you. I would also 
like to thank Andrew Wood, Nick Gilbert, and Sally Cross for their help and advice, 
and for always finding the time to help me when I asked. Special thanks go to Cathy 
Abbott for offering me endless help and support, for being an excellent thesis 
committee chair, and for allowing me to gate-crash your lab meetings, in order to 
gain a greater understanding of the eEF1A field.  
I must also thank all the members of the CF group past and present, James, Javi, 
June, Barbie, Ann, Heather, and Rob, for their support, and for making me feel 
welcome and part of the team. A particular thank you goes to Laura H. for looking 
after me in the lab, generally putting up with my endless questions and, most 
importantly, for being a good friend.  
The CGEM (and IGMM as a whole) has some excellent students, I must thank my 
office friends in particular, Laura M., Faith, and Daniel, for all the useful and random 
conversations and for keeping me entertained for the past four years. I must also 
thank Faith for teaching me the dark art of western blotting and Daniel for all his 
help with qPCR. I would also like to thank all the other students, especially Nidhi, 
Kate, and Katie, but many more, for helping to make my time here an enjoyable one.  
There are so many other people in the CGEM who have helped make my experience 
a great one, too many to name, but I would like to thank Susan, Helen, Rosemary, 
Joyce, and Jennifer in particular, for being so welcoming and for always giving me 
help and advice.   
iv 
 
A special thank you goes to Niamh, for your wisdom, but also for being a great 
friend and an excellent flatmate. This last year would not have been the same without 
you, long may the craziness continue. I would also like to thank my good friend Neil, 
for your words of encouragement, for always being there when I needed to moan, for 
your proofreading skills, for providing just enough of a distraction with the DDD and 
for pints in even numbers, thank you. I must also thank my friends Tom and Kirstie, 
you were always there for me when I needed you and offered me lots of support 
along the way. 
Finally, I want to thank my parents, for always believing in me and supporting me, 
for always being there when I needed a chat or a cheer up and generally for being 





Integration and expression of exogenous genetic material – in particular, transgenes – 
into the genomes of model organisms, cell lines or patients is widely used for the 
creation of genetically modified experimental systems and gene therapy. However, 
loss of transgene expression due to silencing is still a major hurdle which remains to 
be overcome. Judicious selection of integration loci can help alleviate the risk of 
silencing; in recent years the ability to efficiently and specifically target transgene 
integration has been improved by the advent of site-specific nucleases (SSNs). SSNs 
can be used to generate double strand breaks (DSBs) in a targeted manner, which 
increases the efficiency of homologous recombination (HR) mediated transgene 
integration into predetermined loci. In this work I investigate four human genomic 
loci for their potential to act as transgene integration sites which will support robust 
long term expression: the adeno-associated virus (AAV) integration site 1 (AAVS1); 
the human homologue of the mouse Rosa26 locus (hROSA26); the inosine 
monophosphate dehydrogenase 2 (IMPDH2) gene and the eukaryotic translation 
elongation factor 1 alpha 1 (EEF1A1) gene.  I also investigate the potential of 
creating a novel drug-selectable transgene integration system at the IMPDH2 locus to 
allow for rapid and specific selection of correctly inserted transgenes.  
In addition to their ability to drive targeted transgene integration, SSNs can be 
harnessed to specifically disrupt gene function through indel formation following 
erroneous repair of the induced DSB. Using this strategy, I aimed to answer some 
important biological questions about eukaryotic translation elongation factor 1 alpha 
(eEF1A); eEF1A is responsible for providing aminoacylated tRNAs to the ribosome 
during the elongation phase of protein synthesis. Humans and other vertebrates 
express two isoforms, eEF1A1 and eEF1A2 (encoded by EEF1A1 and EEF1A2 
respectively). During development eEF1A1 is replaced by eEF1A2 in some tissues. 
The reasons for this remain elusive, but one explanation may lie in the moonlighting 
functions of eEF1A1, which may not be shared by eEF1A2. Additionally, eEF1A2 
can act as an oncogene, while there is no evidence that eEF1A1 is overexpressed in 
tumours. To begin to untangle these issues I targeted EEF1A1 using SSNs with the 
aim of making a cell line expressing only the eEF1A2 isoform. This work suggests 
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that eEF1A1 may be essential even in the presence of eEF1A2, though further 
studies will be required to confirm this.
 
 
Lay Summary  
The ability to insert genes into the genome is an essential technique in cell biology, 
both for studying gene function, making disease models and ultimately for gene 
therapy, whereby therapeutic genes are delivered to patients to replace the function 
of faulty genes. However, this technique can be hampered when these genes become 
switched off by a process known as silencing. In order to avoid this, a targeted 
approach can be used, whereby safe sites in the genome can be chosen and used to 
specifically integrate the gene. The ability to do this has been greatly improved by 
the use of genetically engineered enzymes called site-specific nucleases. These work 
like molecular scissors which can be made to cut chromosomes at specified positions 
within the genome and vastly increase the efficiency of gene insertion. In this work, I 
have been using this technology to investigate four chromosomal sites in the human 
genome for their potential to support the insertion of genes, without becoming 
switched off or silenced.  
In addition to targeting gene insertion, site-specific nucleases can be used to make 
gene deletions. I have been using this property to try and delete the EEF1A1 gene in 
cells. This gene encodes a protein called eEF1A1, which plays a vital role in the 
cell’s protein production machinery. All cells in the body have eEF1A1 except a few 
specialised cells, such as those in muscles, the heart and some nerves, where a highly 
similar protein – eEF1A2 – performs this role instead. The reasons why we have two 
almost identical proteins, performing the same role remain unknown, but it may be 
due to differences in their other cellular functions. It is known that eEF1A1 performs 
many other roles in the cell, but it is unknown whether eEF1A2 shares these. In 
addition, eEF1A2 is known to play a role in cancer, while this is not the case for 
eEF1A1. I sought to delete eEF1A1 in order to begin to unravel the reasons for this, 
and to allow me to look at the functions of eEF1A2 in more detail. This work seems 
to indicate that eEF1A1 may be essential for cell survival even in the presence of 
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Recent advances have dramatically enhanced our ability to specifically alter DNA 
sequences in vitro and in vivo, a process known as gene editing (Carroll 2014). 
However, the ability to alter the genome by the insertion of exogenous DNA, 
particularly transgenes, is a vital technique in cell biology. It has allowed 
investigators to explore fundamental biological questions and has been instrumental 
in the production of cellular disease models and transgenic animals. It has also been 
useful for the development of recombinant proteins both for research and 
pharmaceutical applications and will have far-reaching implications in the field of 
gene therapy.  
This work will focus on the use of gene editing technologies for the stable integration 
and long term expression of transgenes in human cell lines. This will provide a proof 
of principle for the production of recombinant lentiviral producer cell lines, for use in 
gene therapy applications.  
1.1 Gene Silencing 
A challenge facing all transgenic studies is the loss of transgene expression due to 
silencing. Under normal circumstances, gene silencing is necessary for cellular 
function. Gene expression is not determined by primary DNA sequence alone. In 
addition, it is profoundly influenced by epigenetic factors, notably proteins that 
interact with DNA and each other with short- and long-term effects on transcription. 
Methylation of cytosine residues at CpG dinucleotides also plays an important role.  
However, when exogenous DNA sequences, for example, transgenes, become 
incorporated into the genome, they can be prone to the influence of these factors 
leading to loss of expression. The exact mechanisms of transgene silencing are not 
fully understood, but certain processes are known to be involved. I will begin by 
discussing the structure of chromatin to set the scene for a survey of transgene 
silencing mechanisms.  
1.1.1 Chromatin Structure  
The nuclear DNA of eukaryotes is organised into a higher order structure termed 
chromatin. Chromatin in its lowest order structure is composed of repeating units – 
nucleosomes – made up of 146-bp of DNA wrapped around an octamer of histone 
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proteins, two each of H2A, H2B, H3 and H4 (Luger et al., 1997; Figure 1.1). In 
addition, a fifth histone, H1, interacts with the DNA where it enters and exits the 
nucleosome core (Kamakaka and Biggins, 2005; Figure 1.1). These histones – in 
particular their tail regions – are subject to post-translational modifications (PTMs) 
which can alter the overall structure of the chromatin.  
 
 
Figure 1.1 Structure of a nucleosome. Each nucleosome is composed of 146-bp of DNA (red) wrapped 
around an octamer of histone proteins (blue circles). The octamer is composed of two molecules each of 
H2A, H2B, H3, and H4. Where the DNA enters and exists the nucleosome, it interacts with another histone 
protein, histone H1 (blue rectangle). Nucleosomes represent the lowest order of chromatin structure, 
forming the 10 nm fibre, often referred to as ‘beads on a string’. This is further compacted to form the 
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1.1.2 Histone Modifications 
Histone proteins are each composed of a globular domain and an N-terminal tail. The 
tails are highly basic and protrude from the nucleosomes where they can interact with 
neighbouring nucleosomes. These domains, and to some extent the globular core 
domains, are subject to myriad PTMs. These can affect chromatin structure in two 
ways: 1) they can directly alter the overall charge and thus affect both histone-DNA  
and inter-nucleosome interactions, and 2) they can recruit enzyme complexes which 
can either directly remodel positioning of the nucleosomes or regulate histone PTMs 
(Bannister & Kouzarides 2011). These modifications commonly take the form of 
acetylation and methylation, but other PTMs can also occur, for example 
phosphorylation and ubiquitination.  
Histone acetylation occurs on lysine residues within the histones, resulting in a 
neutralisation of their positive charge and a weakening of their interaction with the 
negatively charged DNA (Bannister & Kouzarides 2011). Within the tail region, 
acetylation commonly occurs at lysines 9 and 14 of histone H3 (H3K9ac and 
H3K14ac).  
Methylation occurs at both lysine and arginine residues, predominantly in the histone 
tail regions. Unlike acetylation, methylation does not affect the charge of the histone. 
Instead, methylated residues can recruit proteins (or protein complexes) which can 
either stabilise chromatin structure or bring about further changes. For example 
tri-methylation of lysine 9 on histone H3 (H3K9me3), which recruits 
heterochromatin protein 1 (HP1) (Lachner et al. 2001). 
The combination of these multiple histone modifications in cis or trans constitute the 
‘histone code’ which can be interpreted by proteins or protein complexes to bring 
about further changes to the chromatin structure (Strahl & Allis 2000). Proteins are 
able to recognise these modifications via specific domains, for example the 
bromodomain is believed to be involved in the recognition and binding of acetylated 
lysine residues (Dhalluin et al. 1999).  
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1.1.3 Chromatin Organisation 
Chromatin can be divided into two groups based on its structure: euchromatin (open 
and transcriptionally active) and heterochromatin (closed and transcriptionally 
repressed). Each type of chromatin is characterised by the presence of different 
histone modifications. H3K9ac, H3K14ac and tri-methylation of lysine 4 of histone 
H3 (H3K4me3) are markers of euchromatin. Acetylation neutralizes the positive 
charge of the lysine residues leading to weakened interactions thus a relaxation of the 
chromatin structure, which is more amenable to transcription (Bannister & 
Kouzarides 2011).   
Heterochromatin is hypoacetylated and is enriched for DNA methylation at CpG 
sites (discussed in 1.1.4 below; Barski et al., 2007; Decottignies, 2014; Saksouk et 
al., 2015). Heterochromatin can be subdivided into constitutive heterochromatin, 
found in centromeres and telomeres, or facultative heterochromatin often containing 
genes, which become silenced during development (Saksouk et al. 2015); each type 
contains a specific pattern of histone PTMs. Constitutive heterochromatin is 
characterised by the presence of H3K9me3 and di- and tri-methylation of lysine 20 in 
histone H4 (H4K20me2/3), which is the hallmark of pericentromeric 
heterochromatin (Saksouk et al. 2015). On the other hand, facultative 
heterochromatin is enriched for tri-methylation of histone H3 lysine 27 (H3K27me3) 
and ubiquitination of lysine 199 of histone H2A (H2AK199ub; Saksouk et al., 2015).  
Heterochromatin is associated with many protein complexes, which help maintain 
and stabilise its structure, but can also initiate the spreading of heterochromatin into 
neighbouring regions. At centromeres it has been shown that H3K9me3 is a crucial 
mediator of the heterochromatic state; proteins containing a chromodomain, such as 
HP1, are able to bind to H3K9me3 (Dillon & Festenstein 2002). The enzyme 
SUV39H is responsible for the majority of H3K9me3 at pericentromeric regions and 
is also involved in DNA methylation via recruitment of DNA methyltransferases 
(DNMTs; Muramatsu et al., 2013). In addition, H3K9me3 is required for the 
recruitment of SUV420H which leads to the di- and tri-methylation of H4K20 
(H4K20me2/3), another hallmark of pericentromeric heterochromatin, which can 
also interact with HP1 (Saksouk et al. 2015).  
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1.1.4 DNA Methylation 
In addition to alterations in the structure of chromatin discussed above, DNA 
modification can also affect transcriptional activation or repression. In many animals, 
plants, and fungi, methylation of DNA only occurs at cytosine residues which are 
often adjacent to guanosine residues in sites termed CpG sites (Suzuki & Bird 2008). 
This is regulated by DNMTs, which convert cytosine bases (found in CpG sites) into 
5-methylcytosines (m5C). Three DNMTs have to date been described: DNMT1, 
DNMT3A and DNMT3B (Saksouk et al. 2015). Generally, the human genome is 
hypermethylated except at certain regions termed CpG islands (CGIs), which are 
often found in the promoter regions of genes (Ioshikhes and Zhang 2000). 
Methylation at these CGIs or in promoters is associated with gene silencing (Suzuki 
& Bird 2008).  
1.2 Transgene Silencing Mechanisms 
1.2.1 Position Effects 
Silencing of transgenes can occur as a direct consequence of their integration site, via 
phenomena known as position effects (PEs); integration into, or close to 
heterochromatic regions can result in transgene silencing due to PEs. PEs can be 
stable, for example, when integration occurs at subcentromeric regions, or variable 
between cells, known as position effect variegation (PEV).  
When transgenes integrate into heterochromatic regions in the vicinity of telomeres 
or centromeres they can be subject to silencing due to the spreading of the 
heterochromatin found in these regions. These regions of constitutive 
heterochromatin are marked by the presence of H3K9me3 which is bound by HP1 
(Dillon & Festenstein 2002). HP1 can recruit histone methyltransferases such as 
SUV39H, capable of methylating H3K9 (Muramatsu et al. 2013), which in turn can 
be recognised by HP1 and thus heterochromatin can propagate and silence the 
transgene expression (Decottignies 2014).  
PEV is caused by incomplete transgene silencing; transgenes (or, in fact, genes 
generally) become silenced in some, but not all, cells leading to a variegated 
phenotype. It was first identified in Drosophila, which showed a variegated 
phenotype following x-ray irradiation (Muller 1930). This resulted from X-ray 
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induced chromosomal rearrangements, which placed the genes involved adjacent to 
heterochromatic regions, leading to silencing.  
Variegated expression can also result from the integration of tandem arrays of the 
transgene, which often leads to extinction of transcription, a phenomenon referred to 
as repeat-induced gene silencing (RIGS). In their 1998 study, Garrick and colleagues 
demonstrated that transgenes inserted in a concatemeric array showed reduced 
expression resulting in a variegated phenotype which was reversed when transgene 
number was reduced. They demonstrated that silencing resulted from 
hypermethylation of the transgenes and adoption of a repressive chromatin local 
environment. However, it seems that the link between RIGS and PEV is a complex 
one and reduction of transgene copy number does not always alleviate PEV. In their 
study, Williams et al. (2008) demonstrated that the effect of reducing transgene copy 
number on silencing is dependent on integration site. In addition, for some 
integration sites, multiple transgene copies may be advantageous. It is likely that a 
complex interplay between the local environment and the transgene ultimately 
determines whether it will be silenced.  
1.2.2 DNA Methylation of Transgenes 
Transgenes that become silenced are associated with increased DNA methylation (Li 
et al. 2001; Pikaart et al. 1998); studies have shown that inhibition of DNMTs results 
in reversal of gene extinction (He et al. 2005; Pikaart et al. 1998). However, it has 
been shown that DNA methylation, whilst important to maintaining the silenced 
phenotype, may not be a causative event (Mutskov & Felsenfeld 2004). Methylated 
DNA can be bound by proteins such as methyl CpG binding protein 2 (MeCP2), 
which contains a transcriptional repressor domain (TRD), but can also recruit protein 
complexes containing histone deacetylases (HDACs), capable of deacetylating 
histones and altering local chromatin structure (Jones et al. 1998; Nan et al. 1998), 
resulting in a more repressive environment.  
DNA methylation clearly plays a role in transgene silencing, but whether it is 
involved in initiating silencing or maintaining the silent state is still unclear, though 
the evidence points to the latter. In their study, Mutskov and Felsenfeld (2004) 
demonstrate that DNA methylation is secondary to transgene silencing and suggest 
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that histone deacetylation may be the triggering event. In addition, Spencer and 
colleagues (2015) demonstrated that histone modifications appear to be responsible 
for the heterogeneity observed in transgene expression between clonal lines. 
However, Feng et al. (2001) showed that orientation dependent transgene silencing 
resulted from DNA methylation and was not due to changes in chromatin structure, 
determined by DNase I hypersensitivity; however, this does not rule out a role for 
histone modification. Interestingly, it has been shown that DNA methylation occurs 
at sites of DNA damage, such as that induced by site-specific nucleases (SSNs), but 
can be altered in a transcription-dependent manner (Morano et al. 2014). This 
evidence seems to indicate that DNA methylation, whilst clearly playing a role in 
transgene silencing, is not the initiating factor, though further studies are required to 
confirm this.  
1.2.3 Transgene Properties 
In addition to the local environment of the integration site, features within the 
transgene can also influence the likelihood of silencing. However, some elements 
have been found to reduce the likelihood of transgene silencing – notably insulators 
and ubiquitous chromatin opening elements (UCOEs).  
1.2.3.1 Exogenous Promoters  
Promoter choice is important to ensure efficient transgene expression. Viral 
promoters have commonly been used due to their high level constitutive expression 
and generally compact nature. However, eukaryotic cells have evolved mechanisms 
to detect viral promoters, such that many virally derived promoters are subject to 
silencing (Papadakis et al. 2004). One of the most commonly utilised viral promoters 
is the cytomegalovirus (CMV) promoter, however this often becomes silenced upon 
integration into the genome (Chen et al. 2011; Krishnan et al. 2006; Teschendorf et 
al. 2002).  
In addition, eukaryotic promoters can be used to drive transgene expression. These 
have the advantage over virally derived promoters that they are not recognised as 
foreign. One of the most widely used constitutively active eukaryotic promoters is 
the elongation factor 1α (EF1α) promoter, which has been shown to be less prone to 
transgene silencing than the CMV promoter (Liu et al. 2009).  
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In addition to constitutively active promoters, tissue-specific promoter can be 
employed to restrict expression. This is particularly beneficial in a gene therapy 
setting as expression is restricted to the tissue of interest, so they have an improved 
safety profile and a more natural expression pattern.  
1.2.3.2 Viral Elements  
Retrovirally integrated transgenes can be silenced because of elements present in the 
integrated provirus. Some retroviral vectors contain silencer elements within their 
long terminal repeats (LTRs), which allow binding of trans-acting factors leading to 
the direct or indirect recruitment of chromatin remodelling factors and subsequent 
silencing of transgene expression (Pannell & Ellis 2001). These mechanisms may 
have evolved as a defence against viral infections. In their study, McInerney et al. 
(2000) demonstrated that long-term silencing of  retroviral vectors cannot be 
reversed by employing DNMT or HDAC inhibitors, suggesting that mechanisms 
other than DNA methylation and histone deacetylation are involved. In order to 
reduce silencing of retroviral elements, insulators can be included in the viral 3’-LTR 
which can help block spread of repressive chromatin (Yi et al., 2011; discussed 
below).  
1.2.3.3 Insulators  
Chromatin insulators are genomic regions, which help to define differentially 
regulated loci, by blocking the action of cis regulatory elements. The best 
characterised insulator is derived from the chicken β-globin locus control region and 
contains a DNase I hypersensitive site (cHS4; chicken hypersensitive site 4; Emery 
et al., 2000). The cHS4 element is 1.2-Kb and is capable of maintaining expression 
of transgenes in a range of cell lines and model systems, though much of this activity 
is contained within a 250-bp region containing a 49-bp cHS4 core that interacts with 
CTCF (Emery et al. 2000). 
Mutskov et al. (2002) showed that cHS4 is able to prevent CpG methylation within 
the promoter region and is associated with higher levels of histone acetylation, 
potentially via the recruitment of histone acetyltransferases (HATs) or inhibition of 
HDACs. While Emery et al. (2000) showed that cHS4 can help protect retroviral 
vectors from PEs. In addition, Sharma et al. (2012) showed that cHS4 can be used in 
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conjunction with transposon-based transgenes to prevent initial silencing. However, 
they show that cHS4 cannot completely protect against silencing of transgenes when 
multiple integrations occur.  
1.2.3.4 Ubiquitous Chromatin Opening Elements (UCOEs) 
UCOEs are genomic regions generally consisting of two divergently transcribed 
promoters, spanning a methylation free CpG island, capable of exerting a dominant 
chromatin remodelling function in order to maintain an open transcriptionally 
permissive local chromatin environment (Ackermann et al. 2014). The best 
characterised UCOE is derived from the human heterogeneous nuclear riboprotein 
A2 B1/ chromobox protein homologue 3 (HNRPA2B1-CBX3) housekeeping gene 
locus, termed A2UCOE (Antoniou et al. 2003). It has been successfully used to 
prevent transgene silencing of both gammaretro- and lentiviral gene therapy vectors 
in Chinese hamster ovary (CHO) cells, the hypermethylating cell line P19, as well as 
murine induced pluripotent stem cells (iPSCs) and embryonic stem (ES) cells 
(Williams et al. 2005; Zhang et al. 2010; Pfaff et al. 2013). In their study, Zhang et 
al. (2010) demonstrated that this is, at least in part, due to methylation resistance.  
However, as the A2UCOE element extends into the first intron of either HNRPA2B1 
or CBX3 or both, it has the potential for insertional mutagenesis as a result of 
aberrant splicing. Indeed, it has been shown to cause upregulation of neighbouring 
genes following aberrant splicing from the UCOE splice donor sites (Knight et al. 
2012). There are two splice donor sites within A2UCOE plus additional potential 
cryptic splice donor sites that can lead to aberrant splicing. However, Knight et al. 
(2012) demonstrated that selective mutagenesis of these sites could alleviate aberrant 
splicing without compromising its ability to regulate silencing.  
More recently, Müller-Kuller et al. (2015) have further improved the safety profile of 
A2UCOE by removal of the HNRPA2B1 promoter. The resulting UCOE – CBX3-
UCOE – maintains the ability to provide an open chromatin environment with 
characteristic changes in promoter CpG methylation and histone modifications, such 
as reduced levels of repressive marks including H3K9me3 and H3K27me3. In 
addition, the activity of this minimal UCOE is locally restricted, such that it doesn’t 
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override tissue specific promoters, adding greater specificity for use in a gene 
therapy setting.  
Transgene silencing is a complex process involving many mechanisms, as discussed 
above. One of the key variables in determining transgene expression is the genomic 
environment at the integration site. However, it is important to bear in mind all 
potential mediators of silencing when creating a strategy for transgene integration.  
1.3 Strategies and Tools for Transgene integration  
Methods for transgene integration can be divided broadly into two groups: random 
integration and targeted integration.  
1.3.1 Random Integration Strategies 
Random integration of transgenes can be achieved by a variety of methods but all 
result in integration of transgenes in a random (or semi random) fashion and does not 
rely on the presence of homology between the targeting vector and the insertion site. 
Random integration mainly occurs as a result of the non-homologous end joining 
(NHEJ) pathway (Sakurai et al. 2010), though other pathways have also been 
implicated; notably, microhomology-dependent random integration (Merrihew et al. 
1996) and the alternative end joining pathway (Iiizumi et al. 2008).  
1.3.1.1 Plasmid DNA 
Since the discovery 35 years ago that isolated DNA could stably integrate into the 
mouse genome (Gordon et al. 1980), this technique has become widespread in the 
generation of transgenic animals. This techniques leads to variable transgene copy 
number and the site of integration is unpredictable (Yan et al. 2010). The exact 
mechanism by which DNA becomes incorporated is not known, but is believed that 
microhomologies (1-10-bp) between the target site and transgene play a role via a 
process known as homologous illegitimate random integration (HIRI) (Yan et al. 
2013; Yan et al. 2010). The advantage of this technique is the simplicity of targeting, 
the plasmid DNA does not require additional reengineering or preparation work prior 
to delivery (Fontes & Lakshmipathy 2013). However, integration efficiency is 
relatively low and so lengthy selection is required, generally by selection of drug 
resistance genes within the targeting cassette. In addition, it has been shown that up 
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to 10% of integrated transgenes carry aberrations – mainly deletions – which could 
hamper downstream applications (Recillas-Targa 2004).  
1.3.1.2 Artificial Chromosomes  
Artificial chromosomes, either bacterial, yeast or P1-derived (BACS, YACs and 
PACs, respectively) are incorporated into the host genome in an analogous manner to 
plasmid DNA. However, unlike plasmid DNA, BACs, YACS and PACs have a 
much greater cargo capacity in the range of 100-1000-Kb. BACS are the most widely 
used of these technologies and have been commonly used in the generation of 
transgenic mice (Chandler et al. 2007). Due to the large capacity of BACs, they can 
accommodate more of the endogenous regulatory landscape of the transgene, as such 
are often less prone to position effects and silencing than other randomly integrated 
transgenes (Beil et al. 2012; Giraldo & Montoliu 2001; Gong et al. 2003). However, 
this does not overcome issues associated with multiple integrations or adverse effects 
due to disruption at the site of integration. Indeed, in their study, Chandler et al. 
(2007), demonstrated that the majority of animals contained between 1 and 25 copies 
per genome. In addition, they showed a strong correlation between copy number and 
expression.  
To overcome the issues associated with random integration and multiple copy 
integration, BACs can be used in conjunction with transposons to give more 
predictable outcomes. In their study, Suster et al. (2009) used BACs in conjunction 
with the Tol2 transposon for delivery into mice and zebrafish and were able to 
demonstrate singe copy integrations free from rearrangements or mutations and 
whose locations could be easily and precisely mapped. 
1.3.1.3 Transposons 
DNA transposons are class II transposable elements, which have been harnessed as 
tools for genome manipulation. Two notable examples are the Sleeping Beauty (SB) 
transposon and the PiggyBac (PB) transposon which are both widely used. The SB 
transposon is a synthetic transposon engineered from inactive members of the 
Tc1/mariner superfamily of transposons (Ivics et al. 1997). The PB transposon 
derived from Trichoplusia ni, has been successfully used in the creation of iPSCs and 
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is often used to deliver transgenes into a wide range of cell types from many 
organisms including mammals (Matteo et al. 2012). 
DNA transposons consist of two functional elements: terminal inverted repeat (IR) 
sequences, which flank the gene to be mobilised and the transposase enzyme, which 
catalyses the reaction (Ammar et al. 2012). The transposase reaction proceeds in a 
“cut and paste” manner in which the transposase recognises the terminal IR 
sequences and catalyses the excision and reintegration of the transposon (Matteo et 
al. 2012). Integration of transposons is essentially random, but a minimal nucleotide 
sequence that varies between transposons is often required, for SB this is 5’-TA (Liu 
et al. 2005), while PB requires a 5’-TTAA sequence (Matteo et al. 2012).  
1.3.1.4 Retroviral Vectors  
Another method that improves the efficiency of transgene integration is the use of 
viruses, in particular retroviruses (Fontes & Lakshmipathy 2013). By their nature, 
retroviruses reverse transcribe their genome and integrate into the host genome via 
the action of the virally encoded integrase (Nisole & Saïb 2004). However, this 
integration is not entirely random, and different viruses show differing integration 
profiles; lentiviruses tend to integrate into active genes whilst gammaretroviruses 
prefer integration close to transcriptional start sites (Mitchell et al. 2004). One of the 
major concerns for the use of retroviral vectors in a gene therapy setting is their 
potential for oncogenesis. Indeed, following the successful treatment of X-linked 
severe combined immunodeficiency disorder (SCID-X1), four out of nine patients 
developed T-cell leukaemia due to the insertion of the gammaretroviral vector in 
close proximity to the LIM-domain only 2 (LMO2) proto-oncogene, leading to its 
activation (Hacein-Bey-Abina et al. 2008). However, much work has focused on the 
improvement in the safety of viral vectors for use in gene therapy. This includes the 
use of self-inactivating (SIN) vectors lacking viral promoters and enhancers in their 
LTRs, to prevent promoting transcription of neighbouring genes. However, residual 
promoter activity still remains in some SIN vectors (Xu et al. 2012). Other groups 
have focused on reengineering integration site preference away from potentially 
harmful chromosomal locations. For example, El Ashkar et al. (2014) reengineered 
the viral integrase from the murine leukaemia virus (MLV) so that it could no longer 
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interact with bromodomain and extra-terminal (BET) family of proteins, normally 
responsible for directing integration. This vector has an altered integration profile, 
which is less prone to correlate with oncogene transcriptional start sites than the wild 
type vector. 
1.3.2 Targeted Integration Strategies  
Unlike random integration strategies, targeted strategies rely on the presence of 
homology between the targeting vector and the integration site; integration occurs in 
a predicable manner at a preselected target locus. This can help to alleviate some of 
the issues associated with random integration, such as insertional mutagenesis, copy 
number variation and the risk of gene silencing.  
1.3.2.1 Homologous Recombination  
Homologous recombination (HR) methods of transgene insertion rely on the use of 
the cell’s HR machinery, and require the presence of regions of homology between 
the incoming DNA and the target locus. However, the efficiency of HR in somatic 
cells is relatively poor, though for unknown reasons, HR occurs more frequently in 
pluripotent ES cells (Houdebine 2002). Due to the relative rarity of HR, cells in 
which this occurs must be selected for, generally by both positive and negative 
selection, to avoid random insertion events. ES cells generated in this way can be 
injected into blastocysts or morula to generate chimeric embryos (Viville 1997). 
Whilst this method can be laborious, it has been successfully used in the generation 
of many transgenic mice. 
1.3.2.2 ΦC31 Integrase  
Recombinases are naturally occurring enzymes, which catalyse the integration of 
small fragments of DNA between two longer DNA fragments. The benefit of this 
methodology is that recombinases do not rely on the cell’s HR repair machinery to 
deliver the transgene and as such it is theoretically applicable to any cell type, even 
quiescent cells in which HR does not occur.  
ΦC31 integrase is a serine recombinase derived from the Streptomyces phage. It 
catalyses the insertion of the phage genome into the bacterial host genome via 
recombination between the phage attachment (attP) site and the bacterial attachment 
 
 
Chapter 1 Introduction   15 
 
(attB) site (Silva et al. 2011). Pseudo integration sites are found in mammalian 
genomes and have been exploited to induce integrase-mediated insertion events at 
specific loci in mammalian chromosomes. The most common site of integration in 
the human genome is on chromosome 19, position 19q13.31 (Chalberg et al. 2006), 
but approximately 100 other pseudo integration sites have been identified. A major 
disadvantage of ΦC31 is that integration can only occur at pseudo integration sites, 
thus cannot be targeted to predetermined loci without first engineering an integration 
site at the locus of interest.  
To overcome the issues of semi-random integration more targeted approaches were 
developed, namely recombinase-mediated cassette exchange (RMCE), in which 
ΦC31 is used to drive integration of transgenes into an engineered locus containing 
the required recognition site. One disadvantage of this approach is the necessity to 
first generate a genomic target site harbouring the required recognition sequences. 
However, this system has been successfully used in a number of cell lines and model 
systems (Bateman et al. 2006; Chen et al. 2011; Belteki et al. 2003).  
In addition, ΦC31 has been successfully used in proof of principle pre-clinical 
studies demonstrating its potential for gene therapy. For example, Ishikawa et al. 
(2006) showed that ΦC31 could drive integration of the common cytokine gamma 
chain gene in human T cell lines, resulting in stable expression and normal IL-2 
signalling. This demonstrated its potential as an alternative strategy for treating 
SCID-X1.  
1.3.2.3 Adeno-associated Virus (AAV) 
AAV is a parvovirus with a linear ssDNA genome of 4.7-Kb, first identified as a 
“virus-like” particle in an adenovirus preparation (Hoggan et al. 1966). The 
discovery that low levels of the viral genome are integrated into the host cell genome 
(Cheung et al. 1980), led to the establishment of AAV as a potential vector for 
transgenesis, particularly in a gene therapy setting (Hastie & Samulski 2015). It has 
subsequently been shown that AAV can be used site-specifically to introduce both 
small and large alterations via HR with efficiencies of integration roughly 1% (Hirata 
et al. 2002). HR via AAV, whilst several orders of magnitude more efficient than HR 
alone, still requires the presence of large regions of homology, generally several 
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kilobases long (Khan et al. 2011), which can be challenging to construct. However, 
AAV can target a wide range of cell types and has been used successfully to target 
immortalised cell lines, primary cells and stem cells – both ES cells and iPSCs (Khan 
et al. 2011).  
One of the advantages of AAV-based vectors is their ability to be pseudotyped to 
specifically target tissues of interest. For example, AAV4 is tropic for the lungs, 
while AAV9 shows a greater preference for the liver and heart (Asokan et al. 2012; 
Zincarelli et al. 2008).  
1.3.3 Endonucleases  
Endonuclease-mediated methods of genome engineering rely on the formation of 
targeted DNA double-strand breaks (DSBs), which increase the rate of HR by several 
orders of magnitude in mammalian cells (Elliott et al. 1998; Liang et al. 1996; 
Choulika et al. 1995; Rouet et al. 1994b). One of two cellular pathways repairs these 
DSBs: HR repair or NHEJ repair. HR is an error-free pathway which uses a template 
to faithfully repair the DSB, as such can be harnessed to create targeted gene 
insertions or to correct gene mutations. However, HR repair is most active during 
late S and G2 phases of the cell cycle (Fung & Weinstock 2011) and does not occur 
in quiescent cells. In contrast, NHEJ predominates in G0 and G1 phases, but remains 
active throughout the cell cycle (Fung & Weinstock 2011); generally, NHEJ is more 
active than HR (Sakurai et al. 2010). NHEJ is an error-prone pathway leading to 
small insertions or deletions (indels) at the site of the DSB so can be harnessed to 
create gene knockouts.  
1.3.3.1 Meganucleases 
Meganucleases (also known as homing endonucleases) have been used for over 15 
years in genome editing applications (Silva et al. 2011). They are found in all 
kingdoms of life and are generally encoded within introns or inteins (Silva et al. 
2011). They are highly specific and in nature have single target loci within their host 
genomes (Stoddard, 2011). Meganucleases have been categorised into five families 
based on sequence and structural motifs: LAGLIDADG, GIY-YIG, HNH, His-Cys 
box and PD-(D/E) XK. 
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The LAGLIDADG family are the most well studied and are commonly used in gene 
targeting applications. All members of this family contain the defining 
LAGLIDADG amino acid sequence which is an essential element for their enzymatic 
activity (Silva et al. 2011). They specifically recognise a 14-40-bp DNA sequence 
and cleavage results in a characteristic 4-nt 3’-OH overhang across the minor groove 
of DNA (Silva et al. 2011).  
DNA-binding specificity of meganucleases shows considerable context dependence 
influenced by neighbouring amino acids and DNA-contacts (Schiffer et al. 2012). 
Despite this, the DNA-binding specificity has been successfully reengineered, 
predominantly using the I-CreI scaffold (a member of the LAGLIDADG family), 
derived from Chlamydomonas reinhardtii.   
In addition to endonuclease activity, meganucleases have been reengineered to 
produce DNA single-strand breaks (nicks); such meganucleases are termed 
meganickases. These are capable of stimulating HR (though with reduced efficiency 
compared to meganucleases) but do not stimulate the error-prone NHEJ pathway 
(Schiffer et al. 2012). 
1.3.3.2 Zinc Finger Nucleases (ZFNs) 
ZFNs are composed of 3-4 zinc finger (ZnF) domains fused to the non-specific 
nuclease domain of the FokI endonuclease via a flexible linker (Figure 1.2). FokI is a 
type IIS restriction endonuclease first isolated from Flavobacterium okeanokoites. 
Unlike type II restriction endonucleases, commonly used in molecular biology, type 
IIS endonucleases cut outside of their DNA recognition site (Carroll 2014). The 
recognition and cleavage domains of FokI can be separated by limited proteolysis (Li 
et al. 1992) and early studies demonstrated that its recognition specificity could be 
altered by linking the nuclease domain to alternative DNA-binding domains, 
including ZnF domains (Kim et al. 1996). FokI nuclease is an obligate dimer: thus 
two ZFNs, binding opposite strands of DNA, are required for DSB formation. 
Following dimerisation of its catalytic domain, FokI cleaves DNA resulting in a DSB 
with characteristic 5’ overhangs (Bitinaite et al., 1998). 
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ZnFs are one of the most common structural motifs in the eukaryotic proteome 
(Rubin et al. 2000). They are small peptides (30 amino acids), which contain a 
Cys2-His2 motif and form a characteristic ββα configuration (Pabo et al. 2001). The 
α-helix projects into the major groove of DNA where it contacts 3-4 contiguous 
bases (Perez-Pinera et al. 2012), such that each ZnF domain recognises a specific 
triplet of DNA bases. Synthetic ZnF domains, which can specifically recognise 
almost all 64 possible nucleotide triplets, have been generated by site directed 
mutagenesis, rational design, and selection of large combinatorial libraries (Perez-
Pinera et al. 2012); thus ZFNs can theoretically be designed to target almost any 
genomic sequence. However, in practice, DNA-binding specificity shows context 
dependence largely influenced by neighbouring ZnF domains. Despite this, ZFNs 
have been successfully utilised for many genome editing applications including gene 
correction (Urnov et al. 2005), gene addition (Moehle et al. 2007) and gene 
knockouts (Perez et al. 2008). Indeed, ZFNs have shown promising results in initial 
clinical trials for human immunodeficiency virus 1 (HIV-1) positive patients. Early 
studies demonstrated the ability of ZFNs to knockout the gene encoding major co-
receptor of HIV-1 viral entry CCR5 (chemokine [CC motif] receptor 5) in T-cells 
which resulted in lower viral loads following engraftment in mice (Perez et al. 2008). 
Subsequent human trials have demonstrated the promise of transplantation of ZFN 
modified autologous T-cells in the treatment of HIV infection (Tebas et al. 2014).
 
 









Figure 1.2 ZFNs binding a DNA target. Each ZFN consists of 3-4 ZnFs, capable of recognising a specific 
triplet of DNA bases (arrows). The ZnFs are conjugated to the non-specific nuclease domain of FokI 
endonuclease, via a flexible linker. Due to the requirement of FokI to dimerise, target sites, on opposite 
DNA strands must be separated by 5-6-bp (when a short linker is used). In the commonly used system, the 
FokI domain is conjugated to the C-terminus of the ZnF cluster. Reprinted by permission from Elsevier 
Ltd: Trends in Biotechnology (Gaj et al. 2013), copyright (2013). 
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1.3.3.3 Transcription Activator-Like Effector Nucleases (TALENs) 
TALENs are programmable, targeted nucleases formed by the fusion of a C-terminal 
truncation of a transcription activator-like effector (TALE) with the nuclease domain 
of the non-specific nuclease domain of FokI.  
TALEs are naturally occurring proteins found in phytopathogenic bacteria of 
Xanthomonas species (Figure 1.3). In nature they are secreted via a type III secretion 
system into the host cell wherein they are trafficked to the nucleus, interact with host 
DNA, and promote transcription of genes beneficial to bacterial colonisation and 
spread (Boch & Bonas 2010).  
In 2009 the TALE cipher (‘TALE code’) was elucidated, revealing that each 
monomer in the DNA-binding domain binds to a single DNA base (Figure 1.3; Boch 
et al. 2009; Moscou & Bogdanove 2009) allowing the generation of TALEs to target 
almost any genomic sequence. Each monomer is composed of 33-35 highly 
conserved amino acids. Two hypervariable residues found at positions 12 and 13, 
termed the repeat variable di-residue (RVD), determine DNA-binding specificity. 
Residue 13 contacts the DNA base while residue 12 stabilises the interaction 
(Bochtler 2012). The four most common RVDs (NI, HD, NG and NN) bind the four 
DNA bases (adenine, cytosine, thymine and guanine, respectively). However, NN 
can also bind to adenine in some contexts. Other monomers have been identified 
with alternative binding specificities, for example NK and NH, which have greater 
specificity for guanine, but are considered weaker than NN (Christian et al. 2012; 
Streubel et al. 2012; Cong et al. 2012; Meckler et al. 2013). Unlike ZFNs, each 
monomer repeat within a TALEN recognises and binds to a single DNA-base and to 
date no context dependence has been observed, meaning TALENs are much more 
flexible than ZFNs and can theoretically bind to any genomic sequence. However, 
the preferred base in the 0 position is a T, specified by a cryptic signal upstream of 
the monomer array, which is similar in structure but not sequence to the other 
monomers (Mak et al. 2012). In nature, TALEs have been found to contain between 
1.5 and 33.5 monomers, though it has been demonstrated experimentally that arrays 
containing less than 6.5 repeats have limited activity (Boch et al. 2009). The final 
monomer is termed the half repeat (or 0.5 repeat) and is composed of 20 amino acids.  
 
 
Chapter 1 Introduction   21 
 
Like ZFNs, TALENs must work in pairs, binding opposite strands of DNA, to allow 
the FokI nucleases domains to dimerise (Figure 1.4). For successful DSB formation, 
the distance between each TALEN binding site, known as the spacer region, must be 
14-20-bp (Sanjana et al. 2012). TALENs have been shown to be at least as efficient 
as ZFNs in side by side comparisons (Mussolino et al. 2011), with a recent study 
showing they can induce up to 10-fold more mutations, via NHEJ repair of DSBs, in 
a zebrafish model (Chen, Oikonomou, et al. 2013). 
Certain criteria must be met for TALENs to successfully bind and cleave at a 
genomic locus of interest. Cermak and colleagues (2011) proposed five criteria based 
on investigation of naturally occurring TALEs. 1) The monomer binding site should 
be preceded by a 5’-T. 2) There should not be a T at position one. 3) There should 
not be an A at position two. 4) They should end with a T. 5) They should have a base 
composition within two standard deviations of the averages which Cermak et al. 
(2011) observed. In order to identify targets which meet these criteria within a 
genomic region of interest, Cermak and colleagues (2011) devised a web-based 
platform which will screen a given genomic region ≤5-Kb. Subsequently, four 
additional criteria were proposed in order to maximise TALEN activity: 1) include at 
least 3-4 strong RVDs; 2) position strong RVDs to avoid long (≥6) stretches of weak 
RVDs, especially at the ends; 3) for high guanine specificity use NH or NK (if 
enough strong RVDs are present), and 4) use NN for guanine if only a few other 
strong RVDs are present (Streubel et al. 2012).
 
 




Figure 1.3 Structure of a TALE molecule. TALEs consist of three domains: the N-terminus, the 
C-terminus, and the DNA-binding array. The N-terminus contains a translocation domain (required for 
secretion) and a cryptic signal that recognises thymine as the first base of the DNA-binding site (Sanjana et 
al. 2012); the C-terminus contains a nuclear localisation signal (NLS) and an acidic activation domain 
(AAD) required for transcription factor function (Bogdanove et al. 2010). The DNA-binding array is made 
up of 1.5-33.5 monomer repeats or monomers. Each monomer recognises one base of DNA, with specificity 
conferred by the repeat variable di-residue (RVD). The four most common RVDs recognise one of the four 
bases of DNA: NG recognises thymine, NI recognises adenine, HD recognises cytosine, and NN recognises 






Figure 1.4 TALENs bound to target site. TALENs bind in pairs, binding opposite strands of DNA. The 
distance between the two TALEN target sites is crucial to allow the FokI nuclease catalytic domains to 
dimerise and must be 14-20 bp. Once activated, FokI cleaves the DNA on both strands resulting in a DSB. 
Unlike ZFNs, TALENs bind their targets in a forward orientation, so that cleavage occurs at the 3’ end of 
each half site. Figure adapted from Sanjana et al. (2012).
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The Zhang laboratory devised a method for TALEN construction (Sanjana et al. 
2012), which uses a hierarchical ligation strategy and makes use of the powerful 
Golden Gate cloning technique (Engler et al., 2009, 2008; Weber et al., 2011; 
oulined in Figure 1.5). The first stage involves the production of a monomer library 
by PCR amplification of the four monomers (containing the four most common 
RVDs – NG, NI, HD, and NN) using primers with ligation adapters, resulting in 18 
different monomers for each of the four templates (72 monomers in total). The 
ligation adapters are designed such that the position of each monomer within the 
array is uniquely defined. Once generated, this library can be used to construct arrays 
containing any combination of monomers, allowing the construction of TALENs 
containing any combination of monomers in their DNA-binding domains.  
Following identification of an appropriate target site, the sequence of monomers is 
divided into three groups of six – termed hexamers. Monomers from the library are 
ligated into circular hexamers using the first Golden Gate cloning reaction (Figure 
3.2, Stage 3). Treatment with PlasmidSafe DNase degrades any non-ligated products, 
as only correctly assembled hexamers can circularise.    
Each hexamer is then amplified, gel purified and ligated into the appropriate 
backbone plasmid using the second Golden Gate cloning reaction. Constructed 
plasmids are then transformed in to competent E. coli. To assess the fidelity of the 
assembly, a colony PCR is carried out and positive colonies are picked for plasmid 
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Figure 1.5 Construction of TALENs. The method devised by Sanjana et al. (2012) uses a hierarchical 
ligation strategy. Stage 1: Production of a library of monomers containing ligation adapters, which will 
specify their position in the monomer array. Stage 2: Individual monomers are ligated to form three 
hexamers (1-6, 7-12 and 13-18) using the Golden Gate cloning strategy. Stage 3: Each ligation adapter is 
designed so that the correctly ligated hexamers will form complete circles; any incorrectly ligated products 
are removed by the action of PlasmidSafe DNase. Stage 4: Correctly, ligated hexamers are individually 
amplified to create linear molecules. Stage 5: The three hexamers are ligated into an appropriate backbone 
vector (which encodes the N- and C-termini, including the cryptic T signal and 0.5 repeat) using the second 
Golden Gate reaction. Stage 6: Assembled TALENs are transformed into competent E. coli, successful 
clones are purified, and sequence verified. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Protocols (Sanjana et al. 2012), copyright (2012).
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TALENs appear to be very specific, with few if any off-target events reported 
(Guilinger, Pattanayak, et al. 2014; Hockemeyer et al. 2011; Mussolino et al. 2011) 
and side by side comparisons show reduced off-target induced cytotoxicity compared 
to ZFNs for some target sites (Mussolino et al. 2011).  
TALENs have been successfully used in a range of tissues and in the generation of 
transgenic animals, including but not limited to zebrafish, mice, pigs and cows 
(Wright et al. 2014). 
Building on the success of trials using ZFNs for treatment of HIV-1 infection 
(detailed above), recent studies have demonstrated the potential of TALENs in both 
the eradication of integrated provirus (Ebina et al. 2015; Strong et al. 2015) and also 
in the prevention of viral entry via CCR5 disruption (Mock et al. 2015; Mussolino et 
al. 2014).  
In addition to nuclease activity, TALEs have the potential to be fused with an array 
of functional domains such as transcriptional activator domains (e.g. VP64), 
repressor domains and chromatin remodelling domains, e.g. cytidine deaminases, 
HATs and DNMTs (Bogdanove and Voytas, 2011) enabling highly specific genome 
editing and regulation.  
1.3.3.4 Clustered, Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/ CRISPR Associated 9 (Cas9) 
The latest development in SSN technology is the CRISPR/ Cas9 system (Cong et al. 
2013; Mali, Yang, et al. 2013; Jinek et al. 2012). Based on the prokaryotic type II 
CRISPR/Cas system, this technology has been adapted for use in mammalian (and 
other) model systems. The prokaryotic CRISPR/Cas systems act like adaptive 
immune systems in bacteria and archaea, identifying and targeting the degradation of 
invading nucleic acid species through short complementary RNAs expressed from 
the CRISPR locus. This locus is composed of short sequences, termed spacers, 
acquired from the integration of DNA from invading viruses or plasmids separated 
by direct repeats. In the type II system, these are expressed as long pre-CRISPR 
RNAs (pre-crRNAs), which are processed by association with trans-activating 
crRNAs (tracrRNAs), RNase III, and Cas9 to produce mature crRNAs. Mature 
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crRNAs interact with tracrRNAs via their repeat sequences (Jinek et al. 2012) and 
form a complex with Cas9. This recognises invading nucleic acid species, through 
complementarity between the crRNA and sequences within the invading nucleic 
acid, termed protospacers as they gave rise to the spacer sequence in a prior 
infection. This leads to the direct cleavage of the incoming DNA species via the 
action of the Cas9 nuclease. Cas9 contains two nuclease domains, homologous to 
HNH and RuvC endonucleases; in wild type Cas9, the HNH-like domain cleaves the 
complementary DNA strand whilst the RuvC-like domain cleaves the non-
complementary DNA strand (Jinek et al. 2012). Cleavage of the target by Cas9 is 
dependent on both base-paring between the crRNA and the presence of a specific 
motif adjacent to the genomic target site known as the protospacer adjacent motif 
(PAM; Jinek et al., 2012). 
The most widely used system for gene editing is based on that of Streptococcus 
pyogenes. It is composed of two main elements: the synthetic single guide RNA 
(sgRNA), and the Cas9 protein (Cong et al., 2013; Jinek et al., 2012; Mali et al., 
2013c; Figure 1.6). The sgRNA is a fusion of the crRNA and the tracrRNA, 
obviating the need for RNase III, and is responsible for target recognition and 
binding via a 20-bp region homologous to the target DNA (protospacer). Interaction 
of the sgRNA with the Cas9 causes a conformational change in the Cas9 protein, 
which facilitates the recognition and binding of the target site in a PAM-dependent 
manner (Anders et al. 2014). Indeed, recognition of the PAM is a prerequisite for 
ATP-dependent strand separation and subsequent sgRNA-target DNA heteroduplex 
formation (Sternberg et al. 2014). The PAM motif for S. pyogenes Cas9 is 5’-NGG, 
which must be present directly 3’ to the target; cleavage occurs 3-bp upstream of the 
PAM (Jinek et al. 2012).  
Unlike ZFN or TALEN technologies, CRISPR/Cas9 does not require the 
reengineering of proteins in order to redirect its target specificity, meaning it is both 
quick and cost effective to produce sgRNAs targeting any loci of interest. Once 
target sites have been identified, oligonucleotides encoding the 20-bp sgRNA target 
sequence (and its reverse compliment) with 5’ ligation adapters can be synthesised 
(Figure 1.7). These oligonucleotides are annealed and phosphorylated, then cloned 
 
 
Chapter 1 Introduction   27 
 
into the backbone vector encoding the sgRNA scaffold, using a Golden Gate reaction 
(Figure 1.7). Constructed plasmids are transformed into E. coli, isolated, purified and 
then sequence verified.  
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Figure 1.6 CRISPR/Cas9 target recognition and cleavage. The sgRNA binds to its genomic target via 
Watson-Crick base pairing, this allows Cas9 to bind and cleave the target sequence following recognition 
of the PAM in the form 5’-NGG for S. pyogenes. Cas9 cleaves the target locus approximately 3-bp 
upstream of the PAM, resulting in a blunt-ended DSB. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Protocols (Ran, P D Hsu, et al. 2013), copyright (2013). 
 
Figure 1.7 sgRNA construction using the Zhang group method (Ran, P D Hsu, et al. 2013). 
Oligonucleotides encoding the top and bottom of the 20-bp target (blue) with ligation adapters are 
synthesised. These are annealed and phosphorylated before ligation into the backbone plasmids using a 
Golden Gate cloning reaction. The backbone plasmid encodes the sgRNA scaffold and a human codon 
optimised Cas9 or Cas9n. In addition, a puromycin resistance gene allows for successfully transfected cells 
to be selected. Reprinted by permission from Macmillan Publishers Ltd: Nature Protocols (Ran, P D Hsu, 
et al. 2013), copyright (2013). 
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Shortly after its inception, it became apparent that relatively high frequency off-
target cleavage could occur (Fu et al. 2013; Hsu et al. 2013; Mali, Aach, et al. 2013; 
Pattanayak et al. 2013). These studies into the fidelity of the RNA-DNA interaction 
revealed that even in the presence of up to five base pair mismatches, the sgRNAs 
could target Cas9 activity, and activity at these sites could be equal to or greater than 
that observed for the intended target site (Fu et al. 2013). This is particularly 
apparent when these mismatches are found in the 5’ portion of the sgRNA – distal to 
the PAM sequence. Indeed, it was also shown that a PAM sequence of 5’-NAG 
could also support Cas9 activity. This was later confirmed by structural analysis of 
the Cas9 protein (Anders et al. 2014). In addition, each of these studies demonstrated 
that off-target activity appeared to be sgRNA dependent; individual guides could 
tolerate different mismatches (both number and location). Most of these studies 
indicated that this off target activity was linked to Cas9 concentration; stringency of 
target recognition is reduced when Cas9 concentration is increased (Hsu et al. 2013; 
Mali, Aach, et al. 2013; Pattanayak et al. 2013). This ability to recognise mismatches 
may be beneficial in the bacterial CRISPR/Cas systems, which are designed to target 
invading viral species that have rapidly evolving genomes; the ability to recognise 
similar but not exactly matching protospacers increases the repertoire of sequences 
that can be targeted.   
Different strategies were developed to address this issue. The double nickase strategy 
makes use of a mutant Cas9 protein: Cas9 nickase (Cas9n). Cas9n carries the D10A 
mutation, which renders its RuvC-like catalytic domain inactive; it induces single 
strand breaks – nicks – rather than DSBs (Figure 1.8). These nicks can be used to 
drive HR repair alone, or two sgRNAs targeting opposite strands of the DNA 
(between 0-pb and 30-bp between 5’ ends) can be used to form DSBs with 5’ 
overhangs (Figure 1.8; Mali et al., 2013a). If nicks are induced at off target sites, 
they are less mutagenic than DSBs as they are repaired via the base excision repair 
pathway, which like HR is much less error-prone than NHEJ. 
 
 













Figure 1.8 CRISPR/Cas9 double nickase strategy. Red lines indicate PAM sequence. In this case, targets 
are located in a tail-to-tail orientation which has been shown to be more efficient than a head-to-head 
orientation (Shen et al., 2014). This method is predicted to be far less mutagenic as off-target nicks have 
less mutagenic potential than off-target DSBs. In addition, the requirement for two sgRNAs reduces the 
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The orientation of the sgRNAs in relation to each other seems to affect the cleavage 
efficiency. Mali and colleagues (2013) indicated that 5’ overhangs are more efficient 
than 3’ overhangs at inducing an NHEJ repair response. However, Shen et al. (2014) 
showed equally robust NHEJ resulting from either 3’ or 5’ overhangs (generated 
using Cas9 nucleases deficient in either the HNH domain or the RuvC-like domain). 
However, they also demonstrated that tail-to-tail orientation is more efficient than 
head-to-head orientation at inducing indels. Though less frequent, Cas9n induced 
SSBs can still result in indels at off-target sites, indicating that some SSBs can be 
converted into DSBs and are repaired via NHEJ (Cho et al. 2014).  
In addition to the use of paired nickases, it was suggested that the use of shorter 
sgRNAs would also increase the stringency of binding site recognition as they would 
be more sensitive to mismatches, thus lead to reduced off target activity (Fu et al. 
2014). In their study, Fu and colleagues (2014) were able to demonstrate that 
sgRNAs containing 17-bp of homology could efficiently induce on-target indels and 
drive HR, but showed a better off target profile than their full length counterparts. 
Though again, sensitivity to mismatches, and thus ability to induce off-target events 
was guide dependent.  
More recently, FokI-Cas9 fusions have been utilised to further increase the fidelity of 
on-target activity and reduce potential off-target recognition (Guilinger, Thompson, 
et al. 2014; Tsai et al. 2014). This method makes use of the nuclease dead Cas9, 
which is fused to FokI. Due to the nature of FokI, nuclease activity can only occur 
when targets sites are positioned to allow for FokI dimerisation, as is the case for 
ZFNs and TALENs. This means that even if the sgRNAs bind to off-target sites, the 
FokI-Cas9 will not be active, unless an adjacent site allows for binding of another 
sgRNA. Indeed, Tsai and colleagues (2014) demonstrated that in a direct 
comparison, monomeric Cas9 nickase could induce indels at a much higher 
frequency than monomeric FokI-Cas9. In addition, they showed that monomeric 
Cas9 nickases could induce point mutations with relatively high frequency (Tsai et 
al. 2014).  
In a direct comparison, the CRISPR/Cas9 system showed more off-target activity 
than TALENs, but this was much lower than initial studies implied, and no off-target 
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activity was detected when a nickase Cas9 was used (Wang et al. 2015). Generally, 
studies investigating off-target activity suggest that this is less of an issue than first 
believed, especially if careful sgRNA design is implemented (Cho et al. 2014; 
Mandal et al. 2014; Smith et al. 2014; Suzuki et al. 2014; Veres et al. 2014).  
One of the benefits of the CRISPR/Cas9 system is the small size of the sgRNAs, 
making it amenable to multiplexing. This can be used for the deletion of large 
segments, by creating two DSBs either side of the region to be deleted (Canver et al. 
2014; Ran, Patrick D Hsu, et al. 2013; Ran, P D Hsu, et al. 2013; J. Zhou et al. 2014; 
Xiao et al. 2013; Gupta et al. 2013), though this has also been achieved with ZFNs 
(Lee et al. 2010). It can also be used to create precise genome rearrangements – 
inversions and translocations – to mimic those observed in diseases such as cancer 
(Choi & Meyerson 2014). In addition, this has the potential to target multiple genes 
simultaneously, which could streamline the production of transgenic animals with 
complex genotypes (Yang et al. 2013).  
Like the TALEN technology, CRISPR/Cas9 has been utilised for genomic 
manipulations other than nuclease activity, use of nuclease dead Cas9 conjugated to 
other enzymes, in particular VP64 for use as a transcriptional activator (Mali, Aach, 
et al. 2013), or repressors (Gilbert et al. 2013). Though other uses, including 
chromatin remodelling, modulation of genomic architecture and Cas9-guided 
recombinases have been proposed (Mali, Esvelt, et al. 2013).  
1.3.3.5 SSN-Mediated Homology Directed Repair (HDR) 
One of the key advantages of the SSNs is their ability to increase the efficiency and 
specificity of transgene integration via homology directed repair (HDR). Early 
studies demonstrated that the provision of a DNA DSB can increase the efficiency of 
transgene integration by several orders of magnitude (Choulika et al. 1995; Elliott et 
al. 1998; Liang et al. 1996; Rouet et al. 1994b). While ZFNs, TALENs, and 
CRISPR/Cas9 each have distinct methods for recognising, binding and cleaving their 
target sites (discussed above) each can be used to drive HDR by the provision of a 
repair cassette with appropriate homology to the target locus. This can be used for 
either gene repair or transgene insertion (Figure 1.9). 
 
 







Figure 1.9 SSN-mediated HDR. Targeted DSBs generated following activity of SSNs can be repaired using 
HDR if a repair template is provided. To make small changes, such as single base changes (often referred to as 
gene editing), the repair template can either be double stranded or single stranded. For larger changes, such as 
gene insertions, a dsDNA template is used (either plasmid or liner). 
 
 
In order for HDR to occur, a repair template must be provided, that can either be 
single stranded DNA (ssDNA) generally in the form of an oligonucleotide (ODN) or 
double stranded DNA (dsDNA), either in linear or circular form (plasmid).  
In their study, Urnov et al. (2005) used ZFNs to generate a single point mutation in 
the interleukin-2 receptor gamma chain (IL2Rγ) gene via HDR using a plasmid 
donor. They were able to achieve an HDR frequency of 18%, with 7% of events 
occurring biallelically. In addition, ZFNs have also been used to successfully 
integrate larger DNA fragments site-specifically. In their study, Moehle and 
colleagues (2007) were able to demonstrate HDR efficiencies of 5%, 6% and 15% 
for integration of a 1.5-Kb promoter-transcription unit, a 900-bp open reading frame, 
and a 12-bp tag, respectively.  
The development of TALENs greatly facilitated the ability to correct gene mutations 
and drive transgene integration, due to their relative ease of design and construction 
compared with ZFNs. This accelerated the use of gene editing particularly for 
potential therapeutic applications. For example, Sun et al. (2012) demonstrated that 
TALENs could be used to specifically edit the human β-globin (HBB) gene, 
associated with sickle cell disease. They were able to demonstrated that TALENs 
increased the editing efficiency >1000-fold and showed no detectable cytotoxicity. In 
addition, TALENs have been used in proof of principal experiments in patient-
derived iPSCs from SCID-X1 patients. Edited cells were capable of producing 
haematopoietic precursors as well as mature NK cells and T cell precursors 
expressing the correctly spliced IL-2Rγ (Menon et al., 2015).  
The advent of the synthetic CRISPR/Cas9 system further accelerated the use of gene 
editing. In their initial study, Mali et al. (2013) were able to demonstrate the use of 
this system for both small gene correction using an ssODN template and insertion of 
larger transgenes from plasmid vectors, with efficiencies greater than comparable 
TALENs. Subsequent studies have confirmed the efficiency of this system; Staahl 
and Doudna were able to demonstrate CRISPR/Cas9 mediated HDR rates of up to 
38% when the system components were delivered as ribonucleoprotein complexes. 
In addition, this system has greatly facilitated the production of transgenic animals 
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from a range of species (Quadros et al. 2015; Auer et al. 2014; Chen, Fenk, et al. 
2013).  
To further improve the efficiency of HDR, Yu et al. (2015) employed the use of 
small molecules to bias the outcome of DSB repair in favour of HDR over NHEJ. 
Using L755507 (a β3 adrenergic receptor partial agonist) and Brefeldin A (an 
inhibitor of retrograde transport from the endoplasmic reticulum to the Golgi 
apparatus), they were able to demonstrate efficiencies 3-fold higher for large 
insertions and up to 9-fold higher for point mutations. The mechanisms via which 
they increase the efficiency of HDR are yet to be elucidated.  
1.4 Target Sites for Long-Term Expression 
Targeted transgene insertion approaches rely on the selection of permissive loci, in 
order to achieve robust long-term expression of the transgene. As discussed above 
(Section 1.2.1), the local chromatin environment of the integrated transgene 
influences whether it will become silenced. In order to reduce the risk of transgene 
silencing, it is important to identify loci which can support transgene expression. It is 
generally understood that open chromatin is more easily targeted than 
heterochromatin, particularly by SSNs (van Rensburg et al. 2013). However, 
transgenes inserted by random integration strategies are more prone to PEs due to 
proximity to heterochromatin. In this work, I have investigated the potential of four 
human genomic loci to support robust long-term transgene expression: the adeno-
associated virus (AAV) integration site 1 (AAVS1); the human homologue of the 
mouse Rosa26 locus (hROSA26); the inosine monophosphate dehydrogenase 2 
(IMPDH2) gene and the eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) 
gene.  
1.4.1 AAVS1 Locus 
The AAVS1 locus was first identified as a preferred site for AAV integration (Kotin 
et al. 1992). It spans approximately 4-Kb on chromosome 19 (position 19q13.42) and 
overlaps exon one of the PPP1R12C gene (also known as MBS85), which encodes 
protein phosphatase 1 regulatory subunit 12C (PPP1R12C). AAVS1 appears to be 
evolutionarily conserved in mammals, with homologues identified in both mouse and 
African green monkey (Dutheil et al. 2004). Investigation of the human locus 
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revealed a DNase I hypertensive site, which is suggestive of an open chromatin 
structure. In addition, an insulator sequence, capable of preventing the spread of 
heterochromatin, was identified at this locus (Ogata et al. 2003). More recently 
Sadelain and colleagues (2012) proposed AAVS1 as a potential ‘safe harbour’ locus 
for transgene integration. It has been shown to be transcriptionally active, lying 
within an open chromatin environment amenable to transgene expression in both 
iPSCs and haematopoietic stem cells (van Rensburg et al. 2013). While integration 
here disrupts PPP1R12C, no adverse consequences have been reported following 
integration. In their study, Henckaerts and colleagues (2009), demonstrated that 
AAV-mediated insertion at AAVS1 results in a partial duplication at the target site, 
thus preserving the PPP1R12C gene. Other studies using AAV-mediated transgene 
integration have also made use of AAVS1. Recchia et al. (2004) showed that 
transgenes can be successfully delivered by adenoviral-AAV hybrid vectors in a 
mouse model as a proof of concept for potential gene therapy.  
AAVS1 has been extensively studied for its ability to support transgene integration 
and expression. Chang and Bouhassira (2012) demonstrated the ability of AAVS1 to 
support integration of a globin transgene following ZFN targeting in iPSCs, as a 
proof of concept for the treatment of α-thalassemia. Transgenes integrated here show 
robust, long-term expression; DeKelver and colleagues (2010) demonstrated that 
transgene constructs integrated at this locus exhibit prolonged expression for at least 
50 generations in a range of cell types. In addition, Smith et al. (2008) were able to 
demonstrate expression of transgenes here even after stem cell differentiation.  
More recently studies using TALENs have further demonstrated the use of this site 
for stable transgene expression in a range of cells. Cerbini at al. (2015) showed that 
AAVS1 could be used as a site for the efficient generation of modified iPSC cells. In 
addition, transgene expression at this site has been extensively characterised, 
particularly in human pluripotent stem cells (Tiyaboonchai et al. 2014).   
1.4.2 hROSA26 Locus 
The hROSA26 locus was first identified as the human homologue of the mouse 
Rosa26 locus (Irion et al. 2007). It is located on human chromosome 3 (position 
3p25.3) in close proximity to the THUMPD3 gene, similar to the mouse Rosa26 
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which overlaps ThumpD3 (Irion et al. 2007). The hROSA26 locus encodes a long 
non-coding RNA, THUMPD3-AS1, whose function is yet to be elucidated. Since its 
discovery over two decades ago in a retroviral gene-trapping screen (Friedrich & 
Soriano 1991), the mouse Rosa26 locus has been commonly used in the creation of 
transgenic animals, as it demonstrates ubiquitous expression during development and 
is not prone to transgene silencing (Zambrowicz et al. 1997). Initial studies of the 
human ROSA26 locus have demonstrated its potential as a transgene integration site. 
Irion and colleagues (2007) showed that it has a broad expression pattern in adult 
tissues and stem cells; transgenes integrated here could be expressed in all three germ 
cell layers following stem cell differentiation. This locus is also conserved, with 
homologues identified in both rat (Kobayashi et al. 2012) and pig (Li et al. 2014), 
both of which show potential as transgene integration sites. Studies of the mouse 
Rosa26 locus have revealed that expression is both promoter and orientation-
dependent; some promoters demonstrate significant differences in expression in a 
sense compared to antisense orientation (Chen et al. 2011).   
1.4.3 IMPDH2 Gene  
The IMPDH2 locus also located on chromosome 3 (position 3p21.31) encodes 
inosine monophosphate dehydrogenase 2 (IMPDH2), responsible for catalysing the 
first committed and rate-limiting step of guanine nucleotide biosynthesis. It is 
believed to be essential for cell survival, and IMPDH2 null mice die in early 
embryogenesis (Gu et al. 2003). In humans there are two IMPDH isoforms, IMPDH1 
and IMPDH2 which both carry out the same function and are expressed to varying 
degrees in most tissues. Both isoforms can be specifically inhibited by the drug 
mycophenolic acid (MPA), making this an attractive locus for the development of a 
drug-selectable transgene integration system (discussed in Chapter 4).  
1.4.4 EEF1A1 Gene  
EEF1A1 encodes the eukaryotic translation elongation factor 1 alpha 1 (eEF1A1). It 
is located on chromosome 6 (position 6q14). Humans also have a second eEF1A 
isoform, eEF1A2, encoded by EEF1A2 on chromosome 20. They are both 
responsible for providing aminoacyl-tRNA (aa-tRNA) molecules to the ribosome 
during the translation phase of protein synthesis. EEF1A1 is almost ubiquitously 
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expressed (Cho et al. 2012), except in a few tissues in which it is replaced by 
EEF1A2 during early postnatal development. The eEF1A1 isoform is believed to be 
expressed in all immortalised cell lines, as such could provide a good site for 
transgene integration. The two proteins are 92% identical at the amino acid level, 
have very similar structures (Soares et al. 2009), and translation efficiencies (Kahns 
1998). The reasons why eEF1A1 is replaced by eEF1A2 in a handful of tissues 
remain to be elucidated, but may potentially be due to differences in their 
moonlighting capacities. In addition to translation, eEF1A has variously been 
implicated in transformation susceptibility (Tatsuka et al. 1992), protein degradation 
and apoptosis (Cho et al. 2012), interactions with the cytoskeleton (Condeelis 1995), 
viral propagation (Mateyak & Kinzy 2010), and ageing (Shepherd et al. 1989). To 
what extent each isoform is involved remains to be confirmed.  
1.5 Applications  
My laboratory, as part of the UK cystic fibrosis (CF) gene therapy consortium 
(UKCFGTC), is interested in the development of recombinant lentiviral vectors for 
use in forthcoming CF clinical trials, which build upon previous trials using a lipid-
based vector (Alton et al. 2015). As such, it would be advantageous to develop a 
lentiviral producer cell line, which could be used for the production of large amounts 
of clinical-grade lentiviral vectors for use in future clinical trials. Once loci, which 
can support robust long-term transgene expression, have been identified and 
validated, they could be used – along with validated SSNs – to express components 
of the lentiviral genome, which would provide a source of clinical grade lentiviral 
vectors.  
Current methods of lentiviral vector production generally rely on transient 
transfection with a DNA cocktail encoding the components of the lentiviral genome, 
typically encoded on three or four separate plasmids, along with the transgene of 
interest. While this successfully generates high lentiviral titres, this method often 
shows poor reproducibility, scale up can be difficult and it requires large amounts of 
highly pure plasmid DNA, which can be challenging and costly to generate.   
One of the problems of lentiviral production is that some viral components are 
cytotoxic – particularly the commonly used envelope protein, G protein from 
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vesicular stomatitis virus (VSV-G) – meaning that prolonged expression is 
impractical. To avoid this, many lentiviral vectors used to date in clinical trials have 
been derived from transient transfection (Aiuti et al. 2013; Biffi et al. 2013; Tebas et 
al. 2013; Cartier et al. 2009).  
To overcome issues of cytotoxicity, inducible promoters can be used so that 
expression of cytotoxic viral components can be turned on only as required. 
Inducible stable producer lines have been successfully generated for some viral 
vectors (Greene et al. 2012; Throm et al. 2009a), however instability of the inducible 
promoters can lead to loss of viral production (Broussau et al. 2008; Ni et al. 2005; 
Farson et al. 2001). In addition, these methods require further purification steps to 
remove induction agents from the harvested virus.  
Identification of loci, which can sustain prolonged transgene expression, and the 
development of tools (namely SSNs) with which to target these sites rapidly and 
precisely, will help to streamline future production of stable producer cell lines. SSN 
technologies will also aid the alteration of developed lines so that alternative 
envelope proteins or different transgenes can be utilised as desired.  
Gene-specific editing can also be used in the study of gene function. In addition to 
their ability to drive the targeted insertion of transgenes, or other exogenous genetic 
material, SSNs can be used to selectively disrupt gene function. This occurs when no 
repair template is provided; the induced DSB is repaired by the cell’s NHEJ repair 
pathway, which is error prone and often results in indels at the site of repair. These 
indels can lead to introduction of stop codons or frame shift mutations and ultimately 
loss of gene expression. This allows for the generation of knockout cell lines or 
transgenic animals in order to study the consequences of the loss of gene function. 
This can be achieved at both the single gene and genome wide level. All of the SSN 
platforms mentioned have been used to successfully generate specific gene 
knockouts in a range of cells and animal models (Carlson et al. 2012; Flemr & 
Bühler 2015; Gaj et al. 2012; Yang et al. 2014; Wettstein et al. 2015). However, the 
ability to multiplex the CRISPR/Cas9 system has allowed for the development of 
genome wide libraries, which can be used for recessive screens (Shalem et al. 2014a; 
Bassett et al. 2015; Koike-Yusa et al. 2013).  
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1.6 Aims  
The main aim of this work was to develop SSNs – particularly TALENs and 
CRISPR/Cas9 – to target each of the four chosen loci and use these to investigate the 
potential of each site to support transgene expression and robust long-term 
expression, as a proof of principle for the development of stable lentiviral producer 
cell lines. In addition, I aimed to develop a drug-selectable transgene integration 
system at the IMPDH2 locus, which would allow for rapid selection of correctly 
integrated transgenes. Finally, I aimed to use SSN technology to generate an 
EEF1A1 knockout cell line, which I could use to investigate the potential 
moonlighting functions of the eEF1A2 isoform.
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Chapter 2  Materials and Methods   
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2.1 General Methods  
2.1.1 Polymerase Chain Reaction 
DNA was amplified using the polymerase chain reaction (PCR). PCR was carried out 
using either Taq polymerase (Sigma-Aldrich®), Q5 high fidelity polymerase (NEB) 
or Herculase II Fusion polymerase (Agilent). The reaction compositions for each are 
given below:  
Taq Polymerase  
Reaction buffer (10x) 1x 
dNTP mix (10 mM)  200 µM (each) 
Forward Primer (10 µM) 0.1 µM 
Reverse Primer (10 µM)  0.1 µM 
Taq   0.05 U 
NF-Water Up to 50 µL 
  
Q5 High Fidelity Polymerase   
Reaction buffer (5x) 1x 
dNTP mix (10 mM) 200 µM (each) 
Forward Primer (10 µM) 0.5 µM 
Reverse Primer (10 µM) 0.5 µM 
Q5 0.02 U/µL 
CG Enhancer (5x) 1x 
NF-Water Up to 50 µL 
  
Herculase II Fusion Polymerase  
Reaction buffer (5x) 1x 
dNTP mix (10 mM) 250 µM (each) 
Forward Primer (10 µM) 0.25 µM 
Reverse Primer (10 µM) 0.25 µM 
Herculase 1 µL 
NF-Water Up to 50 µL 
 
The cycling conditions used for each polymerase are listed below; annealing 
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Taq Polymerase 
94°C 1 min  
94°C  1 min   
Tm° 2 min  30 cycles  
72°C 90 sec  
72°C 5 min   
4°C ∞  
  
Q5 High Fidelity Polymerase 
98°C 30 sec  
98°C  10 sec  
Tm° 30 sec 30 cycles  
72°C 30 sec/Kb  
72°C 2 min   
4°C ∞  
 
Herculase II Fusion 
Polymerase 
95°C 2 min  
95°C  20 sec   
Tm° 20 sec  30 cycles  
72°C 30 sec/Kb   
72°C 3 min   
4°C ∞  
 
2.1.2 Manipulation of Nucleic Acids 
2.1.2.1 Agarose Gel Electrophoresis  
DNA was visualised using agarose gel electrophoresis. 1-2% agarose gels, according 
to the size of DNA fragments to be visualised, were made by dissolving UltraPure™ 
agarose (Invitrogen™) in 1x TBE buffer and heating. SYBR-Safe DNA Gel Stain 
(Invitrogen™) was added from a 10,000x stock to a final concentration of 1x. DNA 
samples were mixed with Orange G buffer prior to loading. DNA size markers were 
run alongside samples to estimate the size of DNA, routinely the 1-Kb Plus DNA 
ladder (Invitrogen™) and the HyperLadder™ 50bp (Bioline) were used. 
Electrophoresis was carried out at 100V in 1x TBE buffer.  
2.1.2.2 DNA Purification  
DNA was purified either using spin columns or by gel extraction methods. Following 
PCR, products were purified using the Wizard SV Gel and PCR Purification System 
Kit (Promega), according to the manufacturer’s instructions. When DNA needed to 
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be separated from products of different sizes, gel extraction was carried out using the 
same kit, after excision of the band from the agarose gel. Purified DNA was eluted in 
NF-water.  
2.1.2.3 DNA Quantification  
DNA concentration was analysed using a NanoDrop1000 Spectrophotometer 
(Thermo Scientific). Purity was assessed using the ratio of absorbance at 260 nm and 
280 nm wavelengths.  
2.1.2.4 Digestion by Restriction Enzymes 
All restriction enzymes were purchased from Roche or NEB. Reactions were carried 
out using optimal buffers, as recommended by the manufacturers. Double digests 
were only carried out where compatible buffers were available. All reactions were 
carried out in a 20 or 25 µL total volume and digestions were incubated at 37°C 
overnight.  
2.1.2.5 Ligations  
Fragments with cohesive ends were ligated overnight at 16°C using T4 DNA ligase 
(NEB). To maximise the ligation efficiency, 1:3 vector:insert molar ratios were used.   
2.1.2.6 TOPO® Cloning  
To sequence individual PCR amplicons, PCR products were cloned using the 
TOPO® TA for sequencing kit (Invitrogen™), according to the manufacturer’s 
instructions. Briefly, 4 µL fresh PCR product (generated with a non-proofreading 
enzyme to ensure presence of 3’-deoxythymidine overhangs) was ligated into a 
pCR™4-TOPO TA vector, by incubation at room temperature for 5 minutes. 
Ligations were transformed using One Shot® TOP10 chemically competent 
Escherichia coli cells (Invitrogen™), according to the manufacturer’s instructions. 
2.1.2.7 Blunt-ended Cloning  
Blunt-ended PCR products were cloned into the pJET1.2/blunt cloning vector, using 
a CloneJET PCR cloning kit (Thermo Scientific). An insert:vector ratio of 3:1 was 
used. Products were ligated using T4 DNA ligase, at room temperature for 30 
minutes. Ligations were immediately transformed using DH5α chemically competent 
E. coli (Invitrogen™) as described in Section 2.3.1.  
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2.1.3 Sequencing 
Sequencing of constructed TALENs was performed by DNA Sequencing & Services 
(MRC PPU, College of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big-Dye version 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. 
All other sequencing was carried out in house using Applied Biosystems Big-Dye 
version 3.1 chemistry. PCR products were first treated with Exo-SAP-IT 
(Affymetrix), 2 µL per 5 µL of PCR product, incubated at 37°C for 15 minutes 
followed by 80°C for 15 minutes.  
The sequencing reaction was set up with the following components:  
Template DNA 2 µL PCR product/ 200ng Plasmid 
Big Dye 1 µL 
Big Dye Buffer (5x) 1.5 µL 
Primer (3.2 µM) 1.5 µL 
NF-Water  up to 10 µL 
 
These were incubated under the following cycling conditions:  
96°C 1 min  
96°C  10 sec  
50° 10 sec 30 cycles  
60°C 4 min  
 
Analysis was carried out by the sequencing technician Agnes Gallagher using an 
Applied Biosystems Genetic Analyzer, model 3130/3730. Interpretation of the results 
was carried out using Geneious® software (version 8.1.6).   
2.1.4 Site-Directed Mutagenesis  
Site directed mutagenesis was carried out to create the IMPDHIY variant cDNA. 
Human IMPDH2 cDNA was purchased from Source Bioscience (clone IRAK12 
A06) and used as a template for site directed mutagenesis. This was carried out using 
the Q5 site directed mutagenesis kit (NEB). In addition, a codon optimised T. foetus 
IMPDH cDNA was synthesised and subcloned into the pcDNA3.1/Zeo(+) vector by 
GeneArt® (Life Technologies).  
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The following primers were used to introduce the sequence changes during the 
exponential amplification stage using Q5 polymerase:  
Forward: 5’-CCAAGCAACAGCAGTGTACAAGGTGTACGAGTATGCACGGCGCTTT 
Reverse: 5’-GGCCGCCCACAGGCCAGCACTTCCTGGATAATGCAGATGGAGCCAC 
This was carried out using the following cycling conditions:  
98°C 30 sec  
98°C  10 sec  
63° 30 sec 25 cycles  
72°C 3 min  
72°C 2 min  
4°C ∞  
 
Amplified product was then subjected to kinase, ligase, DpnI (KLD) treatment; 1 µL 
PCR product was mixed with 5 µL 2x KLD reaction buffer and 1 µL KLD enzyme 
mix in a 10 µL reaction. This was incubated at room temperature for 5 minutes, then 
transformed into NEB 5-alpha competent E. coli, according to the manufacturer’s 
instructions. Plasmids were verified by sequencing and re-isolated using the 
peqGOLD XChange Plasmid Maxi EF Kit (peqlab), to produce sufficient yield for 
subsequent applications.  
2.1.5 Quantitative PCR  
2.1.5.1 cDNA Synthesis 
Synthesis of cDNA was carried out using a nanoScript 2 reverse transcription kit 
(Primerdesign) with an oligo dT primer, according to the manufacturer’s instructions. 
For each RNA sample, a control with no reverse transcriptase was included, to assess 
potential genomic DNA contamination.  
Following synthesis, a control PCR was carried out to check for potential 
contamination using the following primers:  
Forward: 5’-CGGTGTCTGTAGTGGCTTGA 
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This resulted in a product of 238-bp from the cDNA template and 981-bp from a 
genomic DNA template. The PCR was carried out using the following cycling 
conditions:  
98°C 30 sec  
98°C  10 sec  
65°C (-1°C/cycle) 30 sec 10 cycles  
72°C 30 sec  
   
98°C 10 sec  
55°C 30 sec 30 cycles 
72 °C 30 sec  
72 °C 2 min  
4 °C ∞  
 
Products were analysed using agarose gel electrophoresis. Any samples that 
contained genomic DNA contamination were discarded.  
2.1.5.2 geNORM 
A geNORM reference gene kit (Primerdesign) was used to identify appropriate 
reference genes. Reactions were carried out using a panel of six reference genes in all 
cDNA samples. The stability of each reference gene across all samples was 
calculated using qbase+ software (Biogazelle).  
2.1.5.3 Quantitative PCR 
Reactions were carried out using PrecisionPLUS master mix (Primerdesign) with 
SYBR green chemistry. 10 µL reaction volumes were used, with 2.5 µL cDNA at 
1:200 dilution. Each sample was run in triplicate. Primers are listed in Table 2.1. 
Reactions were carried out on an Applied Biosystems 7900HT Fast Real-Time PCR 
detection system using the following cycling conditions:  
95°C 2 min  
95°C  20 sec  
40 cycles  
60°C* 20 sec  
Melt curve  
 
 
* Data acquisition  
Data analysis was carried out using SDS 2.3 software. Samples were excluded from 
analysis if there was a difference between their Ct value and the Ct values of the 
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other replicates in their group (each sample was run in triplicate) of greater than 1 Ct. 
Expression was calculated using the following formula:  
Quantity = 10^((Ct value – Y-intercept)/Slope)    
Y-intercept and Slope were determined from the standard curve for each primer pair.  
Mean expression of each triplicate was normalised to the geometric mean of five 
reference genes, determined by geNORM analysis.  
Table 2.1 qPCR primers. The AAVS1 and hROSA26 loci are not genes, therefore genes in these regions 
were selected to act as surrogate markers of transcriptional activity at these sites, given in parentheses.      
* Primers were designed by Primerdesign;† primer sequence taken from Irion et al. (2007). 
Target Site Primer  Sequence  
AAVS1 
(PPP1R12C) 
Forward  CGCGAGAAGATTTCCCTCCA 
Reverse  CTCTTCAAGCTGCACGGGAC 
hROSA26† Forward  TTATCCGTTGCGTAAGCACAGAGAGG 
(THUMPD3-
AS1) 
Reverse  AGCCTCTGCACACCGTGAGAATAA 
IMPDH2 Forward  CCCAGGCCAAGAACCTCATT 
Reverse  GCCAGCATTCCTGCGTAA 
EEF1A1* Forward  TTTGGGTCGCTTTGCTGTTC 
Reverse  CTTCTTGTCCACTGCTTTGATGA 
EEF1A2* Forward  GTATTGACAAAAGGACCATTGAGAAG 
Reverse  CAGCACCCAGGCATACTTGA 
 
2.1.6 Western Blotting  
2.1.6.1 Protein Quantification and Normalisation 
A BCA protein assay kit (Thermo Scientific) was used to measure the protein 
concentration of each sample. 10 µL of each sample was mixed with 200 µL working 
reagent (reagent A and reagent B, 50:1 ratio), in triplicate, in a 96-well plate on a 
plate shaker for 30 seconds, then incubated at 37°C for 30 minutes. Once cooled to 
room temperature, absorbance was measured at a wavelength of 562 nm using a plate 
reader.  Protein concentration was calculated using a standard curve generated from a 
dilution series of protein standards. The concentration of all samples was normalised 
to that of the least concentrated sample by dilution with RIPA buffer. An equal 
volume of 2x Laemmli buffer was added to each sample, which were vortexed and 
incubated at 100°C for 7 minutes. 10% DTT was added from a 1 M stock solution 
and samples were stored at -20°C.  
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2.1.6.2 SDS-PAGE 
The BioRad Mini PROTEAN 3 mini-gel apparatus was used according to the 
manufacturer’s instructions. 15 µL of prepared protein samples were run on 10% 
SDS-PAGE gels (4.3% stacking gel) at 150 V at 4°C in 1x Tris/Glycine/SDS buffer 
(BioRad) until the dye front reached the bottom of the gel. The prestained broad 
range protein marker (NEB) was routinely run alongside experimental samples to 
estimate protein size.   
2.1.6.3 Blotting 
The BioRad Mini Trans-blot Electrophoretic Transfer Cell was used to carry out 
Western blotting. Immobilon®-FL PVDF membrane (Merck Millipore) was first 
pre-wet in 100% methanol. The membrane, gel, filter papers and sponges were all 
soaked in 1x transfer buffer. The sponge, filter paper, gel and membrane were all 
stacked and assembled into the apparatus. The tank was the filled with 1x transfer 
buffer and run at 100 V at 4°C for 1 hour. Membranes were dried at 40°C for 15 
minutes.  
2.1.6.4 SYPRO® Ruby Total Protein Staining 
To ensure even and complete protein transfer, membranes were treated with 
SYPRO® Ruby Protein Gel stain (Thermo Scientific). All incubation steps were 
carried out on an orbital shaker at room temperature. Dried membranes were re-wet 
in 100% methanol. The membranes were then incubated in 7% (v/v) acetic acid/ 
10% (v/v) methanol for 15 minutes, then washed four times in distilled water, 5 
minutes per wash. The membranes were then incubated with SYPRO® Ruby for 15 
minutes in the dark and then washed four times with distilled water for 1 minute 
each. The membranes were then visualised using the Odyssey® Fc imaging system 
(LI-Cor) at a wavelength of 600 nm.  
2.1.6.5 Antibody Probing of Western Membranes 
All incubation steps were carried out on an orbital shaker at room temperature, 
unless otherwise stated. Membranes were blocked by incubation in Odyssey® 
Blocking Buffer (PBS) (LI-Cor) mixed 1:1 with PBS, at 4°C overnight. Membranes 
were then incubated with primary antibodies diluted in Odyssey® Blocking Buffer 
(PBS) for 2 hours. Membranes were then washed four times in PBS-T, 5 minutes per 
 
 
Chapter 2 Materials and Methods   50 
wash. Membranes were then incubated with fluorescent secondary antibodies (LI-
Cor), diluted 1:5000 in Odyssey® Blocking Buffer (PBS), for 1 hour. Finally, the 
membranes were washed four times in PSB-T, 5 minutes per wash and visualised 
using the Odyssey® Fc imaging system, at 600 nm, 700 nm, and 800 nm 
wavelengths as appropriate.  
Image analysis and quantification was carried out using Image Studio Lite (version 
4.0); for each sample band intensities were normalised to the band intensities of the 
loading control for each sample (GAPDH or Tubulin).  
Table 2.2 Western Blot antibodies.  
Antibody Working Dilution  
Sheep anti-eEF1A1 1:2000 
Mouse anti-Myc (Santa Cruz) 1:2000 
Mouse anti-GAPDH (Merck Millipore) 1:1000 
Rabbit anti-Tubulin (ABCAM) 1:5000 
Anti-rabbit (LI-Cor) 1:5000 
Anti-mouse (LI-Cor) 1:5000 
Anti-goat (LI-Cor) 1:5000 
 
2.2 SSN Construction and Validation 
2.2.1 TALEN Construction 
Target sites were identified using the online software available at https://tale-
nt.cac.cornell.edu/node/add/talen. All TALENs were constructed using the protocol 
developed by the Zhang laboratory (Sanjana et al. 2012), which is outlined below. 
All plasmids used in TALEN construction (Table 2.3) were a gift from Feng Zhang 
(Addgene, Kit #1000000019). 
Table 2.3 Plasmids used in TALEN Construction 
Plasmid Description 
pNI_v2 Monomer plasmid with NI RVD sequence 
pNG_v2 Monomer plasmid with NG RVD sequence 
pNN_v2 Monomer plasmid with NN RVD sequence 
pHD_v2 Monomer plasmid with HD RVD sequence 
pTALEN_v2 (NI) Backbone plasmid with NI 0.5 repeat  
pTALEN_v2 (NG) Backbone plasmid with NG 0.5 repeat 
pTALEN_v2 (NN) Backbone plasmid with NN 0.5 repeat 
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2.2.1.1 Monomer Library Construction  
Each monomer was amplified from a plasmid template (Table 2.3) using primers 
encoding ligation adapters, which define its position in the final monomer array 
(Table 2.4). Each monomer was amplified with 18 primer pairs, such that it could be 
positioned anywhere in the final array. An additional amplification was carried out to 
allow for construction of 17-mer arrays, required in the construction of the AAVS1-
targeting TALEN pair. This resulted in a library of 76 monomers. The primer mixes 
required are listed in Table 2.4.  
Table 2.4 Monomer library construction primers. Each primer pair adds adapters to the monomers such 





Position in Array 
Ex-F1 In-R1 1 
In-F2 In-R2 2 
In-F3 In-R3 3 
In-F4 In-R4 4 
In-F5 In-R5 5 
In-F6 Ex-R1 6 
Ex-F2 In-R1 7 
In-F2 In-R2 8 
In-F3 In-R3 9 
In-F4 In-R4 10 
In-F5 In-R5 11 
In-F6 Ex-R2 12 
Ex-F3 In-R1 13 
In-F2 In-R2 14 
In-F3 In-R3 15 
In-F4 In-R4 16 
In-F5 In-R5 17 
In-F5 Ex-R4 17 (17-mer array) 
In-F6 Ex-R3 18 
 
Monomers were amplified using the following components:  
Monomer template plasmid (5 ng/µL) 1 µL 
dNTPs (10 mM) 1 µL 
Herculase II PCR buffer (5x) 20 µL 
Primer mix (10 µM each) 2 µL 
Herculase II Fusion polymerase 1 µL 
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The reaction was performed using the following conditions:  
95°C 2 min  
95°C  20 sec   
60°C 20 sec  40 cycles 
72°C 10 sec  
72°C 3 min  
4°C ∞  
 
Each reaction was run in duplicate to give a greater yield. Amplified monomers were 
analysed by agarose gel electrophoresis, to ensure correct amplification. Duplicate 
samples were pooled and purified using the QIAquick® PCR purification kit 
(Qiagen®) according to the manufacturer’s instructions. Samples were eluted in 
100 µL Buffer EB. Each monomer was diluted to give a final concentration of 15 
ng/µL (monomers 1, 6, 7, 12, 18 and 18 were diluted to 18 ng/µL as these are 
slightly longer than the other monomers). The monomer library was stored at -20°C.  
2.2.1.2 Construction of Custom TALENs 
Target sequences were divided into three hexamers (for 18-mer arrays) or two 
hexamers and a pentamer (for 17-mer arrays). Each hexamer was assemble by a 
Golden Gate reaction, with the following components:  
BsmBI (10 U/µL) 0.75 µL 
Tango buffer (10x) 1 µL 
DTT (10 mM) 1 µL 
T4 DNA ligase (2000 U/µL) 0.25 µL 
ATP (10 mM) 1 µL 
Six monomers  1 µL each 
 
Reactions were incubated at 37°C for 5 minutes, then 20°C for 5 minutes for 20 
cycles. Ligations were verified by agarose gel electrophoresis. To remove 
unsuccessfully ligated products, the hexamers were treated with PlasmidSafe 
exonuclease, in the presence of ATP (1 mM final concentration) for 30 minutes at 
37°C followed by inactivation at 70°C for a further 30 minutes.  
Next, each hexamer was PCR amplified using Herculase II Fusion polymerase 
(Section 2.1.1), using Hex-F and Hex-R primers (Table 2.5). Products were 
electrophoresed using a 2% agarose gel, bands of the correct size were excised and 
DNA purified using the MiniElute gel extraction kit (Qiagen®) according to the 
 
 
Chapter 2 Materials and Methods   53 
manufacturer’s instructions. Products were eluted in 20 µL Buffer EB. Concentration 
was determined using a NanoDrop1000 Spectrophotometer and the concentration of 
each hexamer (or pentamer) was normalised by dilution with Buffer EB to a final 
concentration of 20 ng/µL. 
The hexamers were assembled into the appropriate backbone plasmid using a second 
Golden Gate reaction using the following components:  
TALE Backbone vector (100 µng/L) 1 µL 
BsaI-HF (20 /µL) 0.75 µL 
NEBuffer 4 (10x) 1 µL 
BSA (10x) 1 µL 
ATP (10 mM) 1 µL 
T4 DNA ligase (2000 U/µL) 0.25 µL 
Three purified hexamers (20 ng/µL each) 1 µL each 
NF-Water  2 µL 
 
The reaction was performed using the following cycling conditions:  
37°C 5 min 
20 cycles 
20°C  5 min 
80°C 20 min  
 
The constructed TALENs (5 µL Golden Gate reaction) were then transformed into 
50 µL DH5α chemically competent E. coli (Section 2.3.1). A colony PCR was 
carried out to identify colonies containing correctly constructed TALENs. Individual 
colonies were picked and streaked on to LB-amp plates, then swirled into 100 µL 
NF-Water. PCR was carried out using Taq (Sigma-Aldrich®) with TALE-Seq-F1 
and TALE-Seq-R1 primers (Table 2.5) on 1 µL of colony suspension. The following 
cycling conditions were used:  
94°C 3 min  
94°C  30 sec  
60°C 30 sec 30 cycles  
68°C 2 min  
68°C 5 min   
4°C ∞  
 
Products were examined following agarose gel electrophoresis. Positive colonies 
were inoculated into 5 mL LB with ampicillin and grown overnight at 37°C, 
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225 rpm. Plasmids were isolated using the QIAprep Spin miniprep kit (Qiagen®) 
according to the manufacturer’s instructions. Correct assembly of TALENs were 
confirmed by sequencing.  



































2.2.2 Construction of sgRNAs 
All sgRNAs were constructed using the protocol developed by the Zhang laboratory 
(Ran, P D Hsu, et al. 2013). All plasmids used in sgRNA construction were a gift 
 
 
Chapter 2 Materials and Methods   55 
from Feng Zhang (Addgene plasmids #48139 and #481411). Target sites were 
identified using online software available at http://crispr.mit.edu/ (Cong et al. 2013). 
Oligonucleotides encoding the top and bottom strands of the 20-bp target with 
ligation adapters were ordered from Sigma-Aldrich: 
Top: 5’-CACCGNNNNNNNNNNNNNNNNNNNN  
Bottom: 5’-AAACNNNNNNNNNNNNNNNNNNNNC  
They were annealed and phosphorylated using T4 PNK at 37°C for 30 minutes, 
followed by 95°C for 5 minutes then cooled to 25°C at -5°C per minute.  
Annealed and phosphorylated oligonucleotides were diluted 1:200 in NF-water, then 
cloned into a backbone plasmid (either pX459 or pX462) using a Golden Gate 
reaction with the following components: 
Backbone plasmid (100 ng/µL) 1 µL 
Diluted oligo duplex 2 µL 
Tango buffer (10x) 2 µL 
DTT (10 mM) 1 µL 
ATP (10 mM) 1 µL 
FastDigest BbsI 1 µL 
T4 Ligase 0.5 µL 
NF-Water  11.5 µL 
 
This was incubated at 37°C for 5 minutes then 21°C for 5 minutes for six cycles. 
Ligated products were treated with PlasmidSafe exonuclease, in the presence of ATP 
(1 mM final concentration) for 30 minutes at 37°C, followed by inactivation at 70°C 
for a further 30 minutes.  
Constructed plasmids were then transformed into DH5α chemically competent E. 
coli (Section 2.3.1). Plasmids were isolated using the peqGOLD Plasmid Miniprep 
kit (C-line) (peqlab), according to the manufacturer’s instructions. Correct 
construction was confirmed by sequencing using the U6-Fwd primer:  
5’-GAGGGCCTATTTCCCATGATTCC  
                                                 
1 Since the completion of this work, a point mutation in the puromycin resistance gene has been 
identified in these plasmids, which makes it less effective in some cell lines. Newer versions are now 
available (Addgene plasmids #62988 and #62987).   
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2.2.3 TALEN in vitro Cleavage Assay 
TALEN proteins were produced in vitro using the TNT® Quick Coupled 
Transcription/Translation System (Promega), according to the manufacturer’s 
instructions. To visualise proteins, reactions were carried out with and without 
Transcend™ Biotin-Lysyl-tRNA, so that the resulting proteins contained biotinylated 
lysine residues. Correct production was confirmed by western blot. Reactions were 
mixed with 2x Laemmli buffer, separated by SDS-PAGE, and transferred to 
membranes (section 2.1.6.3). Membranes were incubated in Western Blue® 
Stabilized Substrate for Alkaline Phosphatase, to visualise biotinylated proteins.  






The in vitro cleavage assay was carried out with non-biotinylated TALENS, using 
the following components: 
DNA target 200 ng 
BSA (10x) 1x 
NEBuffer 4 (10x) 1x 
NaCl (1 M) 0.1 M 
Right TALEN 1 µL  
Left TALEN 1 µL 
NF-Water  up to 10 µL 
 
These were incubated at 37°C for 90 minutes. Reactions were analysed using agarose 
gel electrophoresis.  
2.2.4 Surveyor Assay 
All assays were carried out using the SURVEYOR mutation detection kit for 
standard gel electrophoresis (Transgenomic).   
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2.2.4.1 Assay Optimisation 
For optimisation, the kit’s internal controls were used. PCR amplicons were 
generated from two plasmid templates – Control C and Control G – using the 
following primers:  
Forward: 5’-ACACCTGATCAAGCCTGTTCATTTGATTAC 
Reverse: 5’-CGCCAAAGAATGATCTGCGGAGCTT 
PCR was carried out using either Taq polymerase or Herculase II Fusion polymerase 
(Section 2.1.1), using an annealing temperature of 65°C. This resulted in two 
amplicons, which differed by a single base. In addition, amplification was carried out 
using Herculase II Fusion polymerase using PCR buffer from Sigma-Aldrich®. PCR 
products were analysed by agarose gel electrophoresis, to ensure correct size. PCR 
products were purified using the Wizard SV Gel and PCR Purification System Kit, 
according to the manufacturer’s instructions, and were eluted in Surveyor buffer. The 
concentration was determined using a NanoDrop 1000 Spectrophotometer and were 
diluted to 50 ng/µL in Surveyor Buffer.  
Samples were supplemented with 0.5x, 1x or 2x the standard concentration of 
Herculase II Fusion polymerase before or after cross-hybridisation. Cross-
hybridisation was carried out in a thermal cycler under the following conditions:  
 
95°C, 10 minutes 
95-85°C, -2°C/second 
85°C, 1 minute 
85-75°C, -0.3°C/second 
75°C, 1 minute 
75-65°C, -0.3°C/second 
65°C, 1 minute 
65-55°C, -0.3°C/second 
55°C, 1 minute 
55-45°C, -0.3°C/second 
45°C, 1 minute 
45-35°C, -0.3°C/second 
35°C, 1 minute 
35-25°C, -0.3°C/second 
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Following cross hybridisation, DNA was digested with Surveyor nuclease, using the 
following components:  
MgCl2 (0.15 M) 2 µL 
Surveyor nuclease S 1µL 
Surveyor enhancer S 1 µL 
Reannealed duplex DNA  4 µL 
Surveyor buffer  12 µL 
 
The reaction was incubated at 42°C for 1 hour, and then 2 µL Stop solution was 
added. 10 µL of each reaction was electrophoresed on a 2% agarose gel. Gels were 
visualised using the Odyssey® Fc imaging system at a wavelength of 600 nm. Band 
intensities were calculated using Image Studio Lite. The cleavage fraction (fcut) was 
calculated using the following equation:  
fcut = a / (a + b) 
a = the integrated intensity of both of the cleavage product bands and b = the 
integrated intensity of the uncleaved PCR product band.  
2.2.4.2 Optimised Protocol 
Target sites were amplified by PCR using Taq polymerase (Section 2.1.1). Primers 
and annealing temperatures are listed in Table 2.6.  
Table 2.6 Target-specific Primers  

















Products were analysed using agarose gel electrophoresis, and diluted to 
approximately equal concentrations using 1x PCR buffer.  
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Cross-hybridisation was performed using the conditions detailed in Section 2.2.4.1. 
Reannealed duplexes were then digested with Surveyor nuclease, using the following 
components:  
MgCl2 (0.15 M) 2 µL 
Surveyor nuclease S 1µL 
Surveyor enhancer S 1 µL 
Reannealed duplex DNA  16 µL 
 
The reaction was incubated at 42°C for 1 hour, then 2 µL stop solution was added. 10 
µL of each reaction was electrophoresed on a 2% agarose gel. Gels were visualised 
using the Odyssey® Fc imaging system at a wavelength of 600 nm. Band intensities 
were calculated using Image Studio Lite. The cleavage fraction (fcut) was calculated 
as before. This was used to estimate the percentage of SSN-mediated modification 
using the following equation:  
100 x (1 - (1 - fcut)
1/2)     
2.2.5 Targeting Cassette Construction 
2.2.5.1 AAVS1 Cassette 
The AAVS1 transgene integration cassette was constructed using long multiple 
fragment PCR based on the method described by Shevchuk et al. (2004). The 
homology arms were amplified from HEK293FT genomic DNA. The EGFP 
fragment was amplified from the pEGFP_N1 plasmid.  
Table 2.7 Primers with adapters used to amplify the three fragments.  Adapter sequences are given in 
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The Left arm was amplified using the following components:  
dNTPs (10 mM) 2.5 µL 
Herculase II Fusion Buffer (5x) 10 µL 
gDNA (10ng/ µL) 5 µL 
AAVS1_Left_Fw Primer (50 µM) 1 µL 
AAVS1_Left_Rv Primer (50 µM) 1 µL 
Herculase II Fusion Polymerase  1 µL 
DMSO 1.5 µL 
NF-Water  28 µL  
 
 
The reaction was performed using the following cycling conditions:  
95°C 2 min  
95°C  10 sec  
68°C 30 sec 26 cycles 
72°C 1 min  
72°C 3 min  
4°C ∞  
 
The right arm was amplified using the following components: 
dNTPs (10 mM) 2.5 µL 
Herculase II Fusion Buffer (5x) 10 µL 
gDNA (10ng/ µL) 5 µL 
AAVS1_Right_Fw Primer (50 µM) 1 µL 
AAVS1_Right_Rv Primer (50 µM) 1 µL 
Herculase II Fusion Polymerase  1 µL 
DMSO 1.5 µL 
NF-Water  28 µL  
 
This was performed using the same cycling conditions as the left arm, but with an 
annealing temperature of 69°C.  
The EGFP fragment was amplified using the following components:  
dNTPs (10 mM) 2.5 µL 
Herculase II Fusion Buffer (5x) 10 µL 
pEGFP_N1 (1 µg/mL) 0.3 µL 
EGFP_Fw (50 µM)  1 µL 
EGFP_Rv (50 µM) 1 µL 
Herculase II Fusion Polymerase  1 µL 
DMSO 1.5 µL 
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The reaction was performed using the following conditions:  
95°C 2 min  
95°C  10 sec  
64°C 30 sec 27 cycles 
72°C 2 min 30 sec  
72°C 3 min  
4°C ∞  
 
Correct amplification was confirmed using agarose gel electrophoresis and the 
products were purified using QIAquick® PCR purification kit, according to the 
manufacturer’s instructions, and eluted in 30 µL of 5mM Tris-HCl, pH 8.5.   
The three fragments were fused using the following components:  
 
NF-Water  8.25 µL 
Reaction buffer (5x) 10 µL 
dNTP mix (10 mM) 5 µL 
Q5 0.5 µL 
CG Enhancer (5x) 1 µL 
Left arm 80 ng 
Right arm  90 ng 
EGFP fragment  200 ng 
 
This was incubated using the following cycling conditions: 
98°C 30 sec  
98°C  10 sec  
56°C 30 sec 15 cycles 
72°C 1 min 30 sec  
72°C 2 min  
4°C ∞  
 
Correct fusion was confirmed by agarose gel electrophoresis. The product was 
amplified using the following nested primers:  
Nested_AAVS1_Fw: 5’-CCAAGGACTCAAACCCAGAA 
Nested_AAVS1_Rv: 5’-TTGCTCTCTGCTGTGTTGCT 
This was carried out using Q5 polymerase, with an annealing temperature of 60°C. 
The final product was confirmed using agarose gel electrophoresis and cloned into 
pJET1.2/blunt vector using the CloneJET PCR cloning kit, according to the 
manufacturer’s instruction. This was then transformed into DH5α E. coli. Plasmids 
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were isolated and correct assembly was confirmed by sequencing (primers listed in 
Table 2.10).  
2.2.5.2 IMPDH2 Cassette 
Homology arms were amplified from HEK293FT genomic DNA with Q5 
polymerase using the primers listed in Table 2.8.  
Table 2.8 IMPDH2 homology arm primers. Restriction enzyme adapters are indicated in lowercase.  








The right homology arm and pSicoR-Ef1a-mCh-Puro vector (a gift from Bruce 
Conklin; Addgene plasmid #31845) were digested with EcoRI and KpnI enzymes 
and purified by gel extraction using the Wizard SV Gel and PCR Purification System 
Kit, according to the manufacturer’s instructions. These were ligated using T4 DNA 
ligase and then transformed into DH5α E. coli. The resulting plasmid (pSicoR-Ef1a-
mCh-Puro-IMPDH2_Right) was isolated and correct ligation was confirmed using a 
diagnostic digest.  
The left arm and the pSicoR-Ef1a-mCh-Puro-IMPDH2_Right plasmid were digested 
with XhoI and NotI, then gel purified as before. These were ligated using T4 DNA 
ligase and transformed into DH5α E. coli. Following plasmid isolation, correct 
ligation was confirmed by sequencing (primers listed in Table 2.10).  
2.2.5.3 hROSA26 Cassette 
Homology arms were amplified from HEK293FT genomic DNA with Q5 
polymerase using the primers listed in Table 2.9.   
Table 2.9 hROSA26 homology arm primers. Restriction enzyme adapters are indicated in lowercase.  










Chapter 2 Materials and Methods   63 
The left homology arm and pSicoR-Ef1a-mCh-Puro vector were digested with XhoI 
and NotI and purified by gel extraction using the Wizard SV Gel and PCR 
Purification System Kit, according to the manufacturer’s instructions. These were 
ligated using T4 DNA ligase and then transformed into DH5α E. coli. The resulting 
plasmid (pSicoR-Ef1a-mCh-Puro-hROSA26_Left) was isolated and correct ligation 
was confirmed using a diagnostic digest.  
The right arm was digested with MfeI and KpnI and the pSicoR-Ef1a-mCh-Puro-
hROSA26_Left plasmid was digested with EcoRI and KpnI, then gel purified as 
before. These were ligated using T4 DNA ligase and transformed into DH5α E. coli. 
Following plasmid isolation, correct ligation was confirmed by sequencing (primers 
listed in Table 2.10).  
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2.2.5.4 Integration Detection  
Correct integration of targeting cassettes was determined by PCR using Q5 
polymerase. The primers used are listed in Table 2.11. 
Table 2.11 Primers used to detect correct integration of targeting cassettes. The pSicoR_Rv primer was 








2.3 Bacterial Methods  
2.3.1 Plasmid Transformation 
Chemically competent sub-cloning efficiency DH5α E. coli (Invitrogen™) were used 
for all plasmid transformations, unless otherwise stated. 5 µL cloning reaction was 
incubated on ice with 50 µL E. coli for 30 minutes. Reactions were heat shocked at 
42°C for 20 seconds then returned to ice for 2 minutes. 950 µL S.O.C media 
(Invitrogen™) was added and samples were incubated at 37°C, 225 rpm for 1 hour. 
100µL was spread on LB-agar plates with appropriate antibiotic. Plates were 
incubated overnight at 37°C.  
2.3.2 Plasmid Isolation  
Colonies from LB-agar plates were picked with a sterile loop and inoculated into 5 
mL or 100 mL LB media with appropriate antibiotics, for miniprep and maxiprep 
respectively. Cultures were grown overnight at 37°C, 225 rpm. 
Cultures were pellet by centrifugation at 3000 rpm for 15 minutes or 5000 xg for 15 
minutes, for miniprep and maxiprep respectively. Minipreps were carried out using 
the peqGOLD Plasmid Miniprep kit (C-line) and maxipreps were carried out using 
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2.4 Tissue Culture Methods  
2.4.1 Maintenance of Immortalised cell lines 
Handling of all cell lines was carried out in a biological safety cabinet.  All cells 
were grown in a humidified incubator at 37 °C, 5% CO2. All cells were maintained 
in 75 cm2 flasks (Greiner bio-one). 
Once cells reached 90% confluence, growth media was aspirated from the flask and 
cells were incubated with 3 mL TrypLE Express (Life Technologies) until they lost 
adherence, approximately 5 minutes. 7 mL culture media was added and cells were 
pipetted several times to remove cell clumps. 1 mL of cell suspension was then 
transferred to a new flask containing 25 mL fresh media. Cells were then returned to 
the humidified incubator (37 °C, 5% CO2).  
Cell lines were regularly tested for the presence of mycoplasma infection using a 
MycoAlert™ mycoplasma detection kit (Lonza). Contaminated cells were disposed 
of.  
2.4.2 Transfection  
Cells were seeded according to Table 2.12, 24 hours prior to transfection in 12-well 
plates (Nunc™). On the day of transfection, 2 µg DNA was mixed with 200 µL 
OptiMEM (Life Technologies) media and 4 µL peqFECT DNA transfection reagent 
(peqlab). This mixture was incubated at room temperature for 20 minutes to allow 
DNA-lipid complexes to form, before being added dropwise to the 12-well plate – 
200 µL per well. 
Table 2.12 Cell line manipulation. Seeding densities for 12-well plates are indicated.  
Cell Line Seeding Density  Concentration of 
Puromycin 
A549 1.5 x 105 5 µg/mL 
HEK 293-FT 2.0 x 105 2 µg/mL 
RPE-1 1.5 x 105 5 µg/mL 
HCT116 1.5 x 105 2 µg/mL 
HeLa 1.5 x 105 - 
 
For the cell proliferation assays, cells were transfected in 96-well plates (Nunc™). 
For this, cells were seeded at 1.5 x 104 cells per well 24 hours prior to transfection. 
 
 
Chapter 2 Materials and Methods   66 
Mastermixes for each transfection were used; 200 ng DNA was mixed with 20 µL 
OptiMEM medium and 0.4 µL peqFECT DNA transfection reagent for each well to 
be transfected. These were incubated at room temperature, and then 20 µL was added 
dropwise to each well.  
2.4.3 Cell Proliferation Assay 
2.4.3.1 Drug treatment 
MPA (Sigma-Aldrich®) was reconstituted in DMSO to a stock concentration of 
100 mM, and then serially diluted in culture media to the final working 
concentrations required. Acyclovir monophosphate (Santa Cruz Biotechnology) was 
reconstituted in tissue culture-grate water to a stock concentration of 100 mM, and 
then serially diluted in culture media to the appropriate working concentrations. 24 
hours post transfection, culture media was aspirated and replaced by 200 µL per well 
fresh culture media containing appropriate concentrations of drug(s), or vehicle 
(DMSO) only controls. Cells were then incubated in a humidified incubator at 37 °C, 
5% CO2, for 72 or 120 hours, depending on the experiment.  
2.4.3.2 BrdU ELISA 
Cell proliferation was determined using a Cell Proliferation ELISA, BrdU 
(colorimetric) (Roche) according to the manufacturer’s instructions. Absorbance was 
measured at 370 nm (reference wavelength 492 nm) using a plate reader.  
2.4.4 Isolation of Single Cell Colonies  
2.4.4.1 Puromycin Selection 
24 hours post transfection; media was aspirated and replaced with media containing 
puromycin (Gibco) (Table 2.12). Cells were incubated in the presence of puromycin 
for 48 hours at 37 °C, 5% CO2, in a humidified incubator.  
2.4.4.2 Fluorescence Activated Cell Sorting 
Following 48 hour puromycin treatment, media was aspirated from each well and 0.5 
mL TrypLE Express was added. Plates were returned to the incubator for 
approximately 5 minutes to allow cells to disassociate, and then 0.5 mL media was 
added to each well and cells were pipetted up and down to remove cell clumps. The 
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cell suspensions were transferred to 4.5 mL FACS tubes (BD Falcon). Cells were 
pelleted by centrifugation at 1200 rpm for 5 minutes. Supernatant was aspirated, cells 
were resuspended in 300 µL PBS and placed on wet ice. 
A BD FACSJazz™ machine (BD Biosciences) was used to plate individual cells into 
each well of a 96-well plate containing 100 µL warmed media. This was carried out 
by the FACS technician Elisabeth Freyer.  
Cells were allowed to grow for up to 7 days, at which point colonies deriving from 
single cells were identified. These were left to grow to confluence, before being 
transferred to 48-well plates (Nunc™). Once confluent, these were sequentially 
transferred to larger and larger culture vessels, up to a 25 cm2 flask (Greiner bio-
one).  
2.4.5 Flow Cytometry  
Media was aspirated from each well and 0.5 mL TrypLE Express was added. Plates 
were returned to the incubator for approximately 5 minutes to allow cells to 
disassociate. Then 0.5 mL media was added to each well and cells were pipetted up 
and down to remove cell clumps. The cell suspensions were transferred to 4.5 mL 
FACS tubes (BD Falcon). Cells were pelleted by centrifugation at 1200 rpm for 5 
minutes. Supernatant was aspirated, cells were resuspended in 300 µL PBS and 
placed on wet ice. 
A BD LSR Fortessa machine (BD Biosciences) was used to analyse the number of 
fluorescent cells in each sample. For each experimental sample 50,000 live single 
cells were analysed.  
2.4.6 Genomic DNA Isolation 
Cells were removed from wells by incubation with TrypLE Express. Media was 
added to each well to inhibit the action of the TrypLE Express. Cells were pipetted to 
make a homogenous solution, and then transferred to 1.5 mL tubes. Cells were 
pelleted by centrifugation and media aspirated. Cell pellets were stored at -20°C until 
DNA extraction could be carried out.  
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Genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen), 
according to the manufacturer’s instructions. DNA was eluted in 100 µL buffer AE.   
2.4.7 Total RNA Extraction  
Cells were seeded in 6-well plates at a twice the seeding density of a 12-well plate 
(Table 2.12) and incubated in a humidified incubator for 24 hours at 37 °C, 5% CO2. 
Cells were removed from plates and transferred to 1.5 mL tubes as described in 
Section 2.4.6. Cells were pellet and media removed, pellets were stored at -70°C 
until RNA extraction could be carried out.  
RNA extraction was carried out using RNeasy Plus mini kit (Qiagen®), according to 
the manufacturer’s instructions. RNA was eluted in 30 µL NF-water. RNA samples 
were then treated with TURBO DNase I to remove any genomic DNA 
contamination; 2 U of DNase I were added to each sample and incubated at 37°C for 
30 minutes. Samples were then purified using spin columns (Qiagen®) and eluted in 
30 µL NF-water. RNA concentration and integrity was analysed using an Agilent 
bioanalyser. Any sample with a RIN < 7 was discarded.  
2.4.8 Protein Extraction  
Cells were seeded in 6-well plates as described in Section 2.4.7. Cells were harvested 
and cell pellets made as described above (Section 2.4.7), pellets were stored at -20°C 
until extraction could be carried out. Pellets were resuspended in 200 µL RIPA 
buffer supplemented with a protease inhibitor cocktail (cOmplete tablets, Mini 
EDTA-free EASYpack; Roche) and incubated on a rotating mixer at 4°C for 10 
minutes. Samples were centrifuged at top speed at 4°C for 15 minutes, and the 
supernatant transferred to new 1.5 mL tubes.  
2.4.9 Characterisation of Clonal Lines 
Target regions were amplified by PCR with the same primers used for the Surveyor 
assay (Table 2.6). For EEF1A2, the following primers were used:  
Forward: 5’- TGGTTGAGGAAGGGATCTGG 
Reverse: 5’- GATGGGGACGTGGACACA 
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Table 2.13 Sequencing primers for clonal lines 
Primer Sequence 
EEF1A1_Ex3_Internal_Seq  5’-AATTAAGGGCTGGGGACAAG 
EEF1A1_Ex4_Internal_Seq 5’-CCACCCTACAGCCAGAAGAG 
IMPDH2_Internal_Seq _1 5’-GGAGTGTCAAACCAAGTTTCTG 
IMPDH2_Internal_Seq _2 5’-TGTTCCTGTGTTGTCCTCCTT 




2.5 Statistical Analyses 
All statistical analysis was carried out using Prism 4 (version 4.03; Graphpad). 
Unpaired T-tests were used to compare between two groups of data. ANOVA with 
Bonferroni correction was used to compare multiple groups. P-values of >0.05 were 
considered statistically significant. Data are presented as means ± S.E.M. unless 
otherwise stated.  
2.6 Recipes 
2.6.1 General Recipes 
20x TBE  
216.0 g Tris base 
110.0 g Boric Acid 
80 mL  0.5 M EDTA, pH 8.5  
1x PBS 
8 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
PBS-T 
1x PBS 
0.2% Tween-20  
Orange G Buffer 
100 mg Orange G 
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1x Surveyor Buffer 
10 mM Tris-HCl, pH 8.8 
15 mM MgCl2 
50 mM KCl 
10% Separating Gel (2 Gels) 
6.68 mL dH2O 
4 mL 1.5 M Tris, pH 8.8 
5.2 mL 30% Acrylamide 
80 µL 20% SDS 
10 µL TEMED 
40 µL AMPS 
4.3% Stacking gel (2 Gels)   
5.95 ml dH2O         
2.5 ml 0.5M Tris-HCl pH 6.8       
1.45 ml 30% Acrylamide      
50 µL 20% SDS          
5 µL TEMED         
50 µL 25% AMPS  
Laemmli loading buffer (2x) 
60mM Tris-HCl pH 6.8      
0.1% Bromophenol blue     
10% Glycerol       
2% SDS  
RIPA Buffer 
50 mM Tris pH 7.5       
150 mM NaCl        
0.5% (w/v) Sodium Deoxycholate     
1% (v/v) NP-40 (Igepal)      
0.1% (v/v) SDS    
Transfer buffer (1x) 
700ml dH2O         
200ml Methanol  
100ml TGS (10x)     
2.6.2 Bacterial Recipes 
Luria Broth (LB) 
10.0 g Tryptone 
5.0 g  Yeast Extract 
10.0 g Sodium Chloride 
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LB-Agar  
10.0 g Tryptone 
5.0 g  Yeast Extract 
10.0 g Sodium Chloride 





2.6.3  Tissue Culture Recipes  
HEK 293-FT Growth Media  
Dulbecco’s Modified Eagle Medium (DMEM) 
10% Foetal calf serum (FCS) 
0.1 mM Non-essential amino acids  
2 mM L-Glutamine 
1% Penicillin/Streptomycin  
A549 Growth Media  
DMEM  
10% FCS 
1% Penicillin/Streptomycin  
HeLa Growth Media  
DMEM  
10% FCS 
1% Penicillin/Streptomycin  
RPE-1 Growth Media  
DMEM:F12 
10% FCS 
0.01 mg/mL Hygromycin B  
2 mM L-Gluatmine 
1% Penicillin/Streptomycin  
HCT116 Growth Media  
DMEM:F12 
10% FCS 
2 mM L-Glutamine 
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3.1 Introduction  
Established methods for transgene integration are inefficient and can result in 
variable expression due to silencing. Recently, the advent of SSNs has greatly 
improved the ease and efficiency of specifically targeting transgene integration into 
predetermined loci, which can be chosen for their ability to permit robust long-term 
expression. The challenge is to identify such loci and develop effective SSN tools to 
allow them to be exploited in this way. In this work, I aimed to investigate four 
human genomic loci, to design and build SSNs to target each locus, and to validate 
the ability of each site to support transgene integration and robust long-term 
expression, as a proof of principle for the generation of stable lentiviral producer cell 
lines. The four sites chosen were the adeno-associated virus (AAV) integration site 1 
(AAVS1), the human homologue of the mouse Rosa26 locus (hROSA26), the 
inosine monophosphate dehydrogenase 2 (IMPDH2) gene, and the eukaryotic 
translation elongation factor 1 alpha 1 (EEF1A1) gene. 
The AAVS1 locus located on human chromosome 19 (position 19q13.42), was first 
identified as a hotspot for AAV integration (Kotin et al. 1992). Hallmarks of open 
chromatin, specifically a DNase I hypersensitivity site and an insulator, are found 
here (Ogata et al. 2003) and indicate its potential to support transgene expression. 
The AAVS1 site occurs within the PPP1R12C gene, which encodes protein 
phosphatase 1 regulatory subunit 12C (PPP1R12C) whose function has not been 
fully characterized. Other groups have demonstrated the ability of this locus to 
support transgene integration and expression without observable adverse 
consequences (Chang & Bouhassira 2012; Wang et al. 2012; Zou et al. 2011; 
DeKelver et al. 2010; Smith et al. 2008).  
The hROSA26 locus located on human chromosome 3 (position 3p25.3) was 
identified as the human homologue of the mouse Rosa26 locus (Irion et al. 2007). 
Both the mouse and human ROSA26 loci express an antisense non-coding RNA; for 
hROSA26 this is THUMPD3-AS1 whose function is yet to be characterised. It is 
expressed in a range of adult and embryonic stem cell lines (Irion et al. 2007) and has 
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IMPDH2 on human chromosome 3 (position 3p21.31) encodes IMPDH2, a key 
metabolic enzyme involved in guanine nucleotide biosynthesis and is essential for 
cell proliferation; as such it is ubiquitously expressed. The activity of IMPDH2, and 
its closely related isoform IMPDH1, can be specifically inhibited via the drug 
mycophenolic acid (MPA), making this an attractive site for the development of a 
drug-selectable transgene integration system, discussed further in Chapter 4.  
EEF1A1 encodes the eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), 
and is located on human chromosome 6 (position 6q14). Expression of this gene is 
almost ubiquitous in normal adult tissue (Cho et al. 2012), and is believed to be 
expressed in all immortalized cell lines.  Its canonical role is delivery of aminoacyl 
tRNAs (aa-tRNAs) to the A-site of the ribosome during translation, though other 
moonlighting functions have been identified. These include transformation 
susceptibility (Tatsuka et al. 1992); protein degradation and protection against 
apoptosis (Cho et al. 2012); interaction with the cytoskeleton (Condeelis 1995); viral 
propagation and nuclear transport (Mateyak & Kinzy 2010); neurite outgrowth 
(Hashimoto & Ishima 2011) and a possible role in ageing (Shepherd et al. 1989). It is 
not yet known whether these functions are shared by its closely related isoform 
eEF1A2, which has a reciprocal expression pattern, as appropriate means to probe 
this have yet to be developed. This is further discussed in Chapter 5.  
Currently most clinical-grade lentiviral vectors are produced via transient 
transfection (Aiuti et al. 2013; Biffi et al. 2013; Cartier et al. 2009; Tebas et al. 
2013). Some stable producer lines do exist (Greene et al. 2012; Throm et al. 2009b) 
but these have generally been created by random integration of viral components 
followed by selection. SSNs can be utilised to streamline the production process and 
to make subsequent changes (for example pseudotyping or changing the therapeutic 
gene) more straightforward.  
3.2 Aims  
The aim of the work described in this chapter is to develop SSNs – particularly 
TALENs and CRISPR/Cas9 – to target each of the four chosen loci and use these to 
investigate the potential of each site to support transgene expression and robust long-
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term expression of transgenes in human immortalised cell lines, as a proof of 
principle for the development of a stable lentiviral producer cell line. 
3.3 Results  
3.3.1 Investigating Endogenous Transcriptional Activity of Target Loci 
To maximize the chances of the target loci supporting robust and long-term 
expression of transgenes, they should be in transcriptionally active regions – with an 
open chromatin structure – less susceptible to the silencing effects of 
heterochromatin. In order to assess the transcriptional activity of each of the target 
sites, I carried out qPCRs in a panel of immortalised cell lines derived from a range 
of tissues. To determine the best normalisation strategy, I used the geNorm kit 
(Primerdesign) to analyse the stability of expression of six reference genes across the 
panel of immortalised cell lines. From this, I chose five reference genes, which 
showed the greatest stability: GAPDH, ATP5B, TOP1, UBC, and SDHA.  
The IMPDH2 and EEF1A1 loci encode genes, giving rise to IMPDH2 and eEF1A1 
respectively (Figure 3.1), so I was able to monitor transcriptional activity at each 
locus directly using qPCR. However, as neither the AAVS1 nor hROSA26 loci are 
genes, I had to use surrogate markers of expression. The AAVS1 locus coincides 
with the PPP1R12C gene (Figure 3.1A); in order to observe transcriptional activity 
of this locus I designed primers against PPP1R12C. The hROSA26 locus contains 
the open reading frame for a long non-coding RNA THUMPD3-AS1 (Figure 3.1A); I 
used the expression of this to monitor transcriptional activity at this locus.  
Each of the four target loci are transcriptionally active in all cell lines tested (Figure 
3.1B). IMPDH2 shows the highest level of expression (note y-axis), followed by 
hROSA26, while the least transcriptional activity is seen at the AAVS1 locus, 
however, PPP1R12C shows the most consistent expression across the cell lines 
tested. These data demonstrate that all loci are transcriptionally active in a range of 
cells and so have the potential to be useful sites for transgene integration and 
expression.  
This is in line with data from the ENCODE project (Figure 3.1C), which indicates 
that all target loci lie within transcriptionally permissive regions indicative of open 
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chromatin. This is illustrated by the presence of acetylated histone H3 at lysine 27 
(H3K27Ac). In addition, all loci are associated with multiple DNase I 
hypersensitivity sites, indicating all loci lie within areas of less compact chromatin.   
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Figure 3.1 Continued, page 2 of 2. A) Genomic organisation of target sites. AAVS1 and hROSA26 are not 
genes; to monitor expression, the expression of genes in these regions was investigated. Figure generated 
using USCS genome browser, assembly GRCh37/hg19. B) qPCR expression data for each target locus. 
Expression of each gene is normalised to the expression of five reference genes (GAPDH, SDHA, TOP1, 
UBC, and ATP5B). Data represent the means of three independent experiments. Error bars show S.E.M. 
C) ENCODE data for each target site, showing location of histone H3K27Ac and DNase I hypersensitivity 
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3.3.2 Design and Construction of SSNs  
3.3.2.1 TALENs  
Due to the relative infancy of this technology, and to act as a positive control for the 
methodology, I constructed a TALEN pair targeting AAVS1 which had already been 
shown to be active (Sanjana et al. 2012), alongside a TALEN pair of my own design 
(targeting the hROSA26 locus).  
I used the web-based software devised by Cermak et al. (2011; available at 
https://tale-nt.cac.cornell.edu/node/add/talen) to identify all potential TALEN target 
sites within the locus of interest – hROSA26. The input sequence I used was taken 
from Irion et al. (2007) who first identified the hROSA26 locus. This resulted in 23 
potential TALEN target sites. Of these, only eight had no predicated off-target sites; I 
chose one target site for which I would construct a TALEN pair located downstream 
of the putative exon one, as defined by Irion et al. (2007), within the first intron of 
THUMPD3-AS1. 
I constructed all TALENs using the method devised by the Zhang laboratory 
(Sanjana et al. 2012) which uses a hierarchical ligation strategy and makes use of the 
Golden Gate cloning technique (Engler et al., 2009, 2008; Weber et al., 2011). The 








Table 3.1 Constructed TALENs targeting AAVS1 and hROSA26. Genomic locations are given for entire target sequence including spacer region. Half repeats (encoded by the 
backbone plasmid) are given in parentheses. 
TALEN Genomic Location Target Sequence RVD Sequence 
AAVS1_R 
Chr19: 55627109-55627158 
5’-TGTGGGGTGGAGGGGAC NG NG HD NG NN NG HD NI HD HD NI NI NG HD HD NG NN (NG) 
AAVS1_L 5’-GTCCCCTCCACCCCACA NN NG HD HD HD HD NG HD HD NI HD HD HD HD NI HD NI (NN) 
hROSA26_R 
Chr3: 9437057-9437108 
5’-GTGTGATAGCTTCCAAAT NN NG NN NG NN NI NG NI NN HD NG NG HD HD NI NI NI NG (NG) 
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3.3.2.2 CRISPR/Cas9  
Before I could construct TALENs to target all loci of interest, the CRISPR/Cas9 
system was developed (Cong et al. 2013; Jinek et al. 2012; Mali, Yang, et al. 2013). 
This was shown to be equally active and more easily reengineered. I therefore 
targeted all remaining loci with this system.  
To identify sgRNA target sites I used the software developed by Hsu and colleagues 
(2013; available at http://crispr.mit.edu/). I constructed all sgRNAs (both individual 
and nickase pairs) using the protocol devised by the Zhang laboratory (Ran, P D Hsu, 
et al. 2013). In this method, all components of the system are encoded on a single 
plasmid (pX459 or pX462), which also encodes a puromycin resistance cassette, 
allowing for selection of transfected cells.  
During the development of their CRISPR/Cas9 system, Mali and colleagues (2013) 
constructed two sgRNAs that targeted AAVS1 (T1 and T2) at sites which overlapped 
the target of the TALEN pair I had constructed, as such I continued to use the 
AAVS1 locus as a control. I acquired the gRNA_AAVS1_T2 plasmid as a gift from 
George Church (Addgene plasmid #41818). This would also allow me to compare 
TALEN and CRISPR/Cas9 activity directly, but also to have an externally validated 
reference with which to compare the activity of sgRNAs of my own design and 
construction. The Church laboratory CRISPR/Cas9 system is a two-plasmid platform 
in which a human codon-optimised Cas9 is encoded on one plasmid and the sgRNA 
is encoded on a second plasmid, which must be co-transfected for the system to be 
active (outlined by Mali et al., 2013b). 
I decided it would be useful to compare the activity of the two systems at additional 
loci, to control for any local environmental effects. As I already had an 
hROSA26-targeting TALEN pair, I identified sgRNA target sites in the same region. 
Fortuitously, there was a predicted nickase pair site, which overlapped the TALEN 
target site (Table 3.2). These sgRNAs were identified using the nickase pair design 
tool (available at http://crispr.mit.edu/; Hsu et al., 2013). I made only nickase pairs to 
ensure greater specificity of targeting.  
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I constructed six sgRNAs to target the IMPDH2 locus (Table 3.2), both as individual 
sgRNAs and as three nickase pairs. These nickase pairs were designed prior to the 
availability of dedicated software, so were selected as top scoring individual sgRNAs 
which bound opposite DNA strands within 30-bp of each other. Design 
considerations for these sgRNAs are described in Chapter 4.  
As for the IMPDH2 locus, I constructed the EEF1A1-targeting sgRNAs as both 
individual guides and as nickase pairs (Table 3.2). Like the IMPDH2-targeting 
sgRNAs, I designed these manually from top scoring single guides. I designed these 
sgRNAs to have a dual role: in addition to targeting EEF1A1 as a potential site for 
transgene integration, they were designed to generate EEF1A1 knockout cell lines. 








Table 3.2 Constructed sgRNAs. The genomic location and sequence of each constructed sgRNA is listed below for all four genomic loci. In some cases, sgRNAs were 
constructed for use with either wild type Cas9 or Cas9n (D10A), as indicated by the backbone vector. All backbone vectors also contain a puromycin resistance gene to allow 
for selection of successfully transfected cells.  
Name Target Sequence Genomic Location  Backbone  
sgRNA_hROSA26_92A 5’-GATCCATCTTACATCTTGTTAGG Chr3: 9437039-9437061 
Chr3: 9437089-9437111 
pSpCas9n-2A-Puro 
sgRNA_hROSA26_92B 5’-CAATTTGGAAGCTATCACACAGG pSpCas9n-2A-Puro 
sgRNA_IMPDH2_1+ 5’-AAGCACTGCCCCTACCTTAGGGG Chr3: 49064904-49064926 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_IMPDH2_1- 5’-CTTTTAAACCCCTAAGGTAGGGG Chr3: 49064912-49064934 
Chr3: 49064838-49064860 
pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_IMPDH2_2+ 5’-CCCTCTTACACTATGGAATAAGG pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_IMPDH2_2- 5’-TCCTTATTCCATAGTGTAAGAGG Chr3: 49064839-49064861 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_IMPDH2_3+ 5’-ATTACAGGGGTGAAGTTCTATGG Chr3: 49064698-49064720 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_IMPDH2_3- 5’-TGGGTGTGAATGTATGAACGTGG Chr3: 49064725-49064747 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_EEF1A1_Ex3+ve 5’-GGAGCCCTTTCCCATCTGTAAGG Chr6: 74229225-74229247 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_EEF1A1_Ex3-ve 5’-CGACTCTTAATCCTTACAGATGG Chr6: 74229236-74229258 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
sgRNA_EEF1A1_Ex4+ve 5’-AGACCATTGTTAAAAAGCTCTGG Chr6: 74228618-74228640 pSpCas9-2A-Puro / pSpCas9n-2A-Puro 
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3.3.3 Validation of TALEN Activity in vitro 
To validate the ability of the TALEN pairs to bind and cleave their targets, I carried 
out an in vitro cleavage assay. I generated TALEN proteins in vitro using the TNT® 
quick-coupled transcription/translation kit (Promega). This yielded good expression 
of the TALEN proteins (Figure 3.2A & B); both hROSA26 and AAVS1 TALENs 
were produced at a similar level to the luciferase controls. There was an additional 
band in the hROSA26 left TALEN lane (Figure 3.2A) which is not present in any 
other lane. I carried out a luciferase assay (data not shown), which confirmed the 
activity of proteins produced in vitro.  
I next carried out the in vitro cleavage assay using a PCR-generated target, which I 
incubated with the TALEN proteins. Figure 3.2C illustrates the activity of the 
hROSA26 TALEN pair: following agarose gel electrophoresis of the in vitro 
cleavage reaction, cleavage products of predicted size are present (Figure 3.2C, red 
arrows) and only when the PCR product was incubated with both left and right 
TALEN proteins. An additional band appears to be present when the right TALEN is 
present alone though the smaller cleavage band is absent. However, I was unable to 
show activity for the AAVS1-targeting TALEN pair (Figure 3.2D), which had 
previously been shown to be active (Sanjana et al. 2012).  
Due to the nature of this assay it cannot indicate how the TALENs will act under 
physiological conditions: because of this and the fact I was unable to detect activity 








Figure 3.2 Investigating TALEN activity in vitro.  A & B) TALEN proteins were produced in vitro using 
the TNT Quick Coupled Transcription/Translation Kit (Promega). To allow proteins to be visualised, 
Biotin-Lysyl-tRNAs were used, so that the resulting proteins contained biotinylated lysine residues. 
Proteins were analysed by SDS-PAGE, transferred to membranes and visualised using Western Blue® 
Stabilized Substrate for Alkaline Phosphatase.  A) hROSA26-targeting TALENs. B) AAVS1-targeting 
TALENs. C) in vitro cleavage by hROSA26 TALENs, cleavage bands of predicted size are present (red 
arrows) only when both left and right TALEN proteins are present. D) in vitro cleavage by AAVS1 
TALENs, the predicted cleavage products are not present. E) Schematic of predicted cleavage sites in 
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3.3.4 SURVEYOR Assay: Validation of SSN Activity in cellulo 
I investigated the activity of each SSN following transfection of HEK293FT cells, as 
these cells are customarily used in the production of lentiviral vectors and express the 
SV40 large T antigen, which is required for lentiviral production (Gama-Norton et al. 
2011). I carried out the SURVEYOR assay 24 hours post transfection for all SSNs.  
Figure 3.3 confirms activity of both the TALEN pair I constructed and the sgRNA 
targeting AAVS1, demonstrated previously (Mali, Yang, et al. 2013; Sanjana et al. 
2012). It is interesting to note that I observed 19% indel formation with the 
AAVS1-targeting TALEN pair (Figure 3.3A) compared with 2.5% observed by 
Sanjana and colleagues. In contrast, the indel percentage I observed for the sgRNA 
was similar to that observed by Mali et al. (2013) who used next generation 
sequencing (NGS) to more accurately determine activity.  
I had already demonstrated the potential for the hROSA26-targeting TALEN pair to 
directly bind and cleave their target (Figure 3.2C). However, I wanted to demonstrate 
this under physiological conditions.   
Figure 3.4A demonstrates that the hROSA26-targeting TALEN pair is active in 
cellulo, confirming the in vitro results. In addition, there is no evidence here of the 
right TALEN acting as a homodimer, under physiological conditions.  
I next compared the activity of the TALEN pair and the CRISPR nickase pair, which 
both target the same site within the hROSA26 locus. Figure 3.4B demonstrates the 
activity of both TALENs and CRISPR/Cas9 systems at this site. The CRISPR 
nickase pair resulted in three cleavage products, following agarose gel 
electrophoresis of the SURVEYOR reaction, instead of the expected two products.  
Figure 3.5A shows almost no detectable activity was observed for any of the 
individual sgRNAs targeting IMPDH2; minor activity is seen with sgRNA_1-ve (red 
arrows).  
In addition, there is little evidence of activity for most of the EEF1A1-targeting 
sgRNAs after 24 hours (Figure 3.6). However, sgRNA_EEF1A1_Ex3+ve in 








Figure 3.3 Activity of AAVS1-targeting SSNs. A)  SURVEYOR assay for AAVS1-targeting SSNs. Red arrows indicate cleavage products. Sizes of predicted cleavage 


























































Figure 3.4 hROSA26-targeting SSNs SURVEYOR assay. A) SURVEYOR assay results for hROSA26-targeting TALENs. Red arrows indicate cleavage products, predicted 
sizes are indicated. B) Comparison of the activity of CRISPR/Cas9 and TALENs targeting hROSA26.  C) Schematic of predicted cleavage products for both CRISPR/Cas9 




























































Figure 3.5 SURVEYOR assay for IMPDH2-targeting sgRNAs. A) SURVEYOR assay results. Red arrows 
indicate potential cleavage bands. B) Schematic of predicted cleavage products for individual sgRNAs at 
the IMPDH2 locus. 
 
 





Figure 3.6 SURVEYOR assay for EEF1A1-targeting sgRNAs. A) SURVEYOR assay results. Only 
sgRNA_EEF1A1_Ex3+ve demonstrates any observable activity. B) Schematic of predicted cleavage sites at 
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3.3.4.1 Effect of Puromycin Selection on SURVEYOR Assay Outcome 
I sought to improve the effectiveness of retrieving cells containing targeted indels at 
IMPDH2 and EEF1A1 by selecting for transfected cells with puromycin. I treated 
cells for 48 hours with puromycin following transfection; plasmids encoding the 
CRISPR/Cas9 components also encode a puromycin resistance cassette. After 
selection, I carried out the SURVEYOR assay as before.  
Figure 3.7 demonstrates that all individual sgRNAs (in combination with wild type 
Cas9) targeting both EEF1A1 and IMPDH2 are active following puromycin 
treatment. However, the nickase pairs targeting IMPDH2 still do not show 
convincing activity; pair 1 does show potential activity, as demonstrated by the 
presence of faint bands (Figure 3.7A, red arrows). On the other hand, both of the 
nickase pairs targeting EEF1A1 show robust activity, with no apparent difference 
between head-to-head and tail-to tail oriented pairs.  
In order to better understand the effect of puromycin, I repeated the experiment for 
the IMPDH2-targeting sgRNAs, one batch I treated with puromycin for 48 hours (24 
hour post-transfection), and the other I did not treat with puromycin. In both cases, I 
carried out the SURVEYOR assay 72 hours post transfection  
Figure 3.8 demonstrates that activity is observed for all individual IMPDH2-targeting 
sgRNAs at 72 hours post transfection irrespective of puromycin treatment. However, 
puromycin selection improved the observed indel percentage in most cases; 
therefore, I carried out all subsequent experiments using 48 hour puromycin 







Figure 3.7 SURVEYOR assay post puromycin selection. A) IMPDH2-targeting sgRNAs. All single sgRNAs show activity post puromycin selection. There is limited 
evidence of activity for any of the paired sgRNAs. Red arrows indicate potential cleavage products. B) EEF1A1-targeting sgRNAs. All single and paired sgRNAs 
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Figure 3.8 SURVEYOR assay ± puromycin selection. Cells were transfected with IMPDH2-targeting 
sgRNAs, and incubated ± puromycin, for a total of 72 hours post transfection.  A) SURVEYOR assay on 
samples not treated with puromycin. B) SURVEYOR assay on samples treated with puromycin. C) 
Schematic of predicted cleavage products for all single sgRNAs. 
+ Strand - Strand
178-bp + 257-bp 181-bp + 254-bp
190-bp + 243-bp 180-bp + 253-bp
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3.3.4.2 Assessing SSN Activity in Other Immortalised Cell Lines 
After validating the activity of these SSNs in HEK293FT cells, I wanted to 
investigate if this was consistent in other immortalised cell lines, and investigate 
whether cell line specific differences could be observed. However, if SNPs are 
present at the target site, or within the amplified region, it is almost impossible to 
distinguish these from SSN activity using the SURVEYOR assay, as exemplified by 
the EEF1A1 locus in Figure 3.9.  
Figure 3.9A shows that for sgRNA_EEF1A1_Ex3+ve and sgRNA_EEF1A1_Ex3-ve, 
activity cannot be determined by the SURVEYOR assay; the untransfected control 
lane also has cleavage bands present, which are indistinguishable from the cleavage 
bands indicative of SSN activity (Figure 3.9B). This is due to the presence of two 
SNPs in the amplified region: rs4708060 and rs2073466 (Figure 3.10). I confirmed 
by sequencing that A549 cells are heterozygous for presence of rs4708060 and RPE-
1 cells are heterozygous for rs2073466 (Figure 3.10). I also confirmed that SNPs 
were present at a number of the other target loci; therefore it was not practical to 
continue to use the SURVEYOR assay, as the presence of SNPs interfere with the 
interpretation of the results at this particular locus. 
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Figure 3.9 Activity of EEF1A1 targeting sgRNAs in A549 cells. A) SURVEYOR assay results. All samples, 
even the untransfected control, have the predicted cleavage bands present for Ex3 sgRNAs. B) Schematic 
of predicted cleavage products. 
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RPE-1         GGAGGCTGCTGAGGTATGTTtaataccagaaagggaaagatcaactaaaatgagttttac 60 
HEK293FT      GGAGGCTGCTGAGGTATGTTtaataccagaaagggaaagatcaactaaaatgagttttac 60 
A549          GGAGGCTGCTGAGGTATGTTtaataccagaaagggaaagatcaactaaaatgagttttac 60 
               
 
RPE-1         cagcagaatcattaggtgatttccccagaactagtgagtggtttagatctgaatgctaat 120 
HEK293FT      cagcagaatcattaggtgatttccccagaactagtgagtggtttagatctgaatgctaat 120 
A549          cagcagaatcattaggtgatttccccagaactagtgagtggtttagatctgaatgctaat 120 
               
 
RPE-1         agttaagaccttacttatgaaataattttgcttttggtgacttctgtaatcgtattgcta 180 
HEK293FT      agttaagaccttacttatgaaataattttgcttttggtgacttctgtaatcgtattgcta 180 
A549          agttaagaccttacttatgaaataattttgcttttggtgacttctgtaatcgtattgcta 180 
               
 
RPE-1         gtgagtagatttggatgttaatagttaagatccgacttataaaagtttgatttttggttg 240 
HEK293FT      gtgagtagatttggatgttaatagttaagatccgacttataaaagtttgatttttggttg 240 
A549          gtgagtagatttggatgttaatagttaagatcckacttataaaagtttgatttttggttg 240 
               
RPE-1         cttctgtaacccaaagtgactaaaatcactttggacttggagttgtaaagtggaaactgc 300 
HEK293FT      cttctgtaacccaaagtgactaaaatcactttggacttggagttgtaaagtggaaactgc 300 
A549          cttctgtaacccaaagtgactaaaatcactttggacttggagttgtaaagtggaaactgc 300 
               
 
RPE-1         caattaagggctggggacaaggaaattgaagctggagtttgtgttttagtaaccaagtaa 360 
HEK293FT      caattaagggctggggacaaggaaattgaagctggagtttgtgttttagtaaccaagtaa 360 
A549          caattaagggctggggacaaggaaattgaagctggagtttgtgttttagtaaccaagtaa 360 
               
 
RPE-1         mgactcttaatccttacagatgggaaagggctccttcaagtatgcctgggtcttggataa 420 
HEK293FT      cgactcttaatccttacagatgggaaagggctccttcaagtatgcctgggtcttggataa 420 
A549          cgactcttaatccttacagatgggaaagggctccttcaagtatgcctgggtcttggataa 420 
              ███████████████████████  
 
RPE-1         actgaaagctgagcgtgaacgtggtatcaccattgatatctccttgtggaaatttgagac 480 
HEK293FT      actgaaagctgagcgtgaacgtggtatcaccattgatatctccttgtggaaatttgagac 480 
A549          actgaaagctgagcgtgaacgtggtatcaccattgatatctccttgtggaaatttgagac 480 
               
 
RPE-1         cagcaagtactatgtgactatcattgatgccccaggacacagagactttatcaaaaacat 540 
HEK293FT      cagcaagtactatgtgactatcattgatgccccaggacacagagactttatcaaaaacat 540 
A549          cagcaagtactatgtgactatcattgatgccccaggacacagagactttatcaaaaacat 540 
               
 
RPE-1         gattACAGGGACATCTCAGGTTGG 564 
HEK293FT      gattACAGGGACATCTCAGGTTGG 564 
A549          gattACAGGGACATCTCAGGTTGG 564 
               
 
 
Figure 3.10 Multiple sequence alignment of PCR amplified genomic region from HEK293FT, A549 and 
RPE-1 cell lines. SNPs are highlighted in yellow. Binding site for sgRNA_EEF1A1_Ex3-ve is indicated by 
the green box with the PAM highlighted red. Primer sequences for amplified region are given in capitals. 
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3.3.5 SSN-Driven Transgene Integration  
I had shown that it was possible to generate indels, following NHEJ repair of the 
DSBs, at all my target loci. I next wanted to assess whether I could use these SSNs to 
target transgene integration and if these loci could support robust and long-term 
expression of the integrated transgenes.  
3.3.5.1 Integration at AAVS1 
Both the TALEN pair and the sgRNA targeting AAVS1 can drive HR repair using a 
short repair template (90mer oligonucleotide) at a modified endogenous locus to 
repair an EGFP gene disrupted by a stop codon and a 68-bp genomic fragment from 
the AAVS1 locus (Mali et al., 2013). In addition, the sgRNA has been shown to 
drive transgene integration at the native AAVS1 locus (Mali et al., 2013). I wanted to 
confirm these findings and test the ability of the TALEN pair to drive integration of a 
large DNA fragment at the native AAVS1 locus. I therefore constructed a repair 
cassette containing an EGFP gene under the control of the CMV promoter flanked 
by arms of homology (approximately 800-bp each) to AAVS1 (Figure 3.12A). This 
cassette was co-transfected into cells with either the TALENs or CRISPR/Cas9 
system (T2 sgRNA and Cas9), to test the ability of each system to drive transgene 
integration at this locus. In addition, I included the sgRNA with Cas9n to test if a 
single strand nick could drive integration of a large transgene. I had intended to 
monitor integration via EGFP expression using flow cytometry (Figure 3.11). This 
proved to be imprecise with a heterogeneous cell population and so I carried out a 
PCR-based method for transgene integration detection. This relies on locus specific 
and transgene specific primers, so that a product of 1778-bp would be produced only 






Figure 3.11 EGFP expression in heterogeneous cell populations. EGFP expression was monitored at 48 hours and 2 weeks post transfection. ALL samples showed a rapid 
decline in EGFP expression. There appears to be no apparent trend in the level of EGFP expression and the presence of SSNs.  Data represent the means of two 
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Figure 3.12 Transgene integration at AAVS1. A) Diagram of AAVS1 repair cassette. The cassette contains ~1.6-Kb total homology. The EGFP gene is driven by the CMV 
promoter and contains an SV40 poly A signal.  B) Agarose gel confirming the presence of integrated cassette. Primers specific to the AAVS1 locus and the cassette were 
used to detect the presence of correctly inserted transgenes.  Blue arrow indicates PCR product of predicted size. C) Schematic representation of integration of the cassette 
at the AAVS1 locus. Following cleavage by the SSN. The DSB is repaired by HR using the cassette as a donor template, thus leading to the insertion of the EGFP gene. 
UC = untransfected control. 
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Figure 3.12B shows that both TALENs and CRISPR/Cas9 can drive transgene 
integration, but Cas9n cannot. This confirms the results of Mali and colleagues 
(2013) and demonstrates that TALENs can also drive integration of larger DNA 
fragments into endogenous loci. It also shows that integration is dependent on DNA 
DSB formation, as no targeted integration (at this locus) is observed when the 
cassette alone is transfected into cells. Therefore, both systems can drive the site-
specific integration of large (~1.6-Kb) transgenes.   
3.3.5.2 Integration at hROSA26 
Both the TALEN pair and sgRNA which I used to target AAVS1 were designed by 
others (Mali, Yang, et al. 2013; Sanjana et al. 2012) and the sgRNA had previously 
been shown to facilitate the integration of transgenes (Mali, Yang, et al. 2013). In 
addition, several commercially available transgene integration systems based around 
AAVS1 had been developed (Sigma-Aldrich® Cat. No. CTI1; GeneCopoeia Cat. 
No. SH-AVS-K100). I therefore focused on the hROSA26 region, which had been 
less intensively studied. I also had both a TALEN pair and a double nickase pair of 
sgRNAs targeting an overlapping site at this locus, allowing for direct comparison of 
the two systems.  
I constructed a transgene cassette by cloning PCR-amplified homology arms (~1.8Kb 
total homology) either side of an mCherry reporter gene under the control of the 
EF1α promoter (Figure 3.13), which has previously been shown to drive higher 
transgene expression than the CMV promoter at the Rosa26 locus: this is particularly 
apparent when positioned in a sense orientation (Chen et al. 2011), which this 
cassette was designed to achieve. In addition, the EF1α promoter has been shown to 
be less prone to silencing than CMV (Teschendorf et al. 2002).  
I analysed HEK293FT cells by flow cytometry following transient transfection with 
and without puromycin treatment, to validate mCherry expression and test if this 
could be enriched by puromycin selection.
 
 










Figure 3.13 Diagram of hROSA26-targeting cassette. The cassette contains ~1.8-Kb total homology.  This 
cassette makes use of the mCherry reporter gene driven by the EF1α promoter. This is separated from a 
puromycin resistance gene (PuroR) by a T2A “self-cleaving” peptide sequence. This results in the 
production of the two proteins from a single mRNA. 
 
 






Figure 3.14 Flow cytometric data following transient transfection of cassette, with and without puromycin 
selection. Scatter plots show mCherry expression levels indicated as percentage of live single cells. Red dots 
indicate mCherry positive, live single cells; blue dots are live cells; purple dots are live single cells; black 
dots are dead cells, or cell clumps. For each sample, 50,000 live single cells were analysed. A) Cell only 
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Figure 3.14 demonstrates that a high proportion of cells (58.8% of live single cells) 
expressed mCherry following transient transfection. In addition, transient puromycin 
treatment was able to enrich the number of mCherry positive cells (92% of live 
single cells).  
I next sought to ascertain if the hROSA26-targeting TALENs and CRISPR/Cas9 
nickase pair were able to drive integration of this cassette. Following transfection of 
the TALEN or CRISPR/Cas9 machinery with the cassette, I monitored mCherry 
expression over time using flow cytometry (Figure 3.15).  
Initially, the proportion of mCherry positive cells in each population varied quite 
considerably and expression was rapidly lost over time in all samples (Figure 3.15). 
At 12-days post transfection, I sorted for mCherry expression in each population by 
FACS. I then allowed these populations to propagate to the 6-well plate stage before 
sorting for individual mCherry positive cells to isolate clonal lines again by FACS 
based on mCherry expression. I was able to generate 18 clonal lines: six lines from 
an mCherry control, one line from cassette alone, one line from TALENs and 
cassette and ten lines from CRISPR/Cas9 and cassette. Following a further month of 
culturing, I analysed mCherry expression in each clonal line and employed a PCR-
based method to identify correct integration events.  
I detected high levels of mCherry expression in 2/18 (11.1%) clonal lines, one of 
which was generated with CRISPR/Cas9 and cassette: the other was an mCherry 
control line. In addition, 6/18 (33.3%) lines showed low-level mCherry expression 
(mean 17.9% ± 19.9). However, I was unable to detect correct integration by PCR in 
any of the 18 clonal lines generated (Figure 3.16B), so that in this experiment on-
target integration efficiency was 0% (0/11) of lines generated with SSNs. 
In investigating the causes of this disappointing outcome, I discovered that the 
cassette’s homology arms had inadvertently been cloned in the wrong orientation 
(Figure 3.17C), meaning that HR would result in integration of the plasmid backbone 
and the transgene would be lost (Figure 3.17D). Unfortunately, due to time 
limitations, I was unable to rectify this and reattempt the integration at hROSA26. 
 
 






Figure 3.15 mCherry expression in heterogeneous cell populations. Following transfection, the mCherry 
expression in each experimental sample was monitored by flow cytometry for up to two weeks. The 
expression of mCherry rapidly declined in all experimental samples, with the majority showing <1% single 
live cells 12 days post transfection.   
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Figure 3.16 Integration at hROSA26. Page 1 of 2.  
 
 




Figure 3.16 Continued. Page 2 of 2. A) Scatter plots of flow cytometric data for individual clonal lines. 
Clone number is indicated above each scatter plot. Scatter plots show mCherry expression levels indicated 
as percentage of live single cells. Red dots indicate mCherry positive, live single cells; blue dots are live 
cells; purple dots are live single cells; black dots are dead cells, or cell clumps. For each clonal line, 50,000 
live single cells were analysed. B) PCR detection of correct integration for each clonal line. No lines 
demonstrated correct integration, indicated by the lack of a product band. Green numbers indicate 
mCherry expression between 1-80% live single cells. Red numbers indicate mCherry expression >80% live 















Figure 3.17 Integration at hROSA26. A) Diagram of hROSA26 targeting cassette. The cassette contains ~1.8-Kb total homology. B) Schematic of intended integration at 
hROSA26. Following cleavage by the hROSA26-specific SSNs, the DSB (red line) will be repaired via HR using the cassette as a donor template, resulting in the integration of 
the mCherry transgene unit. C) Diagram of hROSA26, demonstrating incorrect assembly of homology arms.  Both homology arms were clones into the cassette in the reverse 
orientation, so correct integration of the mCherry transgene unit would not occur following HR repair. D) Schematic of predicted outcome of HR repair with the incorrectly 
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3.4 Discussion 
3.4.1 Target Regions are Transcriptionally Active 
The qPCR data demonstrate that all the loci of interest are transcriptionally active 
within the panel of cell lines investigated. This is consistent with the ENCODE data 
for these regions, which indicate that they lie in areas of open chromatin. While these 
data imply that the chromatin is likely to be in an open confirmation at the target loci, 
they do not necessarily indicate the levels of expression that may be achieved upon 
transgene integration, as this will largely be dependent on the promoter within the 
targeting cassette. In addition, the presence of transcriptional activity of endogenous 
genes does not necessarily mean that silencing of transgenes integrated at these loci 
cannot occur. However, knowing that these areas are transcriptionally active suggests 
that these regions are in an environment that is more likely to be permissive to long-
term gene expression.  
3.4.2  Demonstrating Activity of SSNs 
Production of the hROSA26 TALEN proteins in vitro yielded two products for the 
left TALEN, one of expected size and one of a lower molecular weight, 
approximately 73-KDa (Figure 3.2B). This could have been the result of protein 
degradation by phosphatases. This is unlikely as there is no evidence of this in any of 
the other samples, which were prepared simultaneously under the same conditions, 
and this is unlikely to result in a single distinct band. It may also have been the result 
of a cryptic promoter. This would have to be in the repeat region of the TALEN as 
the backbone is the same for all TALENs, thus if it were present in the backbone, 
one would expect to see additional bands for all the TALENs, which is not the case. 
However, this too is unlikely as extensive sequence analysis failed to find a start 
codon positioned to produce a fragment of the length observed (corrected for 
biotinylation). Therefore, a potential explanation is the presence of a cryptic splice 
site within the repeat region of the hROSA26 left TALEN, resulting in a smaller 
spliced fragment.  
The results of the in vitro cleavage assay carried out with the hROSA26 TALEN pair 
suggest that the right TALEN may be able to act as a homodimer. The evidence for 
this is limited to the presence of one potential cleavage band following agarose gel 
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electrophoresis, which is a similar size to the larger of the two predicted cleavage 
products (Figure 3.2C). FokI nuclease activity is dependent on homodimerisation, 
meaning that each TALEN has the potential to homodimerise to bring about nuclease 
activity, resulting in a DSB, as long as appropriate binding sites are present; 
theoretically, the hROSA26 left TALEN can act as a homodimer. More recently, 
newer backbone plasmids have been developed which restrict activity to heterodimer 
formation due to mutations within the FokI nuclease domain (Naitou et al. 2015). 
Despite this, it seems unlikely based on sequence analysis that the right TALEN is 
acting as a homodimer in this instance. Indeed, under physiological conditions, no 
evidence of homodimer activity was observed (Figure 3.4A & B).  
As previously stated, the ability of the AAVS1 TALEN pair to induce indels had 
been demonstrated by others (Sanjana et al. 2012). Initial attempts to replicate this 
were unsuccessful (Figure 3.2D), but I was subsequently able to confirm activity 
better than that observed previously (Sanjana et al. 2012). I was also able to confirm 
activity of gRNA_AAVS1_T2, observing an indel frequency of 21%, which is 
similar to that observed by Mali et al. (2013).   
To demonstrate the utility of the CRISPR/Cas9 system, I also carried out the 
SURVEYOR assay. I was able to confirm the activity of all single sgRNAs in 
combination with wild type Cas9. However, in some cases activity is only apparent 
72 hours post transfection. This suggests that indel frequency increases over time and 
that some less active sgRNAs require a longer period in which to accumulate indels 
above the detection threshold. This is consistent with the findings of Shalem et al. 
(2014b) who also showed that indel frequency accumulates over time.  
The activities of the paired nickases seemed more variable than that of individual 
sgRNAs with wild type Cas9. When I designed the paired nickases for IMPDH2 and 
EEF1A1, little was known about the effect of orientation on activity and no tools 
were available to identify optimal paired target sites, only single target sites. As such, 
I selected high scoring single target sites which occurred on opposite DNA strands 
within 30-bp of each other. Consequently, four out of the five pairs designed were in 
a head-to-head orientation; three of the four head-to-head oriented pairs – those 
targeting IMPDH2 – did not show any observable activity despite each individual 
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sgRNA showing robust activity in the presence of wild type Cas9. However, both 
pairs targeting EEF1A1 were able to demonstrate activity; one pair is in a head-to-
head and the other is in a tail-to-tail orientation. Activity of paired nickases has been 
shown by others to be highly dependent on the orientation of the two sgRNAs with 
regards to each other; tail-to-tail oriented pairs tend to be more active than those 
oriented in a head-to-head configuration (Shen et al. 2014). This is consistent with 
my results for the IMPDH2-targeting pairs, which are oriented in a head-to-head 
configuration and fail to show activity in the SURVEYOR assay. However, the 
nickase pair targeting EEF1A1 (Ex3) which are also in a head-to-head configuration 
show robust activity and do not appear to differ from the other nickase pair (Ex4) 
oriented tail-to-tail, which may indicate a context-dependent effect.  
The nickase pair targeting hROSA26 was designed in light of these observations, and 
was designed in a tail-to-tail configuration to maximize chances of activity, 
(http://crispr.mit.edu/). Indeed, I was able to demonstrate its ability to induce indels 
at its target site (Figure 3.4B). However, in this case three – rather than the expected 
two – cleavage bands were present following digestion with SURVEYOR nuclease. 
Based on the approximate sizes of the cleavage products (~190-bp, ~130-bp, and 
~100-bp) it would seem that the 61-bp overhang caused by the staggered DSB has 
been resolved in multiple ways. An indel close to sgRNA_hROSA26_92A would 
cause cleavage products of ~130-bp and ~160-bp, while an indel close to 
sgRNA_hROSA26_92B would cause cleavage products of ~100-bp and ~190-bp. 
Finally, if an indel were to occur between the two sites then cleavage products of 
~130-bp and ~160-bp would be produced. Based on these predictions, it seems likely 
that the majority of indels have formed at the sgRNA__hROSA26_92B site. The 
presence of the 130-bp bands suggests that indels have formed either between the 
sites or at the sgRNA_hROSA26_92A site. In this case a band of ~160-bp should 
also be observed; this may be present but masked by the ~190-bp band, though a 
higher resolution agarose gel would be required to verify this. In addition, 
sequencing of individual amplicons would give a clearer idea of the range of indels 
following CRISPR/Cas9 activity at this locus.   
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During my investigation of SSN activity in other cell lines, I discovered that SNPs 
could complicate the interpretation of the SURVEYOR assay results (Figure 3.9). 
This has implications for the identification of sgRNA target sites; if SNPs are present 
at the target site, they also have the potential to impede the binding of the sgRNA. 
Consequently, it was not possible to investigate the activity of each SSN in different 
cell lines using the SURVEYOR assay. It has been noted that the activity of the 
CRISPR/Cas9 system can vary between different cell lines (Mali, Yang, et al. 2013). 
This may be due to differences in relative transfection efficiencies, or could suggest 
that cell line specific differences have a bearing on activity. These could either be in 
the relative activities of the HR and NHEJ pathways in different cells or due to 
epigenetic differences. Indeed, for TALENs, it has been demonstrated that CpG 
methylation can impede activity (Bultmann et al. 2012). Methods to overcome this 
have been proposed, which make use of the N* repeat, which is capable of binding to 
5mC (Valton et al. 2012). On the other hand, 5mC has been reported to have little 
effect on the activity of CRISPR/Cas9 (Hsu et al. 2013; Perez-Pinera et al. 2013), 
which may be due to the tolerance of small mismatches between the sgRNA and the 
target site.   
3.4.3 Transgene Integration 
I was able to integrate an EGFP gene into the AAVS1 locus using both TALENs and 
CRISPR/Cas9, but not using the single nickase CRISPR/Cas9 system, using a 
circular plasmid repair cassette with ~1.6-Kb total homology. These are similar to 
the results obtained by Mali and colleagues (2013) who were able to use both 
TALENs and gRNA_AAVS1_T2 in combination with Cas9 to repair a modified 
locus by HR using a linear dsDNA repair template. However, they also demonstrated 
the ability of a gRNA_AAVS1_T2 in combination with Cas9n to drive HR. This 
may be due to differences in the repair templates (linear versus circular plasmid) or 
the nature of the HR event (repair of a locus by removal of a 68-bp fragment 
compared to integration of a transgene ~1.6-Kb). Interestingly, they showed that HR 
driven by CRISPR/Cas9 appeared to be faster than that driven by TALENs, 
suggesting that TALEN-driven HR can take up to 40 hours. This is not consistent 
with the results I obtained; both systems resulted in transgene integration after 24 
hours; however, this may be due to the differences in the detection of successful HR 
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events. In addition, they were able to demonstrate transgene integration using wild 
type Cas9 at the endogenous AAVS1 locus using both ssDNA oligonucleotides and 
dsDNA donor templates, consistent with the results here.  
Building on this, I wanted to demonstrate that hROSA26 could also support 
transgene integration, driven by both TALENs and CRISPR/Cas9, and hoped to 
compare the two systems at this locus. As the AAVS1 region has been more 
extensively studied using ZFN (Chang & Bouhassira 2012; Wang et al. 2012; Zou et 
al. 2011; DeKelver et al. 2010; Smith et al. 2008), TALENs (Cerbini et al. 2015; 
Mussolino et al. 2014; S. Zhang et al. 2014; Maggio et al. 2014; Hockemeyer et al. 
2011) and CRISPR/Cas9 (Cho et al. 2014; Maggio et al. 2014; J.-H. Zhang et al. 
2014; Mali, Yang, et al. 2013), in addition to the appearance of commercially 
available integration systems based upon AAVS1 (Sigma-Aldrich® Cat. No. CTI1; 
GeneCopoeia Cat. No. SH-AVS-K100), I decided to focus my efforts on further 
investigating hROSA26. To achieve this, I constructed a targeting cassette containing 
an mCherry gene and a puromycin resistance cassette under the control of the EF1α 
promoter, with approximately 1.8-Kb total homology. Following transfection and 
selection with puromycin, there was a large difference in the proportions of mCherry 
positive cells in each population, even though each population was transfected with 
the same amount of mCherry-expressing plasmid, with the TALENs and 
CRISPR/Cas9 populations having the lowest levels of mCherry expression (Figure 
3.20). Subsequently the proportion of mCherry expressing cells in each population 
rapidly declined. After sorting for mCherry-expressing cells, the proportions of 
mCherry positive cells in each population remained low (less than 10% single live 
cells). Due to the low numbers of mCherry positive cells, I was only able to generate 
18 clonal lines. Of these, only 2 lines showed high level mCherry expression (greater 
than 80% live single cells) and none demonstrated correct insertion of the cassette at 
the target locus (Figure 3.16A & B). This was unexpected based on the results from 
the AAVS1 locus. However, following further inspection, it became apparent that the 
homology arms within the targeting cassette had been inadvertently cloned in the 
wrong orientation (Figure 3.17C) so that integration of the plasmid backbone and not 
the transgene would occur following HDR of the SSN-induced DSB (Figure 3.17D). 
This explains the lack of correct integration at the target locus and helps to explain 
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the continued loss of mCherry expression even after enrichment by FACS; upon 
integration, the mCherry gene would be lost. It is likely that the clones showing high-
level mCherry expression result from the random integration of the transgene and 
enrichment by FACS has selected for those integrated into loci that permit robust 
expression. It would be worth investigating these clones further and identify the 
integration loci, which may be useful for further studies of transgene integration.  
Some clones demonstrated low-level mCherry expression. These clones are likely to 
harbour random integration of the transgene. However, in these cases, integration 
loci are less permissible to robust expression, or have been subject to incomplete 
silencing. The variegated phenotype observed, is likely due to position effects, which 
are commonly seen following random integration.    
3.5 Future Perspectives 
Due to technical issues and time constraints, I was unable to demonstrate successful 
transgene integration at the hROSA26 locus. Therefore, I could not investigate long-
term expression of transgenes at this locus. It remains important to characterise this 
site as a suitable locus for prolonged expression. The mouse Rosa26 site has been 
used successfully for transgene expression since its identification over two decades 
ago (Friedrich & Soriano 1991), which suggests that the human homologue may be 
an ideal location for efficient transgene expression. Indeed, Irion et al. (2007) 
demonstrated the ability of hROSA26 to support transgene expression even after 
embryonic stem cell differentiation into a range of lineages.   
More recently, homologues of the Rosa26 locus have been identified in rat 
(Kobayashi et al. 2012) and pig (Li et al. 2014), which can both support robust 
transgene expression. This suggests there has been evolutionary conservation of this 
locus; it would be worth investigating how well conserved it is across other 
mammalian and non-mammalian species and if all can support transgene integration.   
Careful choice of transgene integration locus can reduce the risk of subsequent 
transgene silencing, but other factors can also influence this, particularly the design 
of the repair cassette. Studies have shown that different promoters show individual 
susceptibilities to silencing (Spencer et al. 2015; Gray et al. 2011; Papadakis et al. 
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2004). Judicious promoter choice is likely to be necessary for efficient and prolonged 
expression, though identification of appropriate promoters for each target locus may 
only be possible through experimentation. In addition, orientation of integration may 
affect the expression levels. Chen et al. (2011) showed that certain promoters showed 
orientation dependent activity at the Rosa26 locus. Additional cassette design 
considerations can be made in order to maximize the likelihood of optimal transgene 
expression such as inclusion of insulators, though each would likely need to be 
validated experimentally in order to find the optimal cassette design.  
One of the potential outcomes of this work was the development of a stable producer 
cell line for recombinant lentiviral vectors, currently being developed within the 
UKCFGTC. Recently, Sanber and colleagues (2015) have generated a stable 
producer line in which they identified suitable sites for expression by screening 
clones generated following integration of gammaretroviral vectors. They used a non-
cytotoxic envelope protein (RDpro, derived from gammaretroviral RD114 envelope 
glycoprotein), but do suggest that inducible promoters could be used should a 
cytotoxic envelope protein be required.  
This system demonstrates the feasibility of a producer line, but would need to be 
reengineered for each application (e.g. different transgene of interest). To achieve 
this it would be advantageous to have sites known to support expression with an SSN 
toolkit to facilitate integration. This has been demonstrated for AAVS1, and with 
more investigation could prove to be the case for hROSA26. The tools I developed 
here targeting hROSA26, along with the SSNs targeting AAVS1, will be useful for 
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4.1 Introduction  
Transgene integration is a vital tool in cell biology. However, current methods for 
integrating transgenes can be inefficient and usually rely on selection for drug 
resistance genes forming part of the targeting cassette. Transgenes can integrate 
either site-specifically or randomly into the genome of their recipient cell, driven 
respectively by HR and NHEJ DNA-repair pathways (Sakurai et al. 2010). Other 
pathways, such as the alternative end-joining pathway (Iiizumi et al. 2008) and 
microhomology-dependent random integration (Merrihew et al. 1996), have also 
been implicated in the random integration of transgenes. Site-specific transgene 
integration requires targeting cassettes carrying large regions of homology to the 
intended target locus, which can be difficult to construct. In mammals this occurs 
less commonly than random integration (Zheng & Wilson 1990) as NHEJ occurs 
more frequently than HR (Sakurai et al. 2010). However, randomly integrated 
transgenes are prone to position effects and gene silencing, resulting in unreliable 
and unpredictable expression (Sadelain et al. 2012). 
Newer technologies, particularly the advent of SSNs, have helped to overcome some 
of these issues; transgenes can be efficiently targeted to predetermined loci, selected 
for their ability to permit robust and long-term expression, which would reduce the 
risk of gene silencing. In addition, the production of a DSB at the target site increases 
the HR efficiency in mammalian cells by several orders of magnitude (Elliott et al. 
1998; Liang et al. 1996; Choulika et al. 1995; Rouet et al. 1994a). However, 
selecting for site-specific integration events remains reliant on the introduction of a 
selectable marker.  
To help address this issue, I designed a novel drug-selectable transgene integration 
system. The intent was to allow rapid selection of transgenes integrated at the target 
locus (IMPDH2), whilst eliminating cells containing randomly integrated transgenes, 
without the need for an exogenous selection marker. 
4.1.1  Drug-Selectable Transgene Integration System 
The principle of the proposed selection system is based on the fact that the activity of 
both human inosine monophosphate dehydrogenase (IMPDH) isoforms can be 
inhibited by the drug mycophenolic acid (MPA), while variants of IMPDH are 
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known to be severalfold more resistant (discussed in Section 4.1.4). The IMPDH2 
locus will be targeted using the CRISPR/Cas9 system, resulting in a DSB (Figure 
4.1). This will subsequently be repaired via HR using the repair cassette provided. 
The repair cassette will consist of the distal portion of an IMPDH cDNA variant 
(which encodes an IMPDH variant severalfold more resistant to MPA than IMPDH2) 
and a transgene (initially a reporter gene, such as mCherry) in a separate 
transcriptional unit flanked by arms of homology. Once repaired, the locus will 
encode a hybrid IMPDH enzyme capable of conferring resistance to MPA. IMPDH 
is a key metabolic enzyme (Section 4.1.2); its inhibition by MPA should be lethal, 
thus only cells bearing the correct insertion will survive selection in MPA-containing 
media (Figure 4.1). This should result in robust long term expression of the transgene 
which can be observed through monitoring the mCherry signal over time.  
To ensure that the repair cassette encodes a functional enzyme, the CRISPR/Cas9 
system will be used to generate a DBS within intron five of the endogenous IMPDH2 
locus, and the IMPDH variant will contain the endogenous splice acceptor site from 
IMPDH2 to ensure correct processing. The IMPDH2 locus is organised into 14 exons 
and 13 introns spanning 5118-bp on human chromosome 3 (position 3p21.31). The 
enzyme’s active site is encoded by exons nine and ten, and the residues which make 
direct contact with MPA are encoded by exons eight, nine and twelve. For the 
purpose of the drug-selectable transgene integration system, I needed to target the 
IMPDH2 locus upstream of these features, in order to generate a functioning hybrid 
which could confer MPA-resistance to cells. I therefore chose to target intron five. It 
is the largest intron within the IMPDH2 locus and so would give greatest flexibility 
when designing sgRNAs. In addition, it is distal enough from the transcription start 
site that the repair cDNA should not of itself encode an active enzyme, so if random 
integration should occur, it is unlikely that MPA resistance would be conferred. 
Unlike other currently available selection systems, such as those relying on 
exogenous selection markers within the repair cassette, the attractive feature of this 
system lies in the fact that only transgenes correctly integrated at the IMPDH2 locus 
will result in a functional IMPDH variant; the partial cDNA encoding the IMPDH 
variant within the transgene cassette will not produce a functional enzyme unless 
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correctly integrated at the IMPDH2 locus, thus only cells with a correctly integrated 
transgene will be resistant to MPA. 
4.1.2 Inosine Monophosphate Dehydrogenase 
IMPDH (EC 1.1.1.205) is the enzyme responsible for the oxidation of inosine 
monophosphate (IMP) to xanthosine monophosphate (XMP), with concomitant 
reduction of nicotinamide adenine dinucleotide (NAD), the first committed and rate 
limiting step in de novo guanine nucleotide biosynthesis (Figure 4.2). Humans have 
two isoforms, IMPDH1 and IMPDH2 (Natsumeda et al. 1990), which are encoded by 
the genes IMPDH1 and IMPDH2, respectively. These isoforms are 84% identical at 
the amino acid level and have almost indistinguishable kinetic properties. Both 
isoforms are expressed to varying degrees in most tissues, though IMPDH1 is more 
highly expressed in the retina, spleen and resting peripheral blood mononuclear cells 
(Hedstrom 2009), while IMPDH2 is upregulated during proliferation and in some 
cancers (Hedstrom 2009). In addition, IMPDH1 null mice present with retinal 
degeneration (Aherne et al. 2004) while IMPDH2 knockouts die in early 





Figure 4.1 Proposed drug-selectable transgene integration system at IMPDH2. The human IMPDH2 locus will be targeted using the CRISPR/Cas9 system, resulting in a DSB. 
This will be repaired by HR using the repair cassette provided. The repair cassette will consist of the distal portion of an IMPDH variant along with a transgene of interest 
(initially mCherry) flanked by arms of homology. Once integrated, the IMPDH variant will form a hybrid enzyme with the proximal portion of IMPDH2, which will confer 
cells with an increased resistance to MPA, allowing for rapid selection of correctly integrated transgenes. 
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Figure 4.2 Guanine nucleotide biosynthesis.  IMPDH catalyses the conversion of IMP to XMP (bold) which is the first committed and rate limiting step in guanine nucleotide 
biosynthesis. The salvage pathway recycles guanosine and guanine into GMP which can then be used for DNA and RNA synthesis. Key enzymes are indicated in blue.  
Inhibitors are depicted in red.  IMP = inosine monophosphate; XMP = xanthosine monophosphate; GMP = guanosine monophosphate; GDP = guanosine diphosphate; GTP = 
guanosine triphosphate; dGDP = deoxyguanosine diphosphate; dGTP = deoxyguanosine triphosphate; NK = nucleoside kinase; HPRT = hypoxanthine-guanine 
phosphoribosyl transferase; XPRT = xanthine phosphoribosyl transferase; GMPS = GMP synthase; PNP = purine nucleoside phosphorylase; MPA = mycophenolic acid.
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4.1.2.1 Guanine Nucleotide Synthesis 
Cells have two pathways for delivering their guanine nucleotide needs: the de novo 
synthesis pathway and the guanine salvage pathway. IMPDH is essential for the de 
novo synthesis pathway, catalysing the first committed and rate limiting step (Figure 
4.2). In addition to this pathway, cells can also recycle guanine via the salvage 
pathway (Figure 4.2). The main enzyme responsible for this is hypoxanthine-guanine 
phosphoribosyl transferase (HPRT). The activity of these pathways varies depending 
on cell type, with rapidly proliferating cells such as lymphocytes relying almost 
entirely on the de novo synthesis pathway for their guanine nucleotide needs (Allison 
et al. 1977).   
4.1.2.2 Role of IMPDH in Disease 
IMPDH is a key regulator of the guanylate pool, which is essential for many 
metabolic pathways and as such its activity is closely linked with oncogenesis. 
Indeed, IMPDH, primarily IMPDH2, activity and expression is significantly elevated 
in many human and animal tumours (as reviewed by Oláh et al. 2006). In addition, it 
has been demonstrated that IMPDH1 plays a key role in angiogenesis (Chong et al. 
2006; Wu et al. 2006).  
T and B lymphocytes, important modulators of the immune system, are reliant on the 
de novo synthesis pathway for guanine nucleotides and proliferation. Thus, inhibitors 
of IMPDH can be utilised for immunosuppression (Jain et al. 2001); for example, the 
morpholinoethyl ester of MPA, mycophenolate mofetil (MMF), is commonly used as 
an immunosuppressive agent to prevent rejection following solid organ transplant 
(Neyts et al. 1998). 
In addition, microbial IMPDH enzymes are sufficiently distinct from the human 
forms; in recent years, there has been an increasing interest in the development of 
specific IMPDH inhibitors for use in antimicrobial therapy (Braun-Sand & Peetz 
2010; Nair & Shu 2007).  
4.1.3 Mycophenolic Acid 
MPA is a natural compound first isolated from the fungus Penicillium 
brevicompactum and forms the active metabolite of the widely used 
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immunosuppressant MMF. MPA is a specific and potent inhibitor of mammalian 
IMPDH, inhibiting both human isoforms, though it is much less potent for microbial 
IMPDH enzymes. It inhibits IMPDH by trapping the IMP reaction intermediate 
(XMP*) in the enzyme’s active site (E-XMP*), rendering it inactive (Fleming et al. 
1996; Link & Straub 1996). Inhibition of IMPDH results in a depletion of the 
guanylate pool, particularly GMP, and inhibition of DNA synthesis, leading to 
cessation of cell proliferation.  
4.1.4 MPA-Resistant IMPDH Variants 
For the purpose of this study, I am interested in two IMPDH variants which have 
been shown to have increased resistance to MPA compared to human IMPDH2: 
Tritrichomonas foetus IMPDH (Tf-IMPDH) and IMPDHIY. Tf-IMPDH from the 
protozoan T. foetus is 500-fold more resistant to MPA than human IMPDH2 
(Hedstrom 2009). Studies have shown that while some of this resistance is due to 
changes in the residues directly contacting MPA, not all of the resistance can be 
attributed to this (Digits & Hedstrom 1999). Thus, this may add additional 
complexity to the design of the drug-selectable integration system. IMPDHIY is a 
variant of IMPDH first identified in neuroblastoma cells selected for 10,000-fold 
increased resistance to MPA treatment (Hodges et al. 1989). It carries two amino 
acid substitutions: T333I and S351Y. Thr333 is one of the amino acids which 
directly interact with MPA: T333I alone has been shown to increase the Ki of MPA 
300-fold (Sintchak et al. 1996). IMPDHIY contains only two amino acid substitutions 
compared with wild type IMPDH2, and would thus make the design of the repair 
cassette more straightforward.  
4.1.4.1 Comparisons with HPRT and the HAT Selection System 
At first glance, the drug-selectable transgene integration system proposed here may 
seem similar to the HAT (hypoxanthine-aminopterin-thymidine) selection system 
based on the HPRT1 gene (which encodes HPRT). However, a few important 
differences exist. Firstly, cells deficient in HPRT are resistant to the cytotoxic effects 
of 6-thioguanine (6-TG). Therefore, one could imagine integrating transgenes at the 
HPRT1 locus, causing loss of HPRT function, then selecting for integration with 6-
TG. However, this would also select for cells which carry loss of function HPRT1 
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mutations, due to NHEJ repair of the targeted DSB, but which do not have an 
integrated transgene. As NHEJ occurs more frequently than HR (Sakurai et al. 2010), 
one could postulate that the majority of selected clones would carry loss of function 
mutations and not integrated transgenes. Thus, selection would not be specific.  
In contrast, a cell line null for HPRT and therefore sensitive to HAT selection could 
be used. In this instance, the targeting cassette would contain the HPRT1 gene and 
thus integration would render cells resistant to HAT. However, selection of 
integration events would not necessarily be site-specific, as HPRT1 integrated 
anywhere would confer resistance to HAT. Alternatively, a partial HPRT1 cDNA 
could be used to repair the loss of function mutations at the HPRT1 locus, analogous 
to the novel system proposed here. However, both of these methods rely on the 
availability of an HPRT null cell line; this would usually require time-consuming 
preliminary work to generate HPRT1 loss of function mutations in a cell line of 
choice.   
Another unique aspect to the system proposed here is that once validated, it will 
allow for the integration and selection of any transgene of interest, without the need 
for constructing complex targeting constructs with exogenous selection genes. 
Changing the transgene of interest will involve a single subcloning step to swap the 
initial reporter gene for any gene of interest. This can then be targeted to IMPDH2 
and correct integration selected for by MPA treatment.  
4.2 Aims 
The overall aim described in this chapter was to develop a drug-selectable transgene 
integration system at the human IMPDH2 locus. This can be subdivided into the 
following in order to achieve a functional drug selection system:  
1. Design and construct sgRNAs to target intron five of IMPDH2 and assess 
their activity in cellulo.  
2. Assess the ability to select IMPDH variant using MPA treatment.  
3. Demonstrate the ability of IMPDH2 to support transgene expression and 
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4.3 Results 
4.3.1  Targeting IMPDH2 with sgRNAs 
I used the CRISPR/Cas9 system rather than TALENs for the development of this 
system as they have been shown to be equally effective, but sgRNAs can be more 
easily designed and constructed compared with TALENs (as discussed in Chapter 3).  
4.3.1.1  Identifying sgRNA Target Sites 
I identified potential sgRNA target sites using the CRISPR design tool developed by 
the Zhang laboratory (Hsu et al., 2013; available at http://crispr.mit.edu/; described in 
Chapter 3). This gave 22 possible sgRNA target sites. From these I selected six of the 
highest scoring sites which could be used to make three nickase pairs, binding 
opposite DNA strands with less than 30-bp between their target sites. Nickase pairs 
have a reduced off-target profile, thus should help to make the system as specific as 







Figure 4.3 Location of IMPDH2-targeting sgRNAs on human chromosome 3. Green boxes indicate the location of the target sites for each individual sgRNA within intron 5 of 
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4.3.1.2 Validation of sgRNA Activity in cellulo 
The activity of each individual sgRNA (in combination with wild type Cas9), as well 
as each nickase pair (in combination with Cas9n), was determined using the 
SURVEYOR assay and is described in detail in Chapter 3. In summary, each 
individual sgRNA was able to target Cas9 cleavage to the intended target locus, but 
all three nickase pairs failed to demonstrate detectable activity.  
In order to confirm the results of the SURVEYOR assay and observe the range of 
indels generated following CRISPR/Cas9 activity, I generated clonal lines following 
transfection with each sgRNA and wild type Cas9 or each nickase pair by FACS. I 
isolated a total of 11 clonal lines derived from wild type Cas9 and 5 clonal lines from 
Cas9n. Unfortunately, some lines were lost during this process so I was not able to 
isolate clonal lines for all of the individual sgRNA. Following PCR amplification of 
the target region, I cloned and sequenced individual amplicons, the results of which 
are depicted in Figure 4.4. 
Target efficiency is high with 10/11 (90.9%) clonal lines derived from wild type 
Cas9 having an indel at the target site. The observed mutations generally clustered 
around the predicted cleavage site (3-bp upstream of the PAM), though not always. 
In the case of sgRNA_3+, both insertion and deletion occurred downstream of the 
predicted cleavage site (16-bp and 13-bp, respectively). The most commonly 
observed mutations were deletions, ranging from 2-bp to 27-bp. Insertion events 
seem to be restricted to single bases, though in one case there was a large insertion of 
237-bp, which aligns to a region in human chromosome 20 that shares 4-bp 
microhomology with the target. Some clones had more than two mutant alleles. 
Clones derived following transfection with the nickase pairs had no observable indels 







WT C T T T T A A A C C C C T A A G G T A G G G G C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C
Clone 1a C T T T T A A A C C C C T A A - - T A G G G G C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 2
Clone 1b C T T T T A A A C C C C T A - - - + 2 3 7 bp - - - G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 11, ins 237
Clone 1c C T - - - - - - - - - - - - - - - T A G G G G C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 15
Clone 2a C T T T T A A A C C C C T A A G G - - - - - - C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 6
Clone 2b C T T T T A A A C C C C T T A A G G T A G G G G C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C ins 1
Clone 3a C T T T T A A A C C C C T A A G G - - - - - - C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 6
Clonr 3b C - - - - - - - - - - - - - - - - - - - - - - C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 22
Clone 4 C T T T T A A A C C C C T A A - - T A G G G G C A G T G C T T G A G G T C T G C C C T G A T T T T C T T G C del 2
sgRNA_2+
WT C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C
Clone 1a C C T T A T T C C A T A G T G T - - - - - - - - - - - - - - - - - - - - - - - - - - - T C C T T T C T A C T del 27, sub
Clone 1b C C T T A T T C C A T A G T G T T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C ins 1 
Clone 1c C C T T A T T C C A T A - - - - - - G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C del 6
Clone 2 C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C No indel
sgRNA_2-
WT T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T
Clone 1a T C C T T A T T C C A T A G T G T T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T ins 1
Clone 1b T C C T T A T T C C A T - - - - - - A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T del 6
Clone 1c T C C T T A T T C C A T A G T G T T - - - - - - - - - - - - - - - - - - - - - - - - - - - C T T T C T A C T C ins 1, del 27
Clone 2 T C C T T A - - - - - - - - T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T del 8
sgRNA _3+
WT A T T A C A G G G G T G A A G T T C T A T G G A C C A C C A C G T T C A T A C A T T C A C A C C C A A A A C
Clone 1a A T T A C A G G G G T G A A G T T C T A T G G A C C A C C A C G T T T C A T A C A T T C A C A C C C A A A A C ins 1
Clone 1b A T T A C A G G G G T G A A G T T C T A T G G A C C A C C - - - - - - - - - - - - - - A C A C C C A A A A C del 14
sgRNA_3-
WT T G G G T G T G A A T G T A T G A A C G T G G T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A
Clone 1a T G G G T G T G A A T G T A T G - - - - - - - - - G T C C A T A G A A C T T C A C C C C T G T A A T C T C A del 9
Clone 1b T G G G T G T G A A T G T A T - - - C G T G G T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A del 3
Clone 1c T G G G T G T G A A T G T A T - - - - G T G G T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A del 4
Clone 1d T G G G T G T G A A T G T A T G A - - - - - - T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A del 6
Clone 2a T G G G T G T G - - - - - - - - - - - - - - G T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A del 14
Clone 2b T G G G T G T G A A T G T A T G A A A C G T G G T G G T C C A T A G A A C T T C A C C C C T G T A A T C T C A ins 1
sgRNA_2+/sgRNA_2-
WT T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C
WT T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C
Clone 1 T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C No indel
Clone 2 T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C No indel
Clone 3 T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C No indel
Clone 4 T C C T T A T T C C A T A G T G T A A G A G G G T G C T C C C T G T G C C A T G T T G T C C T T T C T A C T C No indel


































Figure 4.4 Range of mutations 
observed following CRISPR/Cas9 
activity at the IMPDH2 locus.  Green 
boxes = sgRNA target; Red boxes = 
PAM; Grey boxes = no change; white 
box = indel; (-) = deletion; red letter = 
insertion; del = deletion; ins = 
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4.3.2 Validation of MPA Sensitivity 
Due to the gene therapy interests of my group, I decided to use HEK293FT cells for 
the creation of the drug-selectable integration system. This cell line is commonly 
used in the production of clinical grade lentiviral vectors and is a highly transfectable 
derivative of the HEK293 cell line, which possesses a stable integration of the SV40 
large T antigen, required for efficient lentiviral production (Gama-Norton et al. 
2011). In order for efficient selection of MPA-resistant IMPDH variants, the host cell 
line (HEK293FT cells) must show sensitivity to MPA treatment. Qasim et al. (2011) 
showed that HEK293 cells are sensitive to treatment with MPA (Figure 4.5B). In 
order to assess the sensitivity of HEK293FT cells to MPA treatment and determine 
any difference in response to HEK293 cells, I carried out a BrdU-based cell 
proliferation enzyme-linked immunosorbent assay (ELISA) following treatment with 
either 10 µM or 100 µM MPA for a period of 72 hours. This involved incubating 
cells with BrdU labelling agent for a period of 2 hours before fixing, permeabilising 
and staining with an anti-BrdU antibody conjugated to peroxidise. Total BrdU 
incorporation (as a marker of cell proliferation) was determined by colorimetric 
readout of the peroxidise-substrate reaction (measured using a plate reader).  
Figure 4.5A demonstrates the dose-dependent sensitivity of both HEK293 cells and 
HEK293FT cells to MPA, with both 10 µM and 100 µM MPA, giving reduced levels 
of cell proliferation compared with the control (vehicle only). There is no significant 
difference between either cell line at both MPA concentrations tested (p = 0.62 for 
10 µM and p = 0.64 for 100 µM). Although these results do not fully replicate the 
findings of Qasim et al. (2011; Figure 4.5B), who were able to show proliferation 
levels of less than 10% of control for the highest MPA concentration tested 
(100 µM), they do demonstrate sensitivity of both these cell lines to short term (72 
hour) treatment with MPA; this ought to have been sufficient to allow for effective 
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Figure 4.5 HEK293 and HEK293FT cell survival following MPA treatment. A) Cells were treated with 0, 
10 or 100 µM MPA for a period of 72 hours. Cell proliferation was determined using a BrdU based ELISA. 
Results are shown as percentage of untreated control (0 µM MPA). No significant difference was found 
between HEK293 and HEK293FT at either 10 µM or 100 µM MPA. Means of 3 independent experiments 
are shown. Error bars denote standard error of the mean (S.E.M.). ns = not significant (p > 0.05). B) 
Figure taken with permission from Qasimet al. (2011) showing the effect of a range of MPA concentrations 
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4.3.3 Validation of IMPDH2 Variants  
To assess the ability of IMPDHIY and Tf-IMPDH (discussed in Section 4.1.4) to 
confer increased resistance to MPA, compared with wild type IMPDH2, I carried out 
the same BrdU-based ELISA described above. In this instance, cells cultured in 96-
well plates were first transfected with cDNA expression vectors encoding each 
variant (or a wild type IMPDH2, to control for changes in resistance due to 
overexpression). Transfection efficiency was estimated using a concurrent 
transfection with an EGFP expression vector, with fraction of EGFP positive cells 
determined using a fluorescence microscope. Transfection efficiency was ≥60%. 
Cells were then treated with either 10 µM or 100 µM MPA for a period of 72 hours, 
24 hours post transfection.  
At the lowest MPA concentration tested (10 µM), neither IMPDHIY nor Tf-IMPDH 
demonstrated greater resistance than overexpression of IMPDH2, with none of the 
three reaching significance over wild type (untransfected) cells (Figure 4.6).  
Interestingly, IMPDHIY did not confer increased resistance to MPA treatment even at 
the highest concentration tested (100 µM) compared to wild type cells and performed 
worse than overexpression of IMPDH2. Thus, IMPDHIY was excluded from further 
experiments. However, Tf-IMPDH did confer increased resistance to MPA compared 
to wild type at both MPA concentrations tested, as demonstrated by the higher level 
of proliferation; this only reaches significance at 100 µM MPA (p = 0.0066), where it 
also demonstrates significantly more resistance to MPA than IMPDH2 
overexpression and IMPDHIY(p = 0.0242 and p = 0.0053, respectively).  
While Tf-IMPDH was able to confer significantly elevated resistance to MPA 
treatment compared to wild type (and IMPDH2 overexpression) at 100 µM, there 
was still a high proportion of wild type cells surviving the MPA treatment 
(approximately 60% of untreated control), making selection of MPA resistant cells 
difficult. It is clear that Tf-IMPDH demonstrates increased resistance to MPA 
treatment over wild type cells, but this difference between Tf-IMPDH-expressing 
cells and wild type cells, though statistically significant, would not underpin a 
practical selection system. To address this, I next tested whether extending the 
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therefore carried out the BrdU-based cell proliferation ELISA after a period of 120 
hours of MPA treatment on cells transfected with either Tf-IMPDH or IMPDH2.  
Tf-IMPDH does not confer significant resistance to MPA compared to wild type 
HEK293FT cells or cells overexpressing IMPDH2 at 10 µM MPA following either 
72 hours or 120 hours of treatment (Figure 4.7). However, at 100 µM MPA, it 
confers significant resistance following both 72 hours and 120 hours of treatment 
over wild type and IMPDH2 overexpression. While Tf-IMPDH confers significant 
resistance at both time points, residual survival of wild type cells is reduced 











Figure 4.6 Validation of MPA resistance of IMPDH2 variants. Cells were transfected with either human 
IMPDH2 (hIMPDH2), human IMPDH2IY (IY) or Tf-IMPDH (Tf) cDNA expression vectors prior to 
treatment with 0, 10 or 100 µM MPA for a period of 72 hours. Cell proliferation was determined using a 
BrdU-based ELISA. Results are shown as percentage untreated control (0 µM MPA). Data represent 
means of 3 independent experiments. Error bars show the standard error of the mean (S.E.M.). Unpaired 



















































Figure 4.7 Validation of MPA resistance of IMPDH2 variants at 72 and 120 hours. Cells were transfected with either human IMPDH2 (hIMPDH2) or T. foetus IMPDH (Tf) 
cDNA expression vectors prior to treatment with 0, 10 or 100 µM of MPA for a period of either A) 72 hours or B) 120 hours. Cell proliferation was determined using a BrdU 
based ELISA. Results are shown as percentage or untreated control (0 µM MPA). Data represent means of at least 3 independent experiments. Error bars depict standard 
error of the mean (S.E.M.). A) No significant differences were found between any sample treated with 10 µM MPA. B) No significant differences were found between any 
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4.3.4 Utilising Salvage Pathway Inhibitors  
In order to improve selection of cells carrying MPA-resistant forms of IMPDH, I 
sought to employ the use of a guanine salvage pathway inhibitor, acyclovir 
monophosphate. As mentioned above (Section 4.1.2.1), cells have two 
interconnected pathways to fulfil their guanine nucleotide requirements: de novo 
synthesis and the guanine salvage pathway. IMPDH plays a pivotal role in the de 
novo synthesis pathway, and inhibition of IMPDH via MPA treatment blocks this 
pathway. Therefore, cells become entirely reliant on the guanine salvage pathway. 
Inhibition of both pathways should select for MPA resistant cells, provided by the 
presence of Tf-IMPDH. 
To investigate the potential of acyclovir monophosphate to modulate the response of 
Tf-IMPDH-expressing cells to MPA treatment, I carried out a BrdU-based cell 
proliferation ELISA. This time, cells were treated with a combination of 100 µM 
MPA and a range of acyclovir monophosphate concentrations (0, 1, 10 and 100 µM) 
for a period of 120 hours, following transfection with Tf-IMPDH (or wild type 
IMPDH2).  
Acyclovir monophosphate did not have the predicted effect: increasing the 
concentration of acyclovir monophosphate (at a constant MPA concentration) did not 
lead to a decrease in cell proliferation in the wild type cells (Figure 4.8). Tf-IMPDH 
transfected cells demonstrated no significant change in cell proliferation across all 
concentrations of acyclovir monophosphate tested (ANOVA, p>0.05). Overall, there 
was a modest decrease in the difference between cell proliferation of wild type cells 
and Tf-IMPDH transfected cells, except at 1 µM, where it slightly increases (Table 
4.1), though this is not significant (ANOVA, p>0.05). In addition, there was no 
significant difference in cell proliferation across all concentrations of acyclovir 
monophosphate tested, for both wild type cells and cells transfected with IMPDH2 
cDNA (ANOVA, p>0.05). Due to this unexpected response, acyclovir 
monophosphate co-treatment with MPA failed to improve selection of Tf-IMPDH 













Figure 4.8 Effect of co-treatment with acyclovir monophosphate and MPA. Cells were transfected with 
either human IMPDH2 (hIMPDH2) or T. foetus IMPDH (Tf) cDNA expression vectors prior to treatment 
with varying concentrations of acyclovir monophosphate (0-100 µM) and 100 µM MPA for a period of 120 
hours. Cell proliferation was determined using a Brd-U based ELISA. Results are shown as percentage 
control (DMSO treated). Data represents 3 independent experiments. Error bars depict standard error of 
the mean (S.E.M.).All significant (p < 0.05) differences are indicated (calculated by unpaired T-test).
100 µM MPA
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Table 4.1 The effect of Acyclovir Monophosphate and MPA co-treatment on the Selection of Tf-IMPDH. 
The differences in the levels of cell proliferation between wild type and Tf-IMPDH following treatment ± 
S.E.M. are listed. No statistical significance was found between any of the concentrations, p>0.05 (ANOVA 




Absolute difference in cell 
proliferation between WT 
and Tf (%) 
0 54.3 ± 13.8 
1 65.3 ± 17.4 
10 40.1 ± 17.0 
100 32.8 ± 17.6 
 
4.3.5 IMPDH2 as a Site for Transgene Integration 
The development of the IMPDH integration system was not further pursued, in light 
of the difficulties in successfully selecting MPA-resistant variants from wild type 
cells. However, it is clear from these experiments that cells can tolerate a degree of 
inhibition of endogenous IMPDH2. Therefore, it should be possible to use the 
IMPDH2 locus as a target for transgene integration, disrupting gene function of one 
allele, without adverse consequences for cell health.  
4.3.5.1 Repair Cassette Design and Construction  
I generated an IMPDH2-targeting transgene integration cassette by cloning PCR-
amplified IMPDH2 homology arms either side of an mCherry transgene under the 
control of the EF1α promoter. The cassette also contains a puromycin resistance gene 
downstream of a P2A signal. Figure 4.9 shows the organisation of the repair cassette, 
which was designed so that any of the six individual sgRNAs could be used to drive 
its integration. It contains a total of approximately 3.5-Kb homology. 
Once constructed and sequence verified, I wanted to ensure that the cassette could 
express mCherry and that this expression could be enriched by transient puromycin 
selection. In order to verify this, I carried out transient transfections with the cassette, 
with and without puromycin selection. I then carried out flow cytometric analysis of 















Figure 4.9 IMPDH2 transgene integration cassette. The cassette has a total homology of ~3.5-Kb, which 
was designed so that any of the six IMPDH2-targeting sgRNAs can be used to drive its integration. The 
reporter gene mCherry is under the control of the EF1α promoter, which also drives the expression of the 
puromycin resistance gene. The T2A “self-cleaving” peptide sequence allows expression of both genes from 











Figure 4.10 Flow cytometric data following transient transfection of cassette, with and without puromycin 
selection. Scatter plots show mCherry expression levels indicated as percentage of live single cells. Red dots 
indicate mCherry positive, live single cells; blue dots are live cells; purple dots are live single cells; black 
dots are dead cells, or cell clumps. For each sample, 50,000 live single cells were analysed. A) Untransfected 
control for cells not treated with puromycin. B) Cells transfected with repair cassette. C) Untransfected 
control for cells treated with puromycin. D) Cells transfected with repair cassette and selected with 
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Figure 4.10 indicates that HEK293FT cells transfected with the cassette express 
mCherry (25.1% of live single cells). In addition, transient puromycin selection 
increased the proportion of living cells expressing mCherry (64.5% of live single 
cells).  
4.3.5.2 Integration of Repair Cassette  
I co-transfected the CRISPR/Cas9 machinery and the repair cassette into HEK293FT 
cells. I treated these with puromycin for a period of 48 hours to select for transfected 
cells. Following recovery from puromycin treatment (a further 48 hours), I monitored 
mCherry expression in each population by flow cytometry (Figure 4.11). 
Initial flow cytometric data show that all cells transfected with the repair cassette 
demonstrate mCherry expression, ranging from 14.5% to 36.3% of living single cells 
(Figure 4.11). The proportion of mCherry expressing cells rapidly declined over two 
weeks until less than 1% of live cells were expressing mCherry. At this point I 
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Figure 4.11 Initial mCherry expression in transfected populations. Analysis was carried out on day two 
following puromycin selection of transfected cells, and then at one week and two weeks post transfection. 
The expression of mCherry rapidly declined in the first week post transfection. After two weeks, all 
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4.3.5.3 Generation of Clonal Lines  
Following recovery from FACS, I sorted the populations of cells enriched for 
mCherry expression into 96-well plates (one cell per well) by FACS, based on 
mCherry expression, in order to isolate clonal lines which retained transgene 
expression. This resulted in a total of 61 clonal lines, 47 of which were treated with 
CRISPR/Cas9 and cassette, 6 lines were derived from an mCherry control and the 
remaining 8 lines were derived from the population transfected with the targeting 
cassette alone. These were allowed to proliferate until the 6-well plate stage, over a 
period of 36 days. At this stage, I monitored mCherry expression in each line using 
flow cytometry (Figure 4.12) and isolated genomic DNA in order to identify clones 
with correct integration at the IMPDH2 locus. To identify clonal lines harbouring 
integration at the IMPDH2 locus, I carried out a PCR-based assay with locus specific 
and cassette specific primers; an amplicon of ~2-Kb can only be produced if the 
cassette has successfully integrated into the IMPDH2 locus (Figure 4.13). 
Figure 4.12 shows the percentage of live cells retaining mCherry expression in each 
clonal line. These lines are 12 weeks post transfection, thus any observed expression 
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Figure 4.12 Continued. Page 5 of 5. Flow cytometric scatter plots showing mCherry expression levels in 
each clonal line, indicated as percentage of live single cells. Red dots indicate mCherry positive, live single 
cells; blue dots are live cells; purple dots are live single cells; black dots are dead cells, or cell clumps. For 















Figure 4.13 A) PCR-based identification of correct integration events at the IMPDH2 locus. PCR was 
carried out using locus specific and cassette specific primers; only clones bearing a correctly integrated 
transgene would produce a product of ~2000-bp. B) PCR-based detection of non-integrated alleles for 
clones which were positive for cassette integration at IMPDH2. Locus specific primers surrounding the 
target site were used, only alleles without integrated transgene would produce a product of ~1900-bp. C) 
Schematic of IMPDH2 locus, indicating location of primers (red arrows) used for integration detection and 
detection of non-targeted alleles. Predicted PCR product sizes are indicated. Clones are labelled as their 
number, 1-61. Red numbers indicate clones which had >80% mCherry expression; green numbers indicate 
mCherry expression of 1-80%. Black numbers indicate <1% mCherry expression. UC = Untransfected 
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CRISPR-mediated insertion of the transgene cassette at the IMPDH2 locus was 
efficient, with 32 out of 47 (68.1%) CRISPR/Cas9-treated lines demonstrating 
correct integration (Figure 4.13A). Of these clonal lines harbouring correct 
integration, 12/32 (37.5%) showed high mCherry expression (>80% of live single 
cells expressing mCherry) and 3/32 lines showed low expression (1.2%, 1.4% and 
10.6% of live single cells expressing mCherry). In addition to these, 11/61 (18%) 
lines showed mCherry expression without integration at the IMPDH2 locus, one of 
these (Clone 5; 1/61; 1.6%) showed high level mCherry expression (95.2% of live 
single cells expressing mCherry), while 10/61 (16.4%) lines showed low level 
mCherry expression (mean mCherry expression of 13.2% ± 17.6). All lines with 
integration at IMPDH2 showed monoallelic integration, as demonstrated by the 
presence of an approximately 1900-bp band following PCR with locus specific 
primers (Figure 4.13B). In some lines, particularly clone 13 (derived from 
sgRNA_1+), there is evidence of indels on the non-targeted allele (indicated by the 
presence of additional bands). Clones 22, 24 and 51 also showed evidence of indels, 
indicated by the presence of a single band, larger than the expected band (Figure 
4.13B). 
4.4 Discussion  
While in principle promising, the drug-selectable transgene integration system 
proposed here proved to be unfeasible in practice. This was mainly due to the high 
levels of residual survival observed in HEK293FT cells, following treatment with 
MPA. However, through initial experiments, I have for the first time, been able to 
demonstrate the potential of IMPDH2 as a novel site for efficient transgene 
integration and its ability to support robust long term expression.  
4.4.1 Targeting IMPDH2 with CRISPR/Cas9  
As demonstrated in Chapter 3, the sgRNAs I designed to target IMPDH2 are all 
active with wild type Cas9 (as determined by the SURVEYOR assay). I confirmed 
this by sequencing individual amplicons from clonal lines. The range of indels 
observed is consistent with that demonstrated by other groups (Shen et al. 2014; 
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these tend to cluster around the predicted cleavage site – 3-bp upstream of the PAM. 
No indels were observed for any of the sgRNAs when provided as a pair along with 
the Cas9n, consistent with the results observed with the SURVEYOR assay (Chapter 
3). This corroborates reports suggesting that a tail-to-tail orientation of the paired 
sgRNAs is favourable (Shen et al. 2014), as these pairs were all orientated in a head-
to-head configuration.  
In some cases more than two mutant alleles were observed in each clonal line. This 
may be due to the presence of at least three IMPDH2 alleles in HEK293FT cells, 
which is unsurprising as these cells are hypotriploid. However, these could also 
result from errors during cloning; FACS is not infallible so some lines could have 
inadvertently resulted from two cells rather than the intended single cell, despite 
careful screening for this during clonal line production.  
4.4.2 Variable Response Following MPA Treatment 
One of the major hurdles in creating the drug selectable transgene integration system 
was the variable response observed following treatment of cells with MPA, 
particularly the high residual survival of wild type cells, ranging from ~40% to ~60% 
of control. This was higher than anticipated based on the results of Qasim and 
colleagues (2011), who showed that HEK293 cells (the parent line of HEK293FT 
cells) had ~10% survival following treatment with MPA. Indeed, I was unable to 
replicate this under the same experimental conditions, observing a mean of ~40% 
survival, following three independent experiments. It is unclear why I consistently 
observed residual proliferation here. A potential explanation is batch variability in 
drug concentration though it seems unlikely that such variation would have been 
large, and would not account for the intra-experiment variability that I also observed. 
It is also a possibility that inter-batch variability in the antibody used in the ELISA 
caused some of the observed differences in residual survival. In addition, potential 
differences in seeding density between experiments may have resulted in apparent 
differences in survival.  
However, the response following treatment of transfected cells was more consistent. 
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seeding density had occurred, then there would be more variation in transfected cell 
response to MPA, mirroring that observed of untransfected (wild type) cells.  
The overall high level of residual survival following MPA treatment indicates that 
the salvage pathway is likely to play a significant role in the provision of guanine 
nucleotides in HEK293FT cells. Treatment with MPA leads to inhibition of the de 
novo synthesis pathway so cells become reliant on the salvage pathway to provide 
their guanine nucleotide needs. However, treatment with MPA may select for cells in 
which the salvage pathway is more active, and this may explain some of the variation 
seen in wild type response to MPA. This may be masked in transfected cells which 
can bypass inhibition via the presence of the IMPDH variant. This, in part, may 
explain the difference in variability of response between transfected and wild type 
cells.  
4.4.3 IMPDHIY did not Confer Increased MPA Resistance 
Interestingly, my findings for IMPDHIY do not replicate those of others in the field. 
Initial studies in MPA-resistant neuroblastoma lines, in which the variant was 
identified, also indicated that gene amplification was present, which could account 
for some, though not all, of the reported increase in MPA resistance (Hodges et al. 
1989). However, in their study, Sintchak et al. (1996) showed that the Thr333Ile 
mutation alone can increase MPA-resistance 300-fold compared to wild type. It 
would therefore be worth investigating whether the Ser351Tyr mutation may in some 
way mitigate the resistance conferred by the Thr333Ile substitution alone. Indeed, the 
activity of IMPDHIY is less than the wild type IMPDH (Farazi et al. 1997) and so this 
may account for its inability to provide increased resistance in this system and may 
explain why it performed worse than overexpression of  IMPDH2 here (Figure 4.6). 
However, it has also been shown by others that overexpression of the IMPDHIY 
variant can confer resistance to MPA above wild type (Sangiolo et al. 2007; 
Schroeder et al. 2006). This disparity may in part be due to cell line differences and 
perhaps the relative activity of the salvage pathway, particularly as these studies were 
conducted in T lymphocytes, which have little or no salvage pathway activity 
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4.4.4  Salvage Pathway Inhibition  
Early biochemical studies indicated the potential of acyclovir monophosphate to 
inhibit HPRT (Tuttle et al. 1983), the key enzyme involved in the guanine salvage 
pathway (Figure 4.2). It was also demonstrated to inhibit purine nucleoside 
phosphorylase (PNP), another enzyme involved in the salvage pathway (Tuttle & 
Krenitsky 1984). However, co-treatment with acyclovir monophosphate and MPA 
did not improve selection of Tf-IMPDH. In fact, acyclovir monophosphate did not 
significantly affect cell proliferation in any treatment group. The reasons for this are 
not clear and further studies, which are beyond the scope of this thesis, would be 
required to identify the underlying mechanisms. 
4.4.5 IMPDH2 Supports Transgene Integration and Expression 
In order to demonstrate IMPDH2 as a suitable site for conventional site-specific 
transgene integration, I designed a targeting cassette which could be incorporated 
following cleavage by CRISPR/Cas9. For initial proof of principle studies, I used an 
mCherry gene under the control of the EF1α promoter so that I could easily monitor 
expression of the transgene once integrated at IMPDH2.  
The data presented here demonstrate the ability of IMPDH2 to support robust long 
term expression of transgenes following CRISPR/Cas9-mediated integration of the 
transgene cassette; 37.5% of integrated clones showed greater than 80% mCherry 
expression after 3 months. As far as I am aware this is the first time IMPDH2 has 
been demonstrated as a site for transgene integration. These data indicate that the 
CRISPR/Cas9 system can be used to efficiently target integration of transgenes (from 
plasmid DNA). The efficiency achieved in this study (68.1% integration) is 
comparable with those demonstrated by other groups in cultured human cells (Byrne 
et al. 2014) and other model systems (Böttcher et al. 2014; Gratz et al. 2014; Yang et 
al. 2013). However, as this work was carried out in cultured cells, it is not necessarily 
predictive for expression in animals or humans.  
Integration efficiency varied depending on the sgRNA used to drive Cas9 cleavage. 
The total number of clones generated from each individual sgRNA also showed 
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that different numbers of clones were generated may itself indicate the usefulness of 
each sgRNA for targeting transgene integration. Indeed, all clones with correct 
integration demonstrating robust mCherry expression were generated with 
sgRNA_2-. The reason why this particular sgRNA should be more efficient at 
driving transgene integration is not clear, though it is common for multiple sgRNAs 
targeting the same locus to show different activities  
In all cases, integration at IMPDH2 appeared to be monoallelic (Figure 4.13B). Due 
to the complex karyotype of HEK293FT cells, it is possible that integration occurred 
at more than one allele, but it remains true that at least one allele with no integration 
is present in all targeted clones. It appears that whilst integration is not biallelic, there 
is evidence that targeting of the non-integrated alleles has occurred. In one case 
(clone 13) it appears that an insertion event has occurred in a non-targeted allele, 
while clones 22 and 24 only show presence of a larger PCR amplicon (suggestive of 
an insertion event at the non-targeted allele). This is similar to the 237-bp insertion I 
observed previously in clonal lines (Section 4.2.1.2). 
Many established cell lines, commonly used in the laboratory, have abnormal 
karyotypes often possessing more or less than the diploid number of chromosomes 
(Table 4.2). This could potentially complicate the production of transgenic cell lines. 
However, in cases where high level protein expression is desirable (for example, 
monoclonal antibody production), the ability to integrate two copies whilst 
preserving a wild type allele may be beneficial. However, in cell lines where the 
chromosomal number is less than diploid, it may be necessary to establish the copy 
number of the target locus, as disruption of a single copy locus may be deleterious, 
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Table 4.4.2 Ploidy of commonly used immortalised cell lines. Data collated from ATCC, Sigma-Aldrich® 
and Creative Bioarray.  
   Chromosome number  
Cell Line Organism Tissue of Origin Modal Diploid 
HEK 293 Homo sapiens Embryonic kidney 64 46 
HeLa Homo sapiens Cervical epithelium  82 46 
A549 Homo sapiens Lung epithelium 66 46 
RPE1 Homo sapiens Retinal pigmented 
epithelium  
46 46 
COS-7 Cercopithecus aethiops Kidney 57 60 
SH-SY5Y Homo sapiens Bone marrow  47 46 
Vero  Cercopithecus aethiops Kidney epithelium 58 60 
HCT116 Homo sapiens Colorectal carcinoma 45 46 
MCF7 Homo sapiens Mammary gland 82 46 
CHO-K1 Cricetulus griseus Ovary 20 22 
HEP-G2 Homo sapiens Liver 52 46 
CACO-2 Homo sapiens Colon 96 46 
 
Rapid decline in the proportion of mCherry-expressing cells occurred following 
transfection (Figure 4.11). This is likely a result of the loss of the plasmid DNA, 
while later loss of expression may be attributed to silencing of integrated copies, or 
outgrowth of cells harbouring integrated transgenes by cells without transgene 
integration.  
Some of the correctly integrated clones demonstrated a variegated phenotype, which 
was also observed in mCherry-expressing lines without correct integration. Indeed, 
clones 28, 32 and 53 showed correct integration but exhibited low levels of mCherry 
expression (1.4%, 1.2% and 10.6% respectively). In addition, 16 lines show correct 
integration but did not express mCherry (Figure 4.12B). Variegated expression of 
transgenes is predominantly caused by position effects. These can result from 
integration of transgenes in or close to heterochromatic regions, such as those found 
near telomeres and centromeres. Under these circumstances, heterochromatin can 
spread to the transgenes and lead to extinction of their expression (Decottignies 
2014). Transfected plasmid DNA becomes linearized upon entry to the nucleus and 
can be ligated to form concatemeric arrays which become integrated into the genome 
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mechanisms (Garrick et al. 1998). It is also possible that mutations or rearrangements 
have occurred in the transgenes during integration which have rendered them 
inactive and may explain why some lines show no expression despite correct 
integration at IMPDH2, though further studies would be required to confirm this. 
The presence of variegation in some clones implies that integration at IMPDH2 does 
not completely prevent partial silencing of the transgene, though the results obtained 
here suggest that this is less common upon integration at IMPDH2 than when the 
transgene is integrated randomly. Further studies are also required to identify the 
underlying mechanisms of the variegated phenotype observed in some clones, and to 
fully characterise IMPDH2 as a site for transgene integration and expression.  
4.5 Future Perspectives 
The results presented here demonstrate the potential of IMPDH2 to enable efficient 
transgene integration –mediated by CRISPR/Cas9 and support robust long term 
expression of transgenes. While showing initial promise, it will be necessary to 
further investigate the potential of IMPDH2 for this purpose. Firstly, I think it 
prudent to generate further clonal lines in order to validate the results obtained here, 
and investigate if the integration efficiencies achieved by each sgRNA can be 
replicated. Should this be the case, I think it wise to perform future experiments with 
sgRNA_2-ve which showed the greatest promise here, both in terms of integration 
efficiency and in robustness of subsequent transgene expression.  
In addition, I think it would be important to further characterise the clonal lines 
generated in this study. Firstly, it would be useful to demonstrate that correct 
integration is single copy and that other random integration events have not 
concurrently occurred. It would also be necessary to sequence integrated transgenes 
to identify any rearrangements or mutations which could have occurred during the 
integration process. This would be particularly important for lines which show 
variegated or no expression. It would also be worth identifying any markers of 
transgene silencing, which may be present, for example DNA methylation or histone 
modifications at the site of the transgene integration. For clones which do not 
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which may prove to be useful in future experiments as sites for transgene integration 
and expression, especially in clones such as clone 5 that showed high level mCherry 
expression. 
Next, I think that the protocol could be further optimised. It should be possible to 
generate clonal lines immediately following transfection. This could be carried out in 
the presence of puromycin selection to investigate whether this would have any 
effect on the proportions of correctly integrated and mCherry-expressing clones. 
A recent study has demonstrated that small molecules , specifically Brefeldin A and 
L755507, could increase the integration efficiency for large transgenes by up to 
threefold (Yu et al. 2015). It would be useful to investigate if these molecules could 
further increase the efficiency of targeting at the IMPDH2 locus.  
Once further optimised, it would be prudent to use a transgene of therapeutic or 
biological interest, rather than a reporter gene, to investigate any gene specific 
factors which affect either the efficiency of integration or the robustness of long term 
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5.1 Introduction 
The genome editing revolution brought about by the availability of SSNs, 
particularly TALENs and the CRISPR/Cas9 system, has great potential for 
improving the way in which we study gene function. Specifically, it has greatly 
improved the ease of creating gene knockouts in many model systems (Chu et al. 
2015; Wettstein et al. 2015; Zhou et al. 2015; Han et al. 2014; Shalem et al. 2014b; 
Yang et al. 2014). One case where this is useful is when studying almost identical 
proteins; for example, the two isoforms of the eukaryotic translation elongation 
factor 1 alpha (eEF1A), eEF1A1 and eEF1A2, which are 92% identical and 98% 
similar at the amino acid level. The eEF1A1 isoform is expressed almost 
ubiquitously except in a few tissues in which it is replaced by the eEF1A2 isoform 
during early postnatal development. It remains unclear why this switch occurs and 
whether other functions, in addition to their role in protein synthesis, unique to each 
isoform may be responsible. In order to study the roles of each isoform in more 
detail, I aimed to create a knockout cell line, which would only express the eEF1A2 
isoform, using CRISPR/Cas9 technology.  
5.1.1 Role in Eukaryotic Translation  
The translation of mRNA into protein is an essential cellular process; as such, 
mediators of this process are key players in cellular survival. Translation is organised 
into three phases, initiation, elongation and termination, each requiring the action of 
several proteins, known as translation factors.  
During the elongation phase, aa-tRNAs are delivered to the ribosome to provide 
amino acids to the growing polypeptide chain (Figure 5.1). This process is facilitated 
by the action of eukaryotic elongation factors (eEFs); eEF1A is a key mediator of 
this process responsible for delivering aa-tRNAs to the ribosome (Figure 5.1). 
 
 






Figure 5.1 Translation Elongation (not to scale). Translation elongation is mediated by eukaryotic 
translation elongation factors (eEFs). During elongation, aa-tRNAs are delivered to the ribosome, so that 
amino acids can be added to the growing polypeptide chain. Firstly, eEF1A binds GTP and then associates 
with an aa-tRNA molecule; eEF1A is responsible for delivery of the aa-tRNA to the ribosomal A site. Once 
the aa-tRNA is bound, eEF1A hydrolyses GTP and the free eEF1A-GDP complex is released from the 
ribosome. The eEF1A-GDP complex then associates with the eEF1B complex (composed of eEF1B, eEF1D 
and eEF1G) which is responsible for the exchange of GDP for GTP, allowing the eEF1A-GTP to associate 
with another aa-tRNA and the cycle to begin again. Once bound to the A site, the aa-tRNA is translocated 
to the P site by the action of eEF2, requiring the energy from GTP hydrolysis. Once here the amino acid 
forms a peptide bond with the last amino acid on the growing polypeptide chain. During translocation, the 
tRNA at the P site (which has delivered its amino acid) is translocated to the E site where it is released and 
can be recycled. Each tRNA molecule has an anticodon, which is complementary to the codon in the 
mRNA molecule and specifies the appropriate amino acid; only complementary tRNAs (carrying the 
respective amino acid) will be able to bind, thus ensuring the fidelity of the growing polypeptide chain. 
Taken with permission from Li et al. (2013).
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5.1.2 eEF1A Isoforms 
5.1.2.1 EEF1A1 and EEF1A2 Genes  
While there are several EEF1A genes in the mammalian genome, only EEF1A1 and 
EEF1A2 are known to be protein coding, encoding the two mammalian isoforms, 
eEF1A1 and eEF1A2, respectively. The other genes are likely to be 
retropseudogenes originating from EEF1A1 (Lund et al. 1996; Lee et al. 1993; 
Madsen et al. 1990).  
The EEF1A1 gene has been mapped to chromosome 6q14 while EEF1A2 is located 
on chromosome 20q13 (Lund et al. 1996). Both genes have eight exons and seven 
introns, with highly similar coding regions, 75% identical at the nucleotide level 
(Knudsen et al. 1993), and conserved intron exon boundaries (Bischoff et al. 2000). 
However, the introns, promoters and untranslated regions (UTRs) show little 
similarity (Bischoff et al. 2000; Knudsen et al. 1993). The EEF1A1 gene spans 
approximately 3.5-Kb, with a strong promoter, TATA box and putative Sp1 and AP1 
transcription factor binding sites (Uetsuki et al. 1989). On the other hand, EEF1A2 
spans ~12-Kb, including a 2-Kb promoter region (Bischoff et al. 2000); this disparity 
in size is largely due to the presence of larger introns in EEF1A2. EEF1A2 lacks  a 
TATA box and a 5’ terminal oligopyrimidine tract (following the CAP structure) 
present in EEF1A1 (Bischoff et al. 2000). Furthermore, EEF1A2 has an enhancer box 
(E-box), EGR (early growth response) transcription factor binding site and a 
myocyte enhancer factor 2 (MEF2) site, not present in EEF1A1 (Bischoff et al. 
2000), suggestive of their independent regulation.  
5.1.2.2 eEF1A1 and eEF1A2 Proteins  
The two isoforms are 92% identical and 98% similar at the amino acid level (Figure 
5.2), and have highly similar structures (Soares et al. 2009).  
The two isoforms show near identical translation efficiencies (Kahns 1998) and the 
residues involved in eEF1B and aa-tRNA binding are completely conserved between 
both isoforms (Soares et al. 2009). However, they differ in their relative affinities for 
GDP and GTP; eEF1A1 binds GTP more strongly than GDP, while for eEF1A2 the 
opposite is true (Kahns 1998), though the residues in contact with GTP/GDP are 
completely conserved between the two isoforms (Soares et al. 2009). However, 
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residues in close proximity to the guanine-binding pocket are isoform specific, in 
particular Asn197/His197; in eEF1A1, Asn197 can form an H-bond with Asp156, 
but such an interaction cannot occur in eEF1A2 between Asp156 and His197 which 
may account for differences observed in GTP/GDP binding (Soares et al. 2009).  
In addition, many of the residues which differ between the two isoforms can be 
differentially post-translationally modified (Soares & Abbott 2013); acetylation, 
phosphorylation, S-nitrosylation and ubiquitination can occur in an isoform specific 
manner (Soares & Abbott 2013). This has led to the hypothesis that differences in the 
post-translational modifications of the isoforms can accentuate the structural 
differences. Indeed, some of the sites that can be post-translationally modified lie 
within known functional regions, including the eEF1B-binding site, which may 
influence the function of each variant. In addition, many of the differentially 
modified residues lie within the two clusters of sequence variation (Soares & Abbott 
2013), potentially indicating a diverged role for each isoform. 
 
 








eEF1A1 1   MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEF1A2 1   MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 61  DKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEF1A2 61  DKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKK 
eEF1A2 121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPAYSEKRYDEIVKEVSAYIKK 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 181 IGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTR 
eEF1A2 181 IGYNPATVPFVPISGWHGDNMLEPSPNMPWFKGWKVERKEGNASGVSLLEALDTILPPTR 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALS 
eEF1A2 241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGILRPGMVVTFAPVNITTEVKSVEMHHEALS 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 301 EALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPV 
eEF1A2 301 EALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEAAQFTSQVIILNHPGQISAGYSPV 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 361 LDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPP 
eEF1A2 361 IDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMVPGKPMCVESFSQYPP 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
eEF1A1 421 LGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK- 
eEF1A2 421 LGRFAVRDMRQTVAVGVIKNVEKKSGGAGKVTKSAQKAQKAGK 
           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
Figure 5.2 Pairwise alignment of eEF1A1 and eEF1A2 amino acid sequences. The protein is organised into 
three domains, domains I, II, and III. There are a total of 36 amino acid differences between the two 
isoforms and 32 of these are found throughout the three domains; the remaining four are found within the 
C-terminal disordered region (Soares et al. 2009). The majority of these variable residues form two distinct 
clusters on one face of the protein – the opposite face to the C-terminal eEF1B-binding site (Soares et al. 
2009). Matching amino acids are highlighted yellow. Residues that differ are highlighted red. Domain 
boundaries are indicated (Domain I: Cyan; Domain II: Green; Domain III: Dark blue). Adapted from 
Soares et al. (2009).
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5.1.2.3 Two Isoforms to Perform One Role  
Even though the two isoforms are highly similar in their structures (Soares et al. 
2009) and translation abilities (Kahns 1998), they show non-overlapping expression 
patterns. The eEF1A1 isoform is almost ubiquitously expressed, while expression of 
eEF1A2 is limited to adult skeletal muscle, heart, large motor neurones, pancreatic 
islet cells and enteroendocrine cells in the gut (Newbery et al. 2007; Knudsen et al. 
1993). This pattern of expression is laid down during development; eEF1A1 is 
expressed ubiquitously in the foetus but is replaced by eEF1A2 in the 
aforementioned tissues during postnatal development. In the mouse this switch has 
completed by postnatal day 21 (Newbery et al. 2007). The reasons for this switch 
remain unclear, though may be due to differences in the activity profiles of each 
isoform. 
5.1.2.3.1 Moonlighting Functions 
In addition to their role in protein synthesis, the two isoforms have been implicated 
in wide ranging cellular processes, which are often unique to each isoform.  
The eEF1A1 isoform is known to bind and bundle actin and microtubules (Murray et 
al. 1996; Shiina et al. 1994). Though this has not been confirmed for the eEF1A2 
isoform, which may hint at a reason why it is expressed – rather than eEF1A1 – in 
certain cells. These cells tend to have a very stable architecture, such as neurones, so 
expression of eEF1A1 may be deleterious. 
It has been speculated that eEF1A also plays a role in proteolysis as it is involved in 
protein quality control via translation-coupled protein degradation (Mateyak & Kinzy 
2010). Studies in vitro have demonstrated its involvement in degradation of N alpha-
acetylated proteins (Gonen et al. 1994) and its ability to facilitate folding of 
denatured proteins (Hotokezaka et al. 2002). UV cross-linking studies have 
demonstrated the interaction of eEF1A with misfolded proteins, but not correctly 
folded proteins, and revealed its interaction with the polypeptide following release 
from the ribosome (Hotokezaka et al. 2002).  
It has emerged that eEF1A1 is involved in eliciting the heat-shock response via 
association with heat shock RNA 1 (HSR1) and together are essential for the 
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trimerisation of monomeric heat shock factor 1 (HSF1). This allows movement to the 
nucleus, where it can bind to heat shock elements (HSEs) to regulate transcription 
(Shamovsky et al. 2006). In addition, eEF1A1 associates with RNA polymerase II 
and the 3’ UTR of heat shock protein 70 (HSP70) mRNA helping to stabilise and 
facilitate its transport from the nucleus to ribosomes (Vera et al. 2014). However, 
these roles are not shared by the eEF1A2 isoform (Vera et al. 2014).  
Several other reports have also shown a role in nuclear transport. It has been 
demonstrated that eEF1A interacts with the nuclear export receptor exportin 5 (Exp5) 
in an aa-tRNA-dependent manner to support export of tRNAs (Bohnsack et al. 2002; 
Calado et al. 2002). This role may not be distinct from its role in translation, 
representing efficient channelling of translation components (Mateyak & Kinzy 
2010). However, more recently eEF1A1 was demonstrated to form part of the 
nuclear export machinery (Khacho et al. 2008).  
In addition, the two isoforms have opposing roles in apoptosis: eEF1A1 promotes 
apoptotic cell death in response to cell stress, while eEF1A2 promotes cell survival. 
Several studies have demonstrated that eEF1A1 is involved in the cytotoxic response 
to oxidative stress (Chen et al. 2000), ER stress and lipotoxicity (Borradaile et al. 
2006). On the other hand, in response to stress cells expressing eEF1A2 have been 
shown to downregulate eEF1A2 and express eEF1A1 (Ruest et al. 2002). 
Furthermore, eEF1A2 directly interacts with Prx-1 to protect cells from stress-
induced apoptosis (Chang & Wang 2007).  
5.1.2.3.2 Roles in Disease 
In addition to their non-canonical roles, each isoform has been implicated in various 
diseases, notably viral infections and cancer. Recently, the eEF1A2 isoform has been 
linked with intellectual disability, autism, and epilepsy.  
The eEF1A proteins, particularly eEF1A1, are implicated in many stages of viral 
infection (reviewed by Li et al. 2013) and this is particularly apparent in the HIV-1 
life cycle (Abbas et al. 2015). In addition, the eEF1A1 isoform has been shown to 
directly interact with the hepatitis B virus protein X (HBx), blocking its ability to 
bundle filamentous actin (Lin et al. 2012).  
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Upregulation of eEF1A2, and EEF1A2 gene amplifications, are commonly found in 
many cancers, particularly in tissues which normally do not express eEF1A2; it is 
also associated with lung and pancreatic cancers (Abbas et al. 2015). Additionally, 
60% of primary breast tumours, 30% of primary ovarian cancers and 43% of 
hepatocellular carcinomas (HCCs) have eEF1A2 overexpression (Abbas et al. 2015). 
It is believed eEF1A2 elicits its oncogenic effect through signalling pathways 
including Akt kinase and phosphoinositide 3-kinase (PI3K), resulting in cytoskeletal 
remodelling, proliferation, survival and invasion (Li et al. 2010; Pecorari et al. 2009; 
Amiri et al. 2007).  
More recently it has emerged that mutations in EEF1A2 leading to single amino acid 
changes in eEF1A2 can lead to autism, intractable epilepsy and intellectual disability 
(Nakajima et al. 2015; Veeramah et al. 2013; de Ligt et al. 2012). To date three 
different amino acid substitutions, found in four patients, have been published: 
Gly70Ser (Veeramah et al. 2013; de Ligt et al. 2012), Asp252His and Glu122Lys 
(Nakajima et al. 2015). All three of these residues are evolutionarily conserved and 
are found in, or close to, the regions involved in binding of eEF1B and GTP/GDP. It 
seems likely that these mutations are affecting translation but the precise underlying 
mechanisms remain to be elucidated. 
5.1.3 Generation of EEF1A1 Knockout Cell Lines 
It is still unclear to what extent these additional roles (distinct from translation) 
overlap between the isoforms. Another important question is why the developmental 
switch happens, why some tissues replace one isoform with an almost identical 
isoform. This may be a consequence of the moonlighting functions of each isoform, 
which may be deleterious in some cell types.  
I aimed to investigate these issues further by developing the tools with which I could 
start to answer these questions. Currently, the appropriate tools with which to 
untangle the different and potentially overlapping roles of the two isoforms are 
lacking; no cell lines expressing only the eEF1A2 isoform, are available. However, 
the availability of SSNs for precise genome editing, has meant that this should now 
be achievable.  
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5.2 Aims  
Use the CRISPR/Cas9 system to knockout the function of EEF1A1 in cell lines that 
express both isoforms in order to study the function of  the eEF1A2 inform in 
isolation, to more fully understand its diverse roles in the cell.   
5.3 Results  
5.3.1 Expression of EEF1A1 and EEF1A2 in Immortalised Cell Lines  
To create a cell line only expressing the eEF1A2 isoform, I needed to identify an 
appropriate starting line that expresses both isoforms. I selected a panel of 
immortalised human lines: RPE-1, HCT116, A549, HEK293FT, and HeLa cells. 
Three of these are cancer lines (A549, HCT116, and HeLa) and so have a good 
chance of expressing the eEF1A2 isoform. In order to quantify the expression of 
each isoform, I carried out qPCR analysis on these lines. The expression of each 
isoform was normalised to a panel of five reference genes, which were found to be 
most stable (as discussed in Section 3.2.1).  
Figure 5.3A shows that EEF1A1 is expressed at fairly comparable levels across all 
lines tested, except in HeLa cells in which it shows higher expression. On the other 
hand, EEF1A2 displays more variability in its expression across the cell lines tested 
(Figure 5.3B), with highest expression seen in HCT116, A549 and HEK293FT cells.   
Unfortunately, due to the lack of eEF1A2-specific antibodies, I was unable to 
investigate protein expression in each line, so I had to rely on the qPCR expression 
data. As HCT116 and HEK293FT cells demonstrated the highest EEF1A2 







Figure 5.3 qPCR expression profiles for EEF1A1 and EEF1A2 in a panel of immortalised cell lines. Expression for each gene was normalised to a panel of five reference genes 
(GAPDH, SDHA, UBC, TOP1 and ATP5B). Each bar represents the mean of three independent experiments. Error bars indicate S.E.M. 
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5.4 Targeting EEF1A1 with CRISPR/Cas9 
In order to knockout the function of eEF1A1 in cells, I planned to disrupt EEF1A1 
using CRISPR/Cas9 technology.  
5.4.1 Identification of CRISPR/Cas9 Target Sites 
Identification of unique target sites within EEF1A1 is complicated by the presence of 
several retropseudogenes in the human genome. In order to improve the specificity of 
the sgRNAs, I chose to target the intronic sequences in the 5’ portion of the EEF1A1 
gene, close to the intron-exon boundaries. I intended to use the double nickase 
CRISPR/Cas9 system to minimise the off-target activity, consequently, I identified 
four intronic sgRNA target sites, which could be used as single guides or as two 
nickase pairs, located upstream of exon three and downstream of exon four (Figure 
5.4).  
I constructed these sgRNAs using the Zhang laboratory method (Ran, P D Hsu, et al. 
2013). I constructed these using both pX459 and pX462 plasmids, so that I could use 
them as either individual sgRNAs or as nickase pairs, respectively. I validated the 
activity of all individual guides and the two nickase pairs in HEK293FT cells using 
the SURVEYOR assay (data in Chapter 3), and was able to demonstrate robust 









Figure 5.4 Genomic location of sgRNA target sites. The position of each sgRNA is indicated by a blue box. The sgRNAs are named after the closest exon and the DNA strand 
on which their target appears. The individual sgRNAs were constructed as both individual sgRNAs (pX459 backbone) and paired nickases (pX462 backbone). Exon numbers 
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5.4.2 Generation of EEF1A1 Knockout Cell Lines 
I initially targeted EEF1A1 in HEK293FT cells as I had confirmed the activity of 
each sgRNA in this line and the qPCR data indicated expression of the eEF1A2 
isoform. Following targeting with the CRISPR/Cas9 system, both individual 
sgRNAs and nickase pairs, I isolated clonal lines using a FACS machine to sort 
individual cells into wells of a 96-well plate. This resulted in three surviving lines 
derived from sgRNA_EEF1A1_Ex3+ve, sgRNA_EEF1A1_Ex4+ve and 
sgRNA_EEF1A1_Ex4+ve/sgRNA_EEF1A1_Ex4-ve nickase pair transfections. Only 
one line (targeted with sgRNA_EEF1A1_Ex4+ve) showed evidence of indels at the 
target site following direct sequencing of the target region (Figure 5.5).  
Figure 5.5 shows the sequence degeneration appearing close to the predicted 
cleavage site, 3-bp upstream of the PAM site (red dashed line). The chromatogram 
shows two distinct traces emerging at the site of cleavage. Based on sequence 
analysis, it appears that a deletion event has occurred. 
I next used HCT116 cells, as they have a near normal karyotype with a modal 
chromosome number of 45, unlike HEK293FT cells whose modal chromosome 
number is 64. This would make subsequent studies of eEF1A2 function more 
meaningful as they would be in a near normal genetic background.  
I used individual sgRNAs with wild type Cas9 for all subsequent experiments (unless 
otherwise stated) as several studies had indicated that off target activity was less 
common than first believed  (Wang et al. 2015; Cho et al. 2014; Mandal et al. 2014; 







Figure 5.5 Chromatogram of an EEF1A1 mutant clonal line. Clone was derived from the transfection of HEK293FT cells with sgRNA_EEF1A1_Ex4+ve. Red dashed line 
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I generated clonal lines, following transfection with all four individual sgRNAs in 
combination with wild type Cas9 and selection with puromycin, by FACS, resulting 
in 32 clonal lines. However, following sequencing, none of the 32 lines showed any 
evidence of indels at the target sites.  
5.4.2.1 Targeting Both EEF1A1 and EEF1A2 
In order to assess the activity of the CRISPR/Cas9 system in HCT116 cells, I 
targeted both EEF1A1 and EEF1A, comparing the ability of each to tolerate indels. 
In order to target EEF1A2, I used a nickase pair of sgRNAs, which were a kind gift 
from Faith Davies. This pair of sgRNAs target exon three of the EEF1A2 gene 
(Figure 5.6) and have been shown to be active in cells (data not shown). To target 
EEF1A1 I used sgRNA_EEF1A1_Ex3-ve and sgRNA_EEF1A1_Ex4-ve, as these 
had the least predicted off-target sites. Following transfection of HCT116 cells, 
puromycin selection and clone isolation by FACS, I was able to generate 14 clonal 
lines, 6 in which I had targeted EEF1A1, and 8 in which I had targeted EEF1A2.  
Amplification of the EEF1A2 target region indicated the presence of a deletion in 
one clone of approximately 300-bp (Figure 5.7A). Direct sequencing of the PCR 
products showed evidence of indels at the target site, indicated by the presence of 
multiple peaks in the chromatograms (Figure 5.7B). However, many of the 
sequences were too distorted to accurately interpret and due to technical issues, I was 
unable to clone and sequence the individual amplicons to reveal the nature of these 
mutations. In contrast, direct sequencing of PCR amplicons revealed no indels for 





Figure 5.6 Genomic location of EEF1A2-targeting sgRNAs. Location of each sgRNA is indicated by the blue boxes. Sequenced for each sgRNA are given in the lower panel 








































Figure 5.7 EEF1A2-targeted clonal lines. A) PCR amplification of target region. Clone 6 has an additional band suggestive of a deletion of approximately 300-bp. 
B) Example chromatogram showing degeneration of sequence at target site; trace from clone 7. Dotted red lines indicate predicted cleavage sites of the paired nickases. 
sgRNA target sites are indicated above and below. 
GATGGTGATGTAGTACTTGGTGG
CCGGGGGCATCGATGATGGTGAT
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5.4.2.2 Targeting Endogenous EEF1A1 in the Presence of Exogenous 
EEF1A1 and EEF1A2 
As EEF1A1 was proving difficult to disrupt, I wanted to see if I could target the 
endogenous EEF1A1 in the presence of exogenous EEF1A1 or EEF1A2 (provided by 
cDNA expression plasmids). The EEF1A1-specific sgRNAs target intronic 
sequences and therefore would only target the endogenous gene and not the cDNA, 
so should have allowed me to mutate the endogenous locus whilst providing cells 
with their eEF1A needs. I also decided to target both HCT116 and HEK293FT cells, 
as HEK293FT cells had proven permissible to CRISPR/Cas9-induced indel 
formation at the EEF1A1 locus and so would maximise the chances of producing a 
mutant line.  
Before generating the clonal lines, I wanted to demonstrate that the cDNAs would 
express correctly in both cell lines. I therefore carried out a transient transfection 
with each construct, then a western blot to indicate protein expression.  
Figure 5.8 demonstrates that cells expressed proteins of expected size following 
transfection with both the EEF1A1 and EEF1A2 cDNA expression plasmids, 
indicating correct expression of both isoforms. 
I used only two gsRNAs, one targeting each intron; I chose 
sgRNA_EEF1A1_Ex3-ve and sgRNA_EEF1A1_Ex4+ve, as their target sites were 
entirely intronic and so should not have impaired exogenous eEF1A1 function. In 
addition, I had already demonstrated the ability of sgRNA_EEF1A1_Ex4+ve to 















Figure 5.8 Western blot following transient transfection of EEF1A cDNAs. Constructs are tagged with a 
Myc tag, allowing for detection using an anti-Myc antibody. Both constructs are expressed in both 
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Table 5.1 Clonal Lines. Clonal lines were generated by isolating single cells following transfection of either 
HEK293FT or HCT116 cells with sgRNA_EEF1A1_EX3-ve and sgRNA_EEF1A1_Ex4+ve in combination 
with wild type Cas9. Some cells were co-transfected with exogenous expression plasmids encoding either 
EEF1A1 or EEF1A2. A total of 36 clonal lines were generated. 
Clone Cell Line  sgRNA  cDNA  
1 HEK293FT Ex3-/Ex4+   
2 HEK293FT Ex3-/Ex4+   
3 HEK293FT Ex3-/Ex4+   
4 HEK293FT Ex3-/Ex4+   
5 HEK293FT Ex3-/Ex4+   
6 HEK293FT Ex3-/Ex4+   
7 HEK293FT Ex3-/Ex4+   
8 HEK293FT Ex3-/Ex4+   
9 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
10 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
11 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
12 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
13 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
14 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
15 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
16 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
17 HEK293FT Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
18 HCT116 Ex3-/Ex4+   
19 HCT116 Ex3-/Ex4+   
20 HCT116 Ex3-/Ex4+   
21 HCT116 Ex3-/Ex4+   
22 HCT116 Ex3-/Ex4+   
23 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
24 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
25 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
26 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
27 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
28 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A1-Myc 
29 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
30 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
31 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
32 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
33 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
34 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
35 HCT116 Ex3-/Ex4+  pcDNA3.1:hEEF1A2-Myc 
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Figure 5.9 PCR analysis of EEF1A1 target region. Primers surrounding both target sites were used to 
identify any large deletions between the two sites. A) Agarose gel electrophoreses of amplified target 
region. Clone 8 shows evidence of a large, approximately 650-bp deletion. Clone information is detailed in 
Table 5.1. NCT = no template control. B) Schematic of target region, sgRNA target sites are indicated by 
the red boxes. Primers used to amplify the target region are indicated by the blue arrows. Approximate 
sizes of PCR amplicons and potential deletion region are indicated. 
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I was able to generate 19 HCT116 clones and 17 HEK293FT clones (Table 5.1). 
Sequencing confirmed that none of the HCT116 lines had mutations in EEF1A1, 
while only one HEK293FT clonal line showed any evidence of EEF1A1 mutation. In 
this case, PCR amplification of the target site indicated the presence of a large 
deletion equal to the loss of exons three and four (~650-bp) on one allele (Figure 
5.9). Two additional bands were present for this clone (clone 8), indicating that three 
alleles are present in HEK293FT cells, two of which appear to have deletions in this 
clonal line, as indicated by the smaller bands on the agarose gel. Sequencing did not 
reveal the nature of the mutation on the remaining allele(s) and, due to time 
constraints, I was unable to investigate this clone further. 
5.4.2.3 Characterisation of the EEF1A1 mutant Line Containing an 
Intronic Deletion 
As discussed in Section 5.3.2, I was able to generate a clonal line in HEK293FT 
cells, which carried an indel. In order to investigate this further I cloned the PCR 
product and sequenced the individual amplicons.  
Figure 5.10 shows that this clone is a compound heterozygote, carrying a deletion of 
8-pb on one allele and 12-bp on the other. Both deletions centre on the predicted 
cleavage site 3-bp upstream of the PAM (highlighted in red). This deletion occurs 
within intron four, 28-bp downstream of exon four. Two amplicons also demonstrate 
base substitutions near the cleavage site (Figure 5.10, red letters).  
In order to determine any effect on the splicing of the eEF1A1 protein, I carried out a 









Figure 5.10 Sequence analysis of EEF1A1 mutant line. Individual amplicons were sequences to reveal the extent of the mutation in the clonal line. Two deletions appear to 
be present, a 12-bp deletion, and an 8-bp deletion. Green boxes = sgRNA target; red boxes = PAM; grey boxes = no change; white box = indel; (-) = deletion; red letter = 
substitution; del = deletion; ins = insertion; > = substitution; WT = wild type.
A G A C C A T T G T T A A A A A G C T C T G G G A A T G G C G A T T T C A T G C T T A C A C A A A
TOPO Clone 3 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 6 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 9 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 10 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 13 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 14 A G A C C G T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12, A>G
TOPO Clone 26 A G A C C A T T G T T A A A - - - - - - - - - - - - T G G C G A T T T C A T G C T T A C A C A A A del 12
TOPO Clone 7 A G A C C A T T G T T A A A A A - - - - - - - - A A T G G C G A T T T C A T G C T T A C A C A A A del 8
TOPO Clone 5 A G A C C A T T G T T A A A A A - - - - - - - - A A T G G C G A T C T C A T G C T T A C A C A A A del 8, T>C

















































Figure 5.11 Western blot of EEF1A1 mutant and wild type. There is no evidence of altered protein size in 
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Figure 5.11 shows that there is no observable difference in protein size between the 
wild type and the mutant lines. However, it appears that expression in the mutant line 
is less than that of the wild type cells. In order to investigate this I quantified 
expression based on three independent experiments (normalised to GAPDH 
expression).  
Figure 5.12 suggests there might be a lower level of protein in the mutant cell lines, 
but there is no significant difference between eEF1A1 protein expression in the 
mutant compared to the wild type (p = 0.77).  
To investigate the effect of the mutation on transcription, I carried out a qPCR on 
both wild type and mutant cells.  
Figure 5.13 shows that the mutant line has an approximately six-fold increase in the 
expression of EEF1A1 at the transcriptional level compared to wild type (p = 0.043).  
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Figure 5.12 Protein expression analysis. Data represent the means of three independent western blots. 
Expression was normalised to the expression of the loading control, GAPDH. Error bars indicate S.E.M. 
Unpaired T-test was used to calculate the p-value. ns = not significant; WT = wild type.  
 
Figure 5.13 qPCR analysis of EEF1A1 expression. Data represent the means of three independent 
experiments. Expression was normalised to the expression of five reference genes. Error bars indicate 
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5.4.2.3.1 Regulatory Elements  
To investigate the increase in transcriptional activity observed in the mutant line 
compared to wild type cells, I looked at the regulatory data provided by the 
ENCODE project; I identified a DNase I hypersensitivity cluster which coincides 
with the site of the deletion (Figure 5.14). In addition, there are four transcription 
factor (TF) binding sites, which are potentially disrupted in the mutant line: 
chromodomain helicase DNA binding protein 1 (CHD1), polymerase (RNA) II 
(DNA directed) polypeptide A (POLR2A), metastasis associated 1 family, member 3 
(MTA3), and signal transducer and activator of transcription 5A (STAT5A) (Figure 
5.15). 
I also used JASPAR software to predict if any TF binding sites were created by the 
deletion; 10 TF binding sites are potentially created, these are listed in Table 5.2.  
Table 5.2 Predicted transcription factor binding sites in EEF1A1 deletion mutant. Mutant sequences for 




CEBPA CCAAT/Enhancer Binding Protein (C/EBP), Alpha 
CEBPB CCAAT/Enhancer Binding Protein (C/EBP), Beta 
FOXH1 Forkhead Box H1 
THAP1 THAP Domain Containing, Apoptosis Associated Protein 1 
NFIC Nuclear Factor I/C (CCAAT-Binding Transcription Factor) 
STAT3 Signal Transducer and Activator Of Transcription 3 (Acute-
Phase Response Factor) 
SRY Sex Determining Region Y 
SOX9 SRY (Sex Determining Region Y)-Box 9 
YYI YY1 Transcription Factor 






Figure 5.14 Regulatory elements at site of EEF1A1 deletion. Deletion is indicated by the red box. Data from the ENCODE project, available through UCSC genome 
browser. The site of the deletion coincides with both a DNase I hypersensitivity cluster and four transcription factor binding sites. Figure generated using UCSC genome 
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5.5 Discussion  
The CRISPR/Cas9 system has been used by many groups to knockout genes in 
different organisms and cell lines (Chu et al. 2015; Wettstein et al. 2015; Zhou et al. 
2015; Han et al. 2014; Shalem et al. 2014b; Yang et al. 2014). However, the creation 
of an EEF1A1 knockout cell line has proved challenging here. All rounds of 
targeting in HCT116 failed to generate any clonal lines carrying a mutation at the 
EEF1A1 locus. While I have generated two mutant lines in HEK293FTs, one of these 
at least maintains a normal eEF1A1 protein level. It is tempting to speculate that 
eEF1A1 may be essential even in the presence of eEF1A2; however, much work 
remains to confirm this.   
5.5.1 Endogenous Expression  
One of the challenges in studying eEF1A isoforms is the lack of specific antibodies. 
Most of the eEF1A2-specific antibodies will in fact, also cross-react with eEF1A1. 
Consequently, in order to determine expression, I had to rely upon qPCR data, which 
may not necessarily reflect the protein expression within the cell. The qPCR data 
indicated that eEF1A2 is expressed most highly in HCT116, HEK293FT and A549 
cells. This is consistent with other reports which have demonstrated expression at the 
transcriptional, and in some cases protein level, in these lines (Krastel et al. 2015; 
Kawamura et al. 2014; Kim et al. 2009).  
5.5.2 Targeting EEF1A1 and EEF1A2 
Initial targeting of EEF1A1 in HCT116 proved unsuccessful, with none of the 32 
clonal lines showing any evidence of CRISPR/Cas9 activity. This could have been 
due to lack of CRISPR/Cas9 activity in this cell line. To investigate this further, I 
decided to target both EEF1A1 and EEF1A2. As I was only able to generate 14 
clonal lines, it is difficult to draw any firm conclusions, but in light of all the rounds 
of cloning it seems plausible to speculate that mutations in EEF1A1 are less well 
tolerated than mutations in EEF1A2, at least in HCT116 cells. In total, I was able to 
generate 57 EEF1A1-targeted clonal lines and eight EEF1A2 clonal lines in HCT116; 
none of these demonstrated indels at the EEF1A1 locus. On the other hand, at least 
two of the eight lines had indels at the EEF1A2 locus. Potentially more of the lines 
also carried EEF1A2 mutations, but I was unable to confirm this due to technical 
 
 
Chapter 5 Development of an EEF1A1 Knockout Cell Line 186 
issues. While not conclusive, this suggests that mutations in EEF1A2 may be better 
tolerated than EEF1A1 mutations, though it will be necessary to fully characterise the 
nature of the mutations observed in EEF1A2. However, it is also possible that the 
EEF1A2-targeting sgRNA nickase pair is more active in HCT116 cells than the 
EEF1A1-targeting sgRNAs. This seems unlikely as I demonstrated robust activity of 
these sgRNAs in HEK293FT cells, so this would have to be due to locus-specific 
difference between the two cell lines. It is possible that for 
sgRNA__EEF1A1_Ex3-ve, activity is reduced by the presence of a SNP at the target 
site; rs2073466 coincides with position one of the sgRNA target site, though, it is not 
known if HCT116 carries this SNP. However, it is unlikely that this would impede 
activity, as it has been shown that sgRNAs can tolerate mismatches in the 5’ end (Fu 
et al. 2013; Hsu et al. 2013; Mali, Aach, et al. 2013; Pattanayak et al. 2013). In 
addition, this does not affect the activity of sgRNA_EEF1A1_Ex4+ve, so cannot 
entirely account for the lack of indels observed.  
It seems plausible to hypothesise that mutations in EEF1A1, leading to alteration in 
expression and protein function, are deleterious to cell health, even in the presence of 
eEF1A2, and so clones die; surviving clones are those which do not carry any 
mutations at this locus. As mutations in EEF1A2 were observed, it is possible that 
this isoform is not essential in the presence of eEF1A1, though further investigation 
is required to confirm the nature of these mutations and the consequences on protein 
level.  
5.5.3 Targeting Endogenous EEF1A1 in the Presence of Exogenous 
eEF1A 
I was unable to generate EEF1A1 mutant lines in HCT116 cells, even in the presence 
of exogenous eEF1A. In addition, I was unable to generate mutant lines from 
HEK293FT cells in the presence of exogenous eEF1A. This is potentially due to the 
loss of the exogenous expression, due to the transient nature of plasmid expression.  
One HEK293FT clone does carry a large deletion in the EEF1A1 gene on one allele, 
equivalent in size to loss of exons three and four, and potentially a smaller deletion 
on a second allele. It seems likely that a deletion of exons three and four would lead 
to a knock out of the gene function, though further investigation is required to 
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confirm this. However, as this is a monoallelic disruption, it is unlikely to cause a 
total loss of eEF1A1 function.  
Other studies have shown disruptions in EEF1A1 in the presence of eEF1A2. In their 
study Potts and colleagues (2015) used the eEF1A1 inhibitor didemnin B which 
stabilises the interaction of aa-tRNA and eEF1A1, preventing translation. In this 
study, they demonstrated that resistant cells were enriched for eEF1A2 expression, 
suggesting that eEF1A2 may be able to account for loss of eEF1A1 function. 
However, it is not known if didemnin B also inhibits other functions of eEF1A1 
outside its role in translation, which do not require its aa-tRNA binding ability. It is 
possible that in these cells eEF1A1 is still able to carry out other non-canonical 
functions and that eEF1A2 only accounts for loss of eEF1A1-mediated translation. 
On the other hand, Borradaile et al. (2006) generated CHO cells carrying a disruption 
in the EEF1A1 gene. These cells also express the eEF1A2 isoform, so one could 
speculate that loss of eEF1A1 is accounted for by eEF1A2. However, these cells still 
expressed eEF1A1, though at a greatly reduced level. It is therefore possible that 
eEF1A2 provided the translation capacity whilst the, albeit reduced, eEF1A1 carried 
out other essential functions in these cells. In addition, Krastel and colleagues (2015) 
demonstrated that the cytotoxic effect of nanocystin A from myxobacteria, were due 
to its inhibition of eEF1A1 and not eEF1A2 in HCT116 cells. This suggests that 
eEF1A1 is essential in these cells, as inhibition, even in the presence of eEF1A2, 
leads to cell death.  
5.5.4 EEF1A1 Mutant Line 
I was able to generate a clonal line from HEK293FT cells with an intronic deletion in 
EEF1A1. Sequencing analysis confirmed the presence of two mutant alleles – 8-bp 
and 12-bp deletions occurring in intron four. In addition to the deletions, two 
amplicons demonstrated base substitutions; these were likely the result of PCR errors 
rather than erroneous DSB repair. It seems possible that there are three EEF1A1 
alleles present in HEK293FT cells (Section 5.3.2.2), though I only observed two in 
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It was possible that these deletions may have knocked out sequences important for 
correct splicing. However, I was able to demonstrate that protein size in the mutant 
line is the same as that in the wild type line, indicating that correct splicing of exon 
four is not inhibited in the mutant line. This does not rule out the possibility of 
impaired splicing efficiency. In addition, this line showed no significant difference in 
protein expression, consistent with the hypothesis that eEF1A1 protein is essential 
even in the presence of eEF1A2. However, it displayed significantly increased levels 
of EEF1A1 transcription, ~6-fold greater than the wild type cells.  
The location of the deletion in this line coincides with a DNase I hypersensitivity 
site. This suggests that this region is likely to be important in the regulation of 
expression, indeed the ENCODE data suggest that there are four TF binding sites 
within this region: CHD1, POLR2A, MTA3 and STAT5A. While these data are 
experimentally generated, this work was not conducted in HEK293FT cells and so 
may not indicate TF binding in this cell line. MTA3 is the only one of these TFs 
associated with transcriptional repression (Brüning et al. 2014) as such seems a likely 
candidate to explain the increased expression observed; loss of binding could lead to 
a loss of repression and therefore an increase in transcription. In addition, using 
JASPAR software, I identified 10 potential TF binding sites, created by the 
mutations. All 10 TFs are associated with promoting transcription so could 
potentially be involved in the upregulation observed in the mutant, though any 
interact would need to be validated experimentally.  
Other intronic deletions have been shown to cause increased gene expression. 
McCready and colleagues (1997) found that deletions in the first intron of murine 
CD4, also  coinciding  with DNase I hypersensitivity sites, led to an increase in 
expression possibly due to loss of negative regulatory elements.  
The difference in expression seen at the level of transcription and translation is 
consistent with reports that demonstrate the up regulation of the protein in response 
to cellular stress. Protein levels are increased at the level of translation, but not at the 
level of transcription following stress (Chen et al. 2000), probably to allow for rapid 
increases in protein level when required. This suggests that regulation of 
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transcription and translation may be uncoupled and that fine-tuning of the protein 
level can occur by regulation at the translational rather than transcriptional level.  
5.6 Future Perspectives 
Due to the time constraints of this project, I have been unable to fully characterise 
the mutant lines I generated. Initial investigation of the line bearing the intronic 
deletion has shown its altered transcription of the EEF1A1 gene. It would be worth 
investigating this further and identifying the specific factor(s) involved.   
For the line bearing the predicted exonic deletion, it would be important to fully 
characterise the nature of this deletion. Any effect this has on both transcription and 
translation could then be investigated. Should protein level be reduced, it would be 
possible to investigate changes in cell proliferation and growth, protein synthesis, 
and response to cellular stress such as heat shock or oxidative stress, which would be 
suggestive of isoform-specific differences. 
In parallel, it would be appropriate to investigate the EEF1A2 mutant lines, generated 
in HCT116 cells. Firstly, it would be necessary to characterise fully the nature of the 
mutations, by cloning and sequencing individual amplicons. These mutant lines 
would provide a useful tool to study the consequences of eEF1A2 disruption; 
abnormalities in functions associated with one or other isoform in these cells could 
be attributed to loss, or reduced function of eEF1A2.   
A recent study has indicated that small molecules can be used to modulate the 
activity of the CRISPR/Cas9 system, favouring either HR or NHEJ depending on the 
desired outcome (Yu et al. 2015). In this study, the authors demonstrated that 
azidothymidine (AZT), a drug used in HIV/AIDS treatment, could be used to 
promote NHEJ repair at the expense of the HR repair pathway, thus increasing the 
knockout efficiency. It would be worth investigating if the use of AZT could aid in 
the generation of EEF1A1 knockout cells.  
An alternative method to generate an EEF1A1 knockout would be to introduce LoxP 
or flippase recognition target (FRT) sites both sides of a critical exon. The 
introduction of the LoxP or FRT sites could be facilitated by the sgRNAs I have 
constructed here. LoxP and FRT sites are short sequences (34-bp), which are 
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recognised by Cre and Flp recombinases, respectively; if two sites are placed 
flanking an exon, expression of the recombinase will lead to a deletion of the exon 
between the two recognition sites. This method has been demonstrated by Chen et al. 
(2015) who introduced biallelic FTR sites flanking an exon of PAX6 using sgRNAs 
targeting either side of the exon and a plasmid donor. A similar method could be 
used to target EEF1A1 using the sgRNAs I have generated here. This would 
demonstrate if eEF1A1 truly is essential even in the presence of eEF1A2; cells would 
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6.1 Targeting Genomic Loci Using SSNs 
The main aim of this project was to develop SSNs to target four genomic loci, which 
I had chosen as candidates to support transgene integration and long-term expression. 
I chose these loci based on evidence suggesting that they are widely expressed. In the 
case of the AAVS1 and hROSA26 loci, their potential to support transgene 
integration had been demonstrated, though I aimed to investigate this further. In 
addition, I intended to develop a drug-selectable transgene integration system at the 
IMPDH2 locus, and an EEF1A1 knockout cell line, in order to probe the biology of 
eEF1A1 and the closely related eEF1A2. In light of this, I designed and constructed a 
range of TALENs and individual sgRNAs to target each locus. I validated the ability 
of each to induce indels at their target site, and demonstrated activity in all cases 
using the SURVEYOR assay. Due to the highlighted incidence of off-target activity 
during the early development of the CRISPR/Cas9 system, I also constructed sgRNA 
nickase pairs for three of my chosen sites; for most of these, I was able to 
demonstrate robust activity. However, those targeting IMPDH2 failed to show robust 
activity; this is likely due to the non-optimal orientation of the sgRNA pairs.  
6.1.1 Transgene Integration  
The four genomic loci I chose are all widely expressed, and I was able to confirm 
transcriptional activity at all loci in a range of immortalised human cell lines. This 
indicates that each has an open chromatin structure, which is more supportive of 
transgene expression. The AAVS1 locus was used as a control locus: SSNs had 
previously been developed to target this region, and others had demonstrated its 
potential to support transgene expression. I was able to confirm the ability of these 
SSNs to induce indels at their target sites and I confirmed that AAVS1 could support 
integration of transgenes. In doing so, I demonstrated the ability of both TALENs 
and CRISPR/Cas9 to drive the integration of large transgenes. This gave me 
confidence that I could achieve this at the other loci.  
Building on this, I intended to integrate the mCherry gene at the hROSA26 locus, 
stimulated by both TALENs and CRISPR/Cas9. However, due to unanticipated 
cloning issues, I did not achieve this in the time available, though I have developed 
the tools with which this locus may be probed in future. The potential of this site to 
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support transgene integration, and subsequent expression, even after stem cell 
differentiation, has been indicated (Irion et al. 2007). This site also appears to be 
evolutionarily conserved (at least in mammals), with homologues recently identified 
in rat (Kobayashi et al. 2012) and pig (Li et al. 2014), in addition to mouse, in which 
it was first found (Friedrich & Soriano 1991). In all cases, it appears this locus can 
support transgene integration and robust expression. It is likely that the human 
ROSA26 locus will prove to be a good site for transgene integration, though further 
work will be required to validate this.  
Whilst selection of permissive sites for transgene integration can help to reduce the 
chances of transgene silencing, it is important to take into consideration other factors 
both within the local environment and the transgene cassette, which can influence 
transgene expression. The mouse Rosa26 locus exemplifies this: transgene 
expression levels demonstrate significant orientation-dependence. Chen et al. (2011) 
showed that some promoters, most notably EF1α, demonstrated a significant 
difference in transgene expression when integrated in the same orientation as Rosa26 
compared to integration in the opposite orientation to Rosa26. In all cases, 
integration in the same orientation as Rosa26 resulted in greatest transgene 
expression. However, in their study, Strathdee and colleagues (2006) demonstrated 
that transgenes integrated in the opposite orientation to Rosa26 showed higher levels 
of expression. They also showed that deletion of upstream sequences reduced 
transgene expression when integrated in the same orientation as Rosa26, suggesting 
that there is transcriptional interference from the endogenous Rosa26 promoter. The 
disparity between these studies is likely due to the presence of an insulator sequence 
in the transgene cassette in the Chen et al. (2011) study, which would have prevented 
any interference from the endogenous promoter. Taken together, these studies 
suggest a potential role for orientation in transgene integration and indicate the 
importance of careful cassette design, to prevent interference from endogenous 
signals.  
Due to time limitations, I could not investigate the ability of all of the chosen loci to 
support transgene integration, though I have developed the tools with which this can 
be achieved in the future.   
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6.2 Development of a Drug-Selectable Transgene Integration 
System 
The development of a drug-selectable transgene integration system was hampered by 
the unexpected leakiness of MPA treatment. The ability of MPA to inhibit IMPDH is 
well documented, but this does not account for other cellular pathways that are 
capable of bypassing IMPDH in fulfilling the cell’s guanine nucleotide needs, 
notably the salvage pathway, resulting in cellular survival despite MPA treatment. 
While the proposed system proved to be impractical to implement, I was 
subsequently able to demonstrate that IMPDH2 could support transgene integration 
and robust long-term expression. However, this work was conducted in cultured 
cells, therefore further work would be required to investigate this in vivo.  
Of the sites I had chosen, IMPDH2 demonstrated the highest level of transcription 
across all cell lines tested. This is indicative of an open chromatin structure, 
permissive to gene expression, indicating its potential to support transgene 
expression. It is clear that local environmental factors can influence transgene 
expression, as discussed above; it would be useful investigating further the link 
between levels of endogenous expression and the ability to support transgene 
expression.  
It is clear from the data presented here that the CRISPR/Cas9 system can efficiently 
target transgene integration: at IMPDH2 68.1% of clones carried a correctly 
integrated transgene. In addition, IMPDH2 can support robust expression, with 
37.5% of the correctly integrated clones demonstrating high-level mCherry 
expression. However, it will be necessary to fully characterise each of these clonal 
lines, particularly why some lines with correct integration, have low, or no transgene 
expression.  
6.3 Targeting EEF1A1 
The data presented here potentially indicate that eEF1A1 is essential even in the 
presence of eEF1A2, as evidenced by the inability to generate mutations resulting in 
a loss of protein expression. This remains to be confirmed for the mutant line 
carrying a potential exonic deletion. In addition, I was able to generate several clonal 
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lines bearing EEF1A2 mutations, which could suggest that the eEF1A2 isoform is 
less essential: full characterisation of these mutant lines will be necessary to confirm 
this. This supports the hypothesis that each isoform has a unique profile of 
moonlighting functions in the cell, such that eEF1A2 is unable to account for a loss 
of eEF1A1. Should this be the case, then this could account for the switch in 
expression that occurs during early postnatal development. The cells that normally 
express the eEF1A2 isoform tend to be terminally differentiated, and so have 
different requirements than rapidly dividing cells, which could be one of the reasons 
for the isoform switch.  
Though unable to create an EEF1A1 knockout line, I was able to generate a clonal 
line carrying a biallelic deletion within intron four. In addition, I generated a clonal 
line with a potential monoallelic deletion of exons three and four. Interestingly, for 
the intronic deletion mutant, I was able to show that the total eEF1A1 protein was 
reduced compared to control cells, though this did not reach significance (p = 0.77), 
while the level of transcription was significantly increased compared to controls (p = 
0.043). The reasons for this were not clear, though it seems likely that binding of 
regulatory factors was altered by the deletion. It is also possible that the deletion 
causes reduced mRNA stability, such that increased transcription is required to 
maintain normal protein level. Further investigation is required to elucidate the 
underlying mechanisms.  
6.4 Future Directions 
6.4.1 Validation of IMPDH2 and hROSA26  
In this thesis, I have demonstrated the potential of IMPDH2 to act as a site for 
integration and long-term expression of transgenes. More work is required to validate 
fully the robustness of this locus for this purpose. Some clonal lines with correct 
transgene integration did not demonstrate mCherry expression; it will be necessary to 
investigate if this is due to integration errors or transgene silencing. If the latter, it 
would be useful to investigate how common this is in subsequent rounds of targeting. 
It would also be useful to investigate the silencing mechanisms involved, so that they 
may be avoided through improved cassette design.  
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The data here indicate that choice of sgRNA may influence the efficiency of 
integration and subsequent expression of the transgene at IMPDH2. It would be 
useful to investigate this further, to identify the underlying reasons behind this, 
which could influence the design of more efficient sgRNAs in the future.  
Though I was unable to characterise hROSA26 as a site for transgene integration, 
others have indicated its potential (Irion et al. 2007), and so it would be beneficial to 
investigate this further. Firstly, it will be necessary to investigate if the SSNs I have 
developed here can drive transgene integration and if these can be expressed long-
term from this locus. As mentioned above, the mouse Rosa26 site shows significant 
orientation-dependent expression of transgenes. It would be worth investigating if 
this is also true for the human gene.  
IMPDH2 shows the highest level of transcription of all the sites I investigated. It 
would be useful to compare expression of integrated transgenes to endogenous 
expression, and to investigate this relationship, which could be useful in the 
prediction of other sites useful for transgene integration.   
Once optimal targeting conditions have been found for each site, it would be 
necessary to integrate a transgene of biological or therapeutic interest, in order to 
demonstrate the utility of each site for relevant applications.   
6.4.2 Targeting EEF1A1  
In light of the data presented here, it seems likely that the use of a more sophisticated 
strategy may be necessary in order to knockout EEF1A1. This could involve 
conditional knockout mediated by LoxP/Cre or FRT/Flp systems. This would help to 
determine if eEF1A1 is essential even in the presence of eEF1A2, as induction of Cre 
or Flp, resulting in EEF1A1 knockout, would cause cell death if this is the case. 
Another option would be to use SSNs to direct changes in EEF1A1 to make it more 
EEF1A2-like. This would help to determine which regions are important to the 
activity of each isoform. However, based on the evidence gathered here, this is likely 
to be a significant technical challenge. 
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6.4.3 Investigating EEF1A1 Mutant Lines 
Initial investigations here demonstrated an interesting disparity between protein and 
mRNA levels in one of the mutant lines. It would be worth investigating the 
underlying causes of this, which could uncover novel regulatory pathways.  
In addition, it will be necessary to characterise the second clonal line. This line 
appears to carry a large deletion on one allele, which corresponds to a loss of exons 
three and four. It is likely that this will have some effect on expression, though the 
extent of this remains unknown.  
6.4.4 Improving SSN Efficiency  
In their recent study, Yu and colleagues (2015) identified small molecule drugs, 
which could be used to bias the outcome of CRISPR/Cas9 cleavage towards either 
NHEJ or HR repair pathways, increasing gene disruption or repair, respectively. It 
would be useful to investigate the effect of these chemicals with the SSNs I have 
developed here, to increase the efficiency of either transgene integration or gene 
knockout.   
6.5 Comparison of the SSN Technologies  
The development of the CRISPR/Cas9 system has made genome editing more 
accessible to a greater number of scientists due to the simplicity of design and ease of 
construction. While this system is undoubtedly a powerful tool, the other available 
SSN systems (namely TALENs, ZFNs and to some extend meganucleases) all have 
their own merits. In most comparisons, TALENs were more highly active than ZFNs 
(Chen, Oikonomou, et al. 2013), and due to their modular nature and relative ease of 
design, the TALEN system rapidly grew in popularity. Studies directly comparing 
CRISPR/Cas9 and TALEN technologies are few, but do suggest that the 
CRISPR/Cas9 is more active in most cases (Mandal et al. 2014; Ding et al. 2013). In 
addition, I observed greater activity for CRISPR/Cas9 in direct comparisons at both 
AAVS1 and hROAS26.  
ZFNs showed significant context dependence: the ability of each ZnF to bind its 
target could be influenced by neighbouring ZnFs (Carroll 2011). This has not been 
observed for TALENs and due to the nature of target recognition, is not an issue for 
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CRISPR/Cas9. In addition, the proprietary nature of the system meant that it was 
difficult to generate highly active ZFNs to target loci of interest.  
The identification of TALEN target sites is limited by several factors. The 
requirement of FokI to dimerise means that the paired binding sites must be situated 
14–20-bp apart (Sanjana et al. 2012). While this potentially limits the number of 
targetable sequences in the genome, it also helps to increase the fidelity of the system 
as such sites are less likely to occur outside of the target locus. Indeed, TALENs 
often show very little evidence of off-target activity (Wang et al. 2015; Smith et al. 
2014; Veres et al. 2014). Due to a cryptic signal within the N-terminal, TALEN 
target sites must begin with a T nucleotide; together with the necessity of the 
14-20-bp spacer region, this can reduce the number of targetable sequences, 
especially compared to CRISPR/Cas9. In addition, several other factors have been 
suggested to improve the activity of the TALENs, which may further reduce the 
number of potential binding sites (Cermak et al. 2011). However, the number of 
repeats in the DNA-binding domain can vary greatly: naturally occurring TALEs can 
contain up to 33.5 repeats and as few as 6.5 have been shown to be active (Boch et 
al. 2009). This greatly increases the repertoire of targetable sites.  
On the other hand, the CRISPR/Cas9 system is only limited by the need for a PAM 
site, in the form 5’-NGG for S. pyogenes Cas9, immediately 3’ of the 20-bp target 
sequence. However, Cas9 molecules from other bacterial species, with different 
PAM requirements have been isolated, including Neisseria meningitides (5’-
NNNNGATT), Streptococcus thermophilus (5’-NNAGAAW), Treponema denticola 
(5’-NAAAAC) and Staphylococcus aureus (5’-NNGRR[T]) (Ran et al. 2015; Cong 
et al. 2013; Esvelt et al. 2013; Hou et al. 2013). In addition, the specificity of S. 
pyogenes Cas9 has been reengineered to allow alternative PAM recognition 
(Kleinstiver et al. 2015). Together, these could be used to increase the repertoire of 
targetable sequences within the genome. 
One of the advantages of the CRISPR/Cas9 system is its compact nature, which 
makes it particularly amenable to multiplexing. Several studies have shown the 
benefits of this approach, including in the induction of targeted gross chromosomal 
rearrangements, namely inversions and translocations (Choi & Meyerson 2014). This 
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has also allowed for the development of large-scale, genome-wide libraries for 
genome wide recessive screens (Bassett et al. 2015; Koike-Yusa et al. 2013; Shalem 
et al. 2014a; Y. Zhou et al. 2014). 
One of the practical advantages of the CRISPR/Cas9 system is the ease of 
construction compared with the other SSN system. A single cloning step is required 
to produce a new sgRNA, compared to the more labour intensive construction of 
TALENs. In my experience, the construction of sgRNAs is generally more efficient, 
resulting in the majority of isolated plasmids carrying the correct insert. On the other 
hand, due the more complex nature of the TALEN construction process, I found that 
many of the resulting plasmids had misincorporation of the monomer repeats. 
However, newer more streamlined TALEN construction techniques have been 
developed, which allow for high-throughput production, such as the FLASH (fast 
ligation-based automatable solid-phase high-throughput) system (Reyon et al. 2012), 
though it is likely that the simplicity of CRISPR/Cas9 construction will lead to its 
replacement of TALENs in many laboratories.  
6.6 Off-Target Activity 
An issue, raised early in the generation of the CRISPR/Cas9 system, was its 
propensity for off-target activity. It was demonstrated that each sgRNA could 
tolerate as many as five mismatches between the RNA and the target site, 
particularly in the 5’ portion of the sgRNA, distal to the PAM site (Fu et al. 2013; 
Hsu et al. 2013; Mali, Aach, et al. 2013; Pattanayak et al. 2013). Later studies also 
demonstrated the ability of 5’-NAG to be recognized by Cas9, rather than the 
expected 5’-NGG PAM site (Anders et al. 2014). In response to these issues, a 
double nickase strategy was devised, making use of the D10A mutant Cas9 (Cas9n) 
in combination with two sgRNAs targeting opposing DNA strands (Mali, Aach, et al. 
2013). In light of these issues, I chose to implement the double nickase strategy for 
my target sites. However, due to issues regarding sgRNA orientation discussed 
earlier, the nickase pairs targeting IMPDH2 failed to show detectable activity. More 
recently, groups have also developed a FokI-Cas9 fusion, which in combination with 
paired sgRNAs, causes DSBs in an analogous manner to TALENs and ZFNs 
(Guilinger, Thompson, et al. 2014; Tsai et al. 2014). Unlike the paired nickase 
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strategy, FokI will not cut unless it dimerises and so activity is more restricted: 
binding sites must be located so that FokI is able to dimerise, further increasing the 
fidelity of the system (Tsai et al. 2014). However, data from whole genome 
sequencing experiments suggest that the off-target profile for the CRISPR/Cas9 
system may be less of an issue than first believed, particularly when carefully 
designed sgRNAs are used (Wang et al. 2015; Cho et al. 2014; Mandal et al. 2014; 
Smith et al. 2014; Suzuki et al. 2014; Veres et al. 2014). In addition, use of truncated 
sgRNAs, removing the 5’ portion, which is most prone to tolerate mismatches, can 
further increase the sgRNA fidelity (Fu et al. 2014). It would be useful to investigate 
the true burden of off-target activity for each of my sgRNAs (and TALENs), though 
this is beyond the scope of this thesis.  
Off-target activity is not unique to the CRISPR/Cas9 system. Though off-target 
activity does not appear to be a problem for TALENs (Wang et al. 2015; Smith et al. 
2014; Veres et al. 2014), it was a significant concern for ZFNs, with some showing 
significant cytotoxicity due to the burden of DSBs (Alwin et al. 2005; Porteus & 
Baltimore 2003; Bibikova et al. 2002). Methods to reduce the off-target cleavage by 
ZFNs were developed, but in many cases led to reduced on-target activity (Söllü et 
al. 2010; Miller et al. 2007; Szczepek et al. 2007). On the other hand, meganucleases 
show probably the greatest specificity in target recognition of all the SSNs (Harrison 
et al. 2014), but they have become less frequently used due to the difficulty in 
reengineering their target recognition. 
6.7 Wider Applications of SSN Technology  
In this work, I have focused on the use of SSN technology to drive transgene 
integration, which can be particularly useful for biotechnology, for example the 
development of stable lentiviral producer cell lines or therapeutic protein production 
systems. However, this technology has myriad potential applications, in basic 
research, gene therapy, and the wider scientific community.  
In the study of gene function, it could be argued that the need for permissive loci is 
negated by the availability of SSNs, which allow scientists to target almost any 
position within the genome, thus allowing direct modifications of genes of interest. 
While this is useful in many applications, the ability to introduce transgenes site-
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specifically into cells is still useful for biotechnology applications, basic research and 
has potential for future gene therapy. The ability to express any gene of interest or 
genes carrying specific mutations is essential to the study of gene function and 
consequences of patient specific mutations. Advances in stem cell technology, 
particularly iPSCs, means that patient-specific mutations can be studied in isogenic 
backgrounds and in disease-relevant cell types, which would otherwise be impossible 
to study, such as neurones. The hROSA26 locus has already demonstrated its 
potential to maintain transgene expression after stem cell differentiation (Irion et al. 
2007). In addition, this technology allows genes to be studied in cells in which they 
would not normally be expressed. 
These tools have huge potential for biotechnology. The range of therapeutic proteins 
is ever increasing, particularly monoclonal antibodies. The production of these 
proteins has often been carried out in bacteria, due to the low cost culturing and ease 
of engineering (Kamionka 2011). However, this can lead to problems with incorrect 
folding, processing and post translational modifications, as such mammalian cell 
systems have become increasingly utilised (Wurm 2004). However, transgenes can 
be subject to silencing. To overcome this, sites which have been demonstrated to be 
less prone to silencing, such as the four potential sites I have chosen here, can be 
exploited. 
Other systems to create stable transgenic cell lines are available, but these generally 
rely upon recombinase mediated transgene insertion such as the Flp-In™ and Jump-
In™ platforms available from Life technologies in a range of cell backgrounds (Cat. 
No’s A14148, A14150, A15007, A15008, R78007, R76007, R75807, R75207, 
R75007, R76207, and R76107). While these are useful tools, they only allow for 
insertions at single sites, so would not be applicable for the generation of stable 
lentiviral producer cell lines, or in other instances where two or more independent 
transgene integration events are desirable. 
6.7.1 Gene Therapy  
This technology provides new and exciting possibilities for gene therapy, both in 
their ability to promote specific HR events, for gene correction or gene addition, and 
in their ability to create specific DNA breaks, for both gene knockout and repair of 
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trinucleotide repeat expansions. Early studies in yeast have demonstrated the ability 
of TALENs to specifically target and delete trinucleotide repeat tracts (Richard 
2015). Subsequent studies in Friedreich’s ataxia patient-derived cells, demonstrated 
that ZFNs could be used to specifically target the trinucleotide repeat region and led 
to a significant increase in frataxin expression, which persisted through 
reprogramming into iPSCs and differentiation into neurones (Li et al. 2015). In 
addition, the development of iPSCs and the means to specifically alter them with 
SSNs opens up new potentials for personalised medicine. For example, Yusa and 
colleagues (2011) demonstrated that targeted correction of the α1-antitrypsin gene 
(A1AT) could be achieved by ZFNs in patient-derived iPSCs and that this restored 
function of A1AT following differentiation into liver cells. Other groups have also 
shown the potential of this strategy for diseases such as SCID-X1. In their study, 
Menon et al. (2015) demonstrated that TALENs could be used to correct mutations 
in the gene encoding IL-2Rγ in patient-derived iPSCs, which could then be 
successfully differentiated to generate mature natural killer cells and T-cell 
precursors, demonstrating the potential for autologous cell therapy. The ability to 
manipulate patient cells ex vivo also holds great potential for many other diseases. 
For example Osborn et al. (2013) illustrated the potential of TALENs to drive HR 
repair of mutations in the COL7A1 gene in fibroblasts derived from recessive 
dystrophic epidermolysis bullosa (RDEB) patients. These demonstrated normal 
protein expression in a mouse model following transplantation of iPSCs.  
In addition, the ability to selectively disrupt gene function has allowed researchers to 
target the CCR5 gene, which encodes the major co-receptor for HIV-1. A mutation in 
CCR5 has been identified in individuals who are resistant to HIV-1 infection. The 
mutation, termed Δ32 (a deletion of 32-bp) results in a severely truncated protein 
which is not detected at the cell surface, and so HIV-1 cannot gain entry (Liu et al. 
1996). The first human clinical trial used ZFNs to knockout CCR5 function, which 
would mimic the effect of the natural Δ32 mutation (Tebas et al. 2014). This trial 
demonstrated the potential and safety of this strategy: most patients showed a 
reduction in the detectable levels of circulating HIV-1 (Tebas et al. 2014). In 
addition, some studies have also focused on eradication of integrated virus using 
TALENs and CRISPR/Cas9 (Hu et al. 2014; Ebina et al. 2015; Strong et al. 2015). 
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The ability to integrate a gene into a locus that will support robust long-term 
expression also has great potential for future gene therapy. The use of SSN-mediated 
targeted integration is likely to be less efficient than integration following retroviral 
delivery. However, the ability to predefine a specific integration site, should be much 
safer than random integration, which in rare cases can lead to activation of 
oncogenes (Hacein-Bey-Abina et al. 2008). One of the disadvantages of the 
CRISPR/Cas9 system is the large size of the Cas9 protein (4-Kb coding sequence) 
which could reduce the efficiency of its delivery and choice of vectors for gene 
therapy. However, alternative Cas9 proteins from other bacterial species have been 
identified, which have a smaller coding sequence, but equivalent cleavage 
efficiencies (Ran et al. 2015). One of the major problems with SSNs, particularly 
CRISPR/Cas9, for gene therapy is their potential for off-target activity. However, as 
more is learnt about the system, better designs will allow for highly specific sgRNAs, 
which have already been demonstrated for some loci (Veres et al. 2014; Smith et al. 
2014). 
Diseases such as CF, which result from mutations in a single gene leading to loss of a 
functional protein, are excellent candidates for gene therapy. In the case of CF, 
provision of the CFTR gene can lead to an improvement of symptoms, as has been 
demonstrated in early clinical trials (Alton et al. 2015). SSNs could be used to repair 
the mutations in CFTR; indeed studies using ZFNs and CRISPR/Cas9 have 
demonstrated the potential of this (Schwank et al. 2013; Lee et al. 2012). However, 
replacement of the gene, by integration into a validated locus, could be used as a one-
size-fits-all solution. The advantage over a patient specific approach is that this only 
requires the testing and validation of a single set of SSNs and integration cassette, 
rather than individual testing of mutation-specific targeting strategies, which would 
each require trails for safety and efficacy. Such an approach could be applicable to 
many diseases, which result from single gene defects.  
6.7.2 Modification of Human Embryos  
The public acceptance of gene therapy rests on the belief that it will be used only to 
treat diseases, not for enhancement, and that these alterations will be in somatic cells, 
so will not be passed on to future generations. However, the development of SSNs, 
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particularly the CRISPR/Cas9 system, means that the possibility of specifically 
manipulating human embryos is now more feasible. In their landmark study, Liang 
and colleagues (2015) demonstrated that high frequency gene editing is achievable in 
human embryos. The study investigated the ability of CRISPR/Cas9 to drive repair 
of mutations in the β-globin gene (HBB), associated with β-thalassemia, in non-
viable triponuclear human embryos. While the authors demonstrated efficient 
cleavage of the target site, repair using the donor was relatively inefficient. They also 
discovered that endogenous homologous templates, notably the δ-globin gene 
(HBD), could compete with the exogenous repair templates. This phenomenon has 
also been shown in mouse embryos (Wu et al. 2013). In addition, many of the edited 
embryos were mosaic, though whether this is linked to their triponuclear nature is 
unknown. Interestingly, the fidelity of sgRNA binding appears less stringent in the 
embryos than in HEK293T cells; none of the predicted off target sites were cleaved 
in the cell line, but two of the top seven sites were cleaved in the embryos. In 
addition, further off target cleavage was confirmed by whole-exome sequencing. 
While the technology is far from being specific enough for the precise manipulation 
required, we are closer than ever to this possibility. This study has caused substantial 
controversy, raising many questions about the ethics of embryo manipulation. One of 
the major reservations of such an approach is the unknown side effects of editing 
within the embryo: do the potential benefits outweigh the risks? One could argue that 
this type of manipulation is unnecessary; such a technique will require screening of 
manipulated embryos to ensure the fidelity of the indented correction, therefore one 
could screen unedited embryos to identify those not carrying the disease variant, 
negating the need for gene editing and its associated risks. It seems that the 
technology is moving faster than the legislation and a more in depth discussion 
within the scientific community, and society in general, is required to identify a 
realistic framework for future human genome modification.  
6.7.3 Modification of Disease-Carrying Organisms  
Another use of CRISPR/Cas9 technology is to engineer ‘gene-drives’ in mosquitoes 
that would render them resistant to Plasmodium and make them less fertile, which 
could help to reduce the incidence of malaria. However, we must also be aware of 
the potential consequences of such work, which could render the mosquito extinct, 
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having knock-on effects within the ecosystem, specifically for bats and other 
insect-eating species. In addition, it is vital to ensure that these modifications cannot 
be passed to other species, which could lead to unpredictable environmental 
consequences.  
6.7.4 De-extinction 
One of the more unusual applications to emerge from this technology is the de-
extinction movement, which aims to restore extinct species such as the passenger 
pigeon and the woolly mammoth. However, de-extinction is not a new idea, for 
example, researches have been able to resurrect the genome of the 1918 influenza 
virus, but the technology to facilitate it has become more widely available and 
affordable. While this area of research is controversial, there are some potential 
benefits. One of the major proponents is George Church, whose group were one of 
the first to develop the CRISPR/Cas9 system, and is keen to promote the benefits of 
this idea. It is believed that bringing back ancient diversity could help to reverse 
radical changes in ecosystems, and may even help to slow the effects of global 
warming (Church 2013). In addition to bringing back extinct species, this technique 
could help existing species by reintroducing lost diversity in those that have become 
too inbred, such as the Tasmanian devil.  
6.8 Closing Remarks 
In this thesis, I have demonstrated some of the potential of SSN technology and 
identified a novel site for transgene integration, IMPDH2. Genome engineering is a 
rapidly evolving field and it is clear that SSNs are useful tools, which will become 
increasingly integral to basic research, biotechnology, and gene therapy. The future 
holds many exciting opportunities and it is likely that increasingly sophisticated 
approaches to gene editing will be developed. 
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